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ABSTRACT 
SURVEILLANCE OF EMERGING LIVESTOCK VIRUSES 
 
FATEN A OKDA 
2017 
Accurate and rapid diagnostic tests are essential for the management and control 
of emerging infectious diseases. Therefore, the overall goals of studies presented in this 
dissertation were to provide improved diagnostic and surveillance capabilities for several 
emerging viral diseases impacting the livestock industry and to provide insight into 
appropriate control strategies. 
Recent, severe outbreaks of porcine epidemic diarrhea virus (PEDV) in Asia and 
North America highlighted the need for well-validated diagnostic tests for identification 
of PEDV infected animals and evaluation of their immune status. PEDV was first 
detected in the U.S. in May 2013 and another swine coronavirus, porcine 
deltacoronavirus (PDCoV) was identified in the U.S. in February 2014. Both pathogens 
spread rapidly across the U.S., severely impacting the swine industry. As part of this 
project, well-validated serological assays for the detection of antibodies against PEDV 
and PDCoV were developed. Monoclonal antibodies (mAbs) against selected PEDV and 
PDCoV structural proteins were also developed and applied to serological and antigen 
detection assays. Newly developed fluorescence-based virus neutralization assays also 
provide valuable tools for assessment of vaccine candidates or protective immunity. 
The PEDV spike (S) glycoprotein plays a key role in virus entry into target cells 
and mediates the functions of receptor binding and fusion during entry. Therefore, 
immunodominant neutralizing epitopes of PEDV were identified using a panel of S-
xviii 
 
 
 
 
specific mAbs. Epitope mapping by peptide ELISA revealed that seven mAbs recognized 
linear neutralizing epitopes located in the N-terminus of the S2 glycoprotein subunit. 
Two mAbs recognized a neutralizing epitope located in the C-terminus of S2, while only 
one neutralizing mAb reacted against a region of the S1 glycoprotein subunit. These 
results indicate that the S2 glycoprotein subunit contains major antigenic determinants 
and, perhaps, the immunodominant neutralizing epitopes of PEDV.  
 Influenza D virus is a recently described virus that affects cattle and limited 
serological testing capability is currently available. Therefore, new ELISA-based 
serological assays based on expressed protein antigens representing conserved regions of 
the nucleoprotein and hemagglutinin-esterase proteins were developed. Results of these 
assays correlate well with hemagglutination inhibition (HI) and virus neutralization 
assays, providing new tools for ongoing sero-surveillance and control efforts. 
 
1 
Chapter 1 
Introduction 
Surveillance of new emerging viruses requires a thorough understanding of the 
existing and emerging infections and diseases to develop the fastest, most accurate, and 
most dependable diagnostic approaches.  Establishment of diagnostic reagents and assays 
addressing new emerging diseases, especially viruses, plays an important role in 
supporting the livestock economy. It can also protect the food production animal, 
livestock industry, companies, farms, wild life animals and animal industries by saving 
millions of animals that can die from new devastating emerging viruses. The newly 
emerging viruses I am investigating are porcine epidemic diarrhea virus (PEDV), porcine 
deltacoronavirus (PDCoV), and Influenza D virus (IDV). 
Coronaviruses are enveloped, positive sense RNA viruses that consist of several 
genera, including Alphacoronavirus, Betacoronavirus, Gammacoronavirus and the 
recently described genus, Deltacoronavirus. Some of the most important porcine 
coronaviruses include porcine epidemic diarrhea virus, porcine respiratory coronavirus 
(PRCV), and transmissible gastroenteritis virus (TGEV); all members of the genus 
Alphacoronavirus [1]. 
Almost four years ago, an economically devastating swine disease was identified 
in United States (U.S.) pig farms, causing severe enteric disease associated with 
dehydration followed by high mortality in suckling piglets (50-100%). It was caused by 
the acute, highly contagious PEDV. A year later, PDCoV was first identified in the U.S. 
but presented itself with less severity. Pigs of all ages are susceptible to PEDV and 
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PDCoV; but, older pigs usually showed a milder form of the disease with less mortality 
[2,3]. PEDV, a member of the genus Alphacoronavirus and family Coronaviridae [4,5,6], 
was first recognized in Europe in 1978 as the causative agent of porcine epidemic 
diarrhea (PED). A novel PDCoV was identified in swine feces in Ohio farms and linked 
with enteric disease similar to PEDV in the U.S. [7]. PDCoV has been identified in 
numerous different U.S. states and Canada, associated with acute diarrhea and vomiting 
in the absence of other identifiable pathogens. 
Although the analysis of field data and the field observations in the U.S. is 
confounded by the co-infections with PEDV or other pathogens. PDCoV infections cause 
less severe clinical disease than PEDV [8,9]. The severity of disease in both gnotobiotic 
and conventional piglets has further defined the pathogenicity and pathogenesis of the 
virus. PDCoV causes diarrhea and vomiting in all age groups and mortality in nursing 
pigs with lower mortality rates than that shown in cases of PEDV.  
The Orthomyxoviridae family contains some of the most important emerging 
virus diseases infecting both humans and animals. The family is characterized by 
antigenic shift and antigenic drift mutations. Historically, it included three genera: 
Influenza A Virus (IVA), Influenza B Virus (IVB), and Influenza C virus (ICV). In 2011, 
a novel virus belonging to a putative new genus was isolated from pigs with influenza-
like illness in Oklahoma [10] and designated as Influenza D virus (IDV) [11].  Although 
the first isolation was from swine, cattle are considered the main reservoir hosts for this 
newly discovered virus. IDV strains have been isolated from cattle in several different 
states in the U.S. [11,12,13,14], China [15], France [16], Italy [17], Mexico [18] and 
Japan [19].  
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Influenza C virus and IDV are enveloped RNA viruses in the family 
Orthomyxoviridae. They are closely related to each other and contain seven genomic 
segments and a hemagglutinin-esterase fusion protein responsible for recognition, 
binding, and destruction of host receptors. ICV and IDV are different than IVA or IVB 
that contain eight segments. No re-assortment occurs between ICV and IVA strains, but 
IDV strains isolated from swine and cattle have been found to frequently reassort with 
each other [11]. The lack of rapid clinical diagnostic tests for IDV limits the ability to 
respond appropriately to it. Many methods of virus isolation and serological analysis used 
in research are not designed for clinical use and probably underestimate the actual 
prevalence of IDV due to low viral loads in the respiratory tract which are detected using 
the current reverse transcriptase polymerase chain reaction (RT-PCR).  
Humans closely working with swine and poultry are at high risk of zoonotic 
infection with an influenza virus. During the 1918 pandemic, there was the first 
connection between influenza in swine and humans, when both swine and human 
populations became ill simultaneously [20]. In 1976, transmission of an influenza virus 
from pigs to humans was first documented, subsequently zoonotic infections have 
occurred throughout the world [21].  
Our overall project objectives were to: develop, validate and apply serological 
assays for PEDV, PDCoV in swine and IDV in cattle. Also, we conducted detailed 
characterization and epitope mapping of the PEDV spike protein using monoclonal 
antibodies and evaluated the neutralizing ability of the spike specific monoclonal 
antibodies against PEDV infection in Vero cells. This work is justified because these are 
all very important diseases with significant economic impact and current serological tests 
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are marginal or not available at all. Serological tests are critical for the management and 
control of these diseases. One of the assays, the fluorescent microsphere immunoassay 
(FMIA), will allow multiplexing, so eventually we can test for previous exposure to 
many different diseases at the same time. 
 
Dissertation Organization 
This dissertation is composed of two published papers in BMC Veterinary 
Research and one ready for submission, plus a chapter on influenza D diagnostics. A 
comprehensive literature review is included for all viruses in Chapter 2. 
Chapter 3 is a published paper entitled: “Development of an indirect ELISA, 
blocking ELISA, fluorescent microsphere immunoassay and fluorescent focus 
neutralization assay for serologic evaluation of exposure to North American strains of 
Porcine Epidemic Diarrhea Virus”. The objective of this study was to develop and 
validate multiple improved serological assays for PEDV, including an indirect ELISA 
(iELISA), a highly specific monoclonal antibody-based blocking ELISA (bELISA), an 
FMIA that can be multiplexed to monitor exposure to multiple antigens and pathogens 
simultaneously, and a fluorescent focus neutralization assay (FFN) to measure functional 
virus neutralizing antibodies. 
Chapter 4 is a published paper entitled: “Development of monoclonal antibodies 
and serological assays including indirect ELISA and fluorescent microsphere 
immunoassays for diagnosis of porcine deltacoronavirus”. The overall objective of this 
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project was to develop and validate selected diagnostic reagents and assays for PDCoV 
antigen and antibody detection.  
Chapter 5 is entitled “The S2 glycoprotein subunit of porcine epidemic diarrhea 
virus contains immunodominant neutralizing epitopes”. Our goal in this project was to 
develop and characterize a panel of monoclonal antibodies to different antigenic and 
neutralizing epitopes on the spike (S) protein of PEDV.  
Chapter 6 involves studies to develop serological assays for IDV and a 
seroprevelance survey of IDV in cattle using ELISAs based on different putative epitopes 
of IDV in cattle. The overall objective of this project was to develop and validate 
diagnostic assays selecting for IDV antigen and antibody to IDV antigens in diagnostic 
samples. Most of the recently published virological surveys are based on the initially 
described RT-PCR method, designed on the PB1 gene. It is important to extend the 
investigation to different animal species and geographic areas, which requires a 
continuous update of molecular diagnostic tests. Also, the availability of alternative 
serological assays is essential to confirm data and to ensure the detection of the widest 
number of strains. 
Chapter 7 consists of a general discussion summarizing the research results and 
discusses the implications for future research.   
  
6 
 
 
 
 
Chapter 2 
Review of Literature 
Coronaviruses 
Coronaviruses (CoVs) have high zoonotic potential and are a major cause of a 
variety of diseases in animals and humans, for example Severe Acute Respiratory 
Syndrome (SARS) and Middle Eastern Respiratory Syndrome (MERS).  The CoVs 
belong to the order Nidovirales, and the family Coronaviridae contains two subfamilies, 
Coronavirinae and Torovirinae [22]. The first member of the coronavirus family was 
discovered in the 1930s. After the SARS outbreak shook the world in 2002–2003, 
substantial focus was placed on the epidemic potential of CoVs, leading to the 
identification of many new family members. The sudden appearance of MERS in 2012 in 
the Middle East demonstrated the capability of coronaviruses to jump across species. The 
diseases associated with coronaviruses were mainly of veterinary interest and several 
cause life-threatening diseases among animals. Coronaviruses spread among a wide 
variety of mammals and birds, causing acute or persistent enteric and respiratory diseases 
and, in some rarer cases, neurologic disease or hepatitis. In the U.S., TGEV and now 
PEDV lead to fatal, watery diarrhea and dehydration in piglets. Avian infectious 
bronchitis virus (IBV), a highly contagious respiratory infection in chickens, causes a 
severe economic loss by reducing meat and egg production [23]. 
Genomic Structure of Coronavirus 
Coronaviruses are enveloped, spherical or pleomorphic single-stranded positive 
sense RNA viruses. CoVs have a genome size of approximately 25.4–31.7 kb which 
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replicates in the host cell cytoplasm [22]. Upon the fusion between the virion envelope 
and the host cell membrane, they deliver their nucleocapsid into the host cell. The spike 
glycoprotein is a primary determinant of cell tropism, pathogenesis, and mediates virus 
entry. CoVs spike proteins are classified as a Class I fusion protein responsible for 
binding to the receptor on the host cell. After binding to the receptor, fusion occurs 
through a process driven by major conformational changes of the S protein. The 
conformational change of the S protein is initiated by receptor binding, low pH exposure 
and proteolytic activation [24]. 
The genome contains six to ten open reading frames (ORFs) which are packaged 
into a helical nucleocapsid surrounded by host derived lipid bilayer. The first ORF 
represents two-thirds of the genome and encodes the replicase proteins. The last third of 
the genome contains the structural protein genes in a fixed order: (HE)-S-E-M-N. More 
accessory proteins could be present between these genes [25]. 
The virion envelope includes three viral proteins, the S protein, the membrane 
protein (M) and the envelope protein (E). In addition, some coronaviruses contain a 
hemagglutinin esterase. The M and E proteins have a critical role in virus assembly. The 
S protein is the key of viral entry and determines host range [26]. Enveloped viruses 
require fusion with a host cell membrane in order to introduce their genome into the host 
cell. Combining cell-biological, infection, and fusion assays, it can be clearly 
demonstrated that the CoV family enters cells via clathrin-mediated endocytosis. 
Moreover, although some CoVs depend on a low pH for fusion, some rely on trafficking 
to lysosomes for proteolytic cleavage of the S protein and membrane fusion to occur [27]. 
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Following the fusion and initial binding of the receptor, CoVs fuse their envelope 
with the host cell membrane and then deliver their nucleocapsid to the target cell. The S 
protein leads the process of entry by mediating receptor binding and membrane fusion. 
The fusion process requires a major conformational change of the S protein. 
Coronaviruses are characterized by the wide variation of their receptors and their 
mechanism of triggers to activate fusion [8]. 
Coronavirus nonstructural proteins  
The proteolytic cleavage of pp1a and pp1ab by the viral protease--chymotrypsin-
like protease generates the coronavirus nonstructural proteins (nsp) and protease-papain-
like proteases play a critical role in viral replication and transcription [28]. Nonstructural 
protein 1(nsp1) is the first N-terminal protein released from the ORF1a polyprotein pp1a 
which is found only in the alpha and beta coronavirus genus. The sequence and structure 
of nsp1 is different among genera and shares low homogeneity. TGEV nsp1 is a protein 
of 9 kDa and 28 kDa for SARS-CoV. Nsp1 can functionally suppress the innate immune 
response and the expression of host mRNA [29].  
Nsp2 is also cleaved from pp1a by the protease activity of nsp3 (PLpro domain). 
Nsp2 is dispensable for viral replication as the mouse hepatitis virus (MHV) and SARS 
CoV with nsp2 deletions could survive in cell culture. The nsp2 deletion results in 
attenuated viral growth and RNA synthesis defects [30]. Nsp3 carries one or two papain-
like proteases that belong to the cysteine protease family [31]. The nsp3 is a subunit of 
alpha coronaviruses and subgroup 2a beta coronaviruses which contain two active 
papain-like protease domains, PL1pro and PL2pro. The PLpro protein is responsible for 
9 
 
 
 
 
the cleavages between nsp1-nsp2, nsp2-nsp3, and nsp3-nsp4 regions of the coronavirus 
[32]. Nsp 4 is critical in double membrane vesicles (DMV) biogenesis. Nsp 5 is a 3C-like 
protease (Mpro, 3CLpro), or the main protease of coronavirus that is responsible for 
processing eleven cleavage sites from nsp4 to nsp16. Nsp5 is essential for virus 
replication [31]. Mutations in the cleavage sites at nsp6-nsp7, nsp7-nsp8, nsp8-nsp9, and 
nsp10-nsp11 showed a lethal effect on viral propagation [33]. Nsp6, together with nsp3 
and nsp4, are considered the membrane anchor proteins which compromise the 
transmembrane domains and participate in formation of reticulovesicular network and 
double membrane vesicles (DMV) [34].  
Nsp7 and nsp8 form a hollow cylinder-like complex on the surface of an inner 
channel for binding to the double stranded RNA. They initiate the de novo RNA 
synthesis. Nsp7 structure is featured with 3 α-helix bundles found at the N-terminal, 
HB1, HB2 and HB3, and one α- helix is present at the C-terminal. Two different 
conformations, nsp8I and nsp8II have a “golf-club like structure”, of which the N 
terminal is the shaft containing an α- helix, while the C terminal is the head containing 3 
α- helices and 7 β-strands. Eight copies of nsp7 cross link with four copies of nsp8I and 4 
copies of nsp8 II respectively leading to the formation of the hexadecamer [35]. Nsp9 has 
RNA and DNA binding activity while the interaction between nsp10 and nsp14 or nsp16 
has a valuable role in the fidelity and methylation of the virus. The nsp10 is the main 
activator of nsp14 and nsp16. The nsp14 has two domains: S-adenosyl methionine -
dependent (guanine-N7) methyltransferase at the C-terminal and 3’ to 5’ exonuclease at 
N-terminal. The nsp16 acts as the AdoMet-dependent (nucleoside-2’O)-methyltransferase 
[36].  
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Nsp11 is essential for the viral replication. Nsp12 is the viral RNA dependent 
RNA polymerase with canonical motifs which are located at the C-terminal. Nsp12 
functions as the trigger of the RNA extension with help from a primer, which results from 
the de novo synthesis of nsp8 in coronaviruses. Nsp13 is a helicase of the virus, which 
directs both RNA and DNA in a 5’-to-3’ direction. Nsp13 has RNA 5’-triphosphatase 
activity related to the viral capping process. Nsp15 is a viral endoribonuclease, of which 
the C-terminal region [37,38,39]. 
Coronavirus structural proteins  
The structural proteins; S, E, M, and N are translated from multiple sub-genomic 
mRNAs and contribute to the architecture of the virus particle. The S protein is 
characterized by a typical structure of a crown-like corona in a form of trimers, and is 
displayed on the virus membrane. The S protein is classified as a class I viral fusion or 
type I transmembrane protein. It is cleaved into S1 and S2 subunits by the protease, 
including trypsin and cathepsin required during the infection [40]. This cleavage is 
essential to trigger the cell-to-cell fusion and virus entry into cells. The S1 subunit carries 
the receptor binding domain, which is responsible for receptor binding, host range, and 
virus cell and tissue tropism [41]. The S2 subunit contains a fusion peptide, heptad repeat 
regions 1 and 2, which acts as critical component for virus-host fusion and syncytial 
formation. Furthermore, S proteins from most coronaviruses, including SARS-CoV, 
MHV and PEDV, are able to be cleaved by trypsin at two specific sites. One cleavage 
site, S1/S2, which is located at the boundary of the S1 and S2 site and the S2’ site, 
located close to the fusion peptide. The S2’ is considered to be crucial for fusion activity 
of the S protein [42].  
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The N protein is the most abundant protein in virus infected cells. The N protein 
harbors the viral genome RNA molecule in a ribonucleoprotein complex. The N protein 
consists of an N-terminal domain, a C-terminal domain, and intrinsically disordered 
regions, in which multiple sites within the three regions are able to bind and activate with 
RNA [43]. Moreover, the N protein has been determined to associate with the replication 
transcription complex; for example, the N protein of MHV binds to the viral nsp3 
through the N-terminal domain and the linker region. Also, N protein of SARS-CoV 
inhibits the synthesis of interferon (IFN)-β [44]. Recently, PEDV N protein was 
demonstrated to antagonize IFN-β production through sequestering interaction between 
interferon regulatory factor 3 and TANK binding kinase 1, which is a critical step in type 
I IFN signaling [45]. The M protein is the most abundant in the viral envelope and both 
M and E proteins have been demonstrated to be essential for virus assembly. 
Replication/transcription complex of coronavirus 
The replication transcription complex of most CoVs contains all non-structural 
proteins (nsp1-15 or nsp16). The replication transcription complex is associated with the 
double membrane vesicles derived from endoplasmic reticulum. The non-structural 
proteins of SARS-CoV, nsp3, 4 and 6 are able to induce the double membrane vesicles 
formation and initiate the replication transcription complex anchor to the membrane. 
Double membrane vesicles are an ideal place for RNA replication and provide the 
protection from host defense mechanisms that could be triggered by dsRNA 
intermediates during the replication [46].  
Swine Coronaviruses 
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Porcine coronaviruses are considered a highly significant cause of enteric and 
respiratory disease of swine. Five CoVs have been identified in pigs: TGEV, porcine 
respiratory coronavirus (PRCV), PEDV, hemagglutinating encephalomyelitis virus 
(HEV), and PDCoV. Within the past four years, PEDV and PDCoV were detected in the 
U.S. domesticated pig population.  In 1946, an alphacoronavirus, porcine TGEV, was 
identified as a devastating enteric disease of pigs in the U.S. In 1984, another U.S. 
porcine -CoV, PRCV, was officially identified as a deletion mutant of TGEV. PRCV is 
characterized by having a different viral tropism from intestinal to respiratory epithelia. 
PRCV replicates almost entirely in the respiratory tract and is similar to other porcine 
viral pneumonias. Later, in 1971, PEDV was identified in the United Kingdom. PEDV is 
similar to TGEV in which they both replicate in small-intestinal enterocytes. PEDV 
causes life threatening acute enteric disease in suckling piglets due to profuse watery 
diarrhea, emesis, and dehydration with high morbidity and mortality. Since 2010, 
different variant strains of PEDV other than the classic European strain (CV777) have 
appeared in China, South Korea, Japan, and different Asian countries, leading to 100% 
mortality in suckling piglets. PEDV was identified as a new cause of neonatal diarrhea in 
Iowa in May 2013, consequently the infection rapidly spread to more than 30 states, 
Canada, and Mexico causing devastating economic losses in the swine industry 
[47,48,49]. During an investigation for new CoVs in a variety of mammalian and avian 
species, the species deltacoronavirus was discovered [8]. In February 2014, the Ohio 
Department of Agriculture officially documented the identification of PDCoV in the US. 
PDCoV causes severe, watery diarrhea, and vomiting appears within 48–72 h post 
infection [50]. Examples of coronavirus genus and species are shown in Table 2.1. 
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Table 2.1. Coronavirus taxonomy 
  
Genus Species Receptor 
Alpha-
coronavirus 
 
*Alphacoronavirus 1 comprising: Feline coronavirus 
serotype 2, Canine coronavirus serotype 2, 
Transmissible gastroenteritis virus (TGEV) 
*Human coronavirus 229E 
*Human coronavirus NL63 
*Porcine epidemic diarrhea virus PEDV 
*Rhinolophus bat coronavirus HKU2 
*Scotophilus bat coronavirus S12/05 
*Miniopetrus bat coronavirus 1 
*Miniopetrus bat coronavirus HKU 8 
Aminopeptidase 
N 
 
Aminopeptidase 
N 
Aminopeptidase 
N 
Aminopeptidase 
N 
ACE2 
Aminopeptidase 
N 
Beta-
coronavirus 
 
*Betacoronavirus 1 comprising: Bovine coronavirus 
(BCoV), Human coronavirus OC43 (HcoV-OC43), 
Equine coronavirus (ECoV), Human enteric 
coronavirus (HECoV), Porcine haemagglutinating 
encephalomyelitis virus(PHEV), Canine respiratory 
coronavirus (CCoV) 
*Murine coronavirus comprising: mouse hepatitis 
virus (MHV)\, Rat coronavirus, Puffinosis virus 
 *Human coronavirus HKU 9 *Rousettus bat 
coronavirus HKU 4 
*Tylonyeteris bat coronavirus HKU 5 
SARs coronavirus comprising: Human SARs 
coronavirus and Rhinolophus bat virus 
Neu 5,9 AC2 
 
 
 
Neu 5,9 AC2 
 
CEACAMI 
 
ACE2 
Gamma-
Coronavirus  
Avian coronavirus comprising: IBV and various 
coronavirus infecting turkey, goose, duck, pigeon 
and pheasant 
Beluga whale coronavirus SW1 
 
Delta-
Coronavirus 
Bulbul coronavirus HKU11, Thrush coronavirus 
HKU12, Munia coronavirus HKU 13 
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Porcine Epidemic Diarrhea Virus (PEDV) 
Evolution and Epidemiology  
Porcine epidemic diarrhea virus is the cause of an economically devastating swine 
disease.  The disease causes high mortality and morbidity in pigs, especially in young 
piglets. The causative agent belongs to the genus Alphacoronavirus in the family 
Coronaviridae, [51]. PEDV was initially identified in Europe in 1978 [25]. The virus was 
detected in Japan in 1982, spreading to several neighboring countries, including China, 
Korea, Thailand, Vietnam and Taiwan, in which the virus remains endemic to date 
[5,52,53]. 
Since 2010, highly virulent PEDV spread in China then appeared in the U.S. in 
2013, causing health concerns and significant economic loss, followed by spreading to 
Canada and Mexico [47,54,55]. PEDV is an enteropathogenic virus which targets the 
epithelia of the small intestine, leading to villous atrophy causing severe diarrhea, 
vomiting, and dehydration followed by high mortality rates (50-100%) in suckling piglets 
and weight loss secondary to diarrhea in older animals [2,3]. The virus replicates 
primarily in enterocytes of the small intestines leading to villous atrophy and 
malabsorptive diarrhea followed by electrolyte imbalance, metabolic acidosis and death. 
Characteristic clinical signs of PED include watery diarrhea, vomiting, anorexia, 
dehydration and death of piglets while in older pigs the disease is usually milder resulting 
in low mortality rates. Trypsin is required for the activation of virions to aid in the 
membrane fusion through it is role in cleaving the spike glycoprotein [56]. 
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PEDV genome organization and viral gene function 
The PEDV genome is a large (~28 Kb) enveloped, positive-sense, single stranded 
RNA virus which contains seven open reading frames (ORF1a, ORF1b, and ORF2-6). 
The genome is arranged into orderly 5′-UTRs (5′-untranslated regions), the polymerase 
gene, spike (S), open reading frame 3 gene (ORF3), envelope (E), membrane (M), 
nucleocapsid (N), and 3′-UTR. Subgenomic mRNAs of PEDV are transcribed from its 
genomic RNA, then translated producing viral proteins [27,57,58]. ORFs 1a and 1b 
encode large polyproteins (pp1a and pp1b). These large proteins are cleaved by viral 
encoded proteases into 16 non-structural proteins (nsp1-16) involved in basic 
mechanisms of viral RNA transcription and replication [6].  
Four structural proteins are encoded in ORFs2-6, including the spike (S,180–220 
kDa) glycoprotein, membrane (M, 27– 32 kDa) protein, envelope (E,7 kDa) protein, and 
the nucleocapsid (N, 55–58 kDa) protein, and one more accessory protein ORF3 [49,59]. 
The M and N proteins are conservative proteins that are often used for the development 
of serological and other diagnostic assays for PEDV [42,60]. 
Tropism 
The homogenous or heterogenous proteases activate the fusion process between 
the viral envelope and the cell membrane and facilitate the viral RNA genome release 
into the cytoplasma. Firstly, the replicase polyproteins 1a and 1ab are synthesized and 
then the viral proteases cleave it into 16 nsps, including nsp3 and nsp5. Secondly, the 
nsps participate in genome replication and synthesis of full-length negative-strand RNA 
at a low concentration, which acts as the template for full-length genomic RNA. Nested 
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genome is specific characteristic of coronaviruses and other Nidoviruses, with 
subgenomic mRNAs that an identical 3’ end terminal and 5’ leader sequence. Finally, 
mRNAs are translated to viral structural proteins and extra accessory proteins. After 
synthesis and posttranslational modification in the endoplasmic reticulum and Golgi 
compartment, mature structural proteins are then assembled with genomic RNA into 
virions. The virion is released outside the cell by exocytosis for the next generation 
infection [61]. 
PEDV evades the innate immune response as it does not evoke a vigorous IFN 
response. PEDV infection interferes with the activation of interferon regulatory factor 3 
that leads to blocking of the synthetic dsRNA-induced IFN-β. PEDV replicase encoded 
papain-like protease 2 is an IFN antagonist which depends on the catalytic activity for its 
function. PEDV Papain-like protease 2 inhibits RIG-I- and STING-activated IFN 
expression (the key components of the signaling pathway for IFN expression) through a 
co-immunoprecipitation and deubiquitination process which interferes with the RIG-I- 
and STING-mediated signaling pathway. PEDV infection represses the production of 
IFN-β [62]. 
PEDV receptor binding and cell entry are essential steps in the cycle of viral 
infection and critical determinants of viral host range and tropism which makes these 
processes important targets for antiviral discovery. The envelope-anchored spike protein 
initiates the virus entry into the cells. The spike ectodomain contains a receptor-binding 
subunit, S1, and a membrane fusion subunit, S2. The S1 subunit consists of two domains, 
an N-terminal domain and a C-terminal domain, which work as receptor-binding 
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domains. The ability of coronavirus receptor-binding domains to recognize the receptor 
determines the host range and tropism of coronaviruses [63]. 
PEDV uses porcine aminopeptidase N as its receptor. Addressing whether it uses 
sugar co-receptors is critical for developing effective vaccines and antiviral drugs to 
control PEDV. The S1-N-terminal domain and C-terminal domain (NTD-CTD) fragment 
might serve as a subunit vaccine candidate. Monoclonal antibodies against S1-NTD-CTD 
may serve as immunotherapeutic agents to block PEDV attachment to both the 
aminopeptidase N receptor and the sugar co-receptor. In addition, sugar or sugar 
analogues may serve as antiviral drugs to block PEDV attachment to its sugar co-
receptor. The development of these antiviral strategies is important because of the 
damaging impact that PEDV exerts on the U.S. pork industry [64]. 
The trimetric spike proteins characterize the virion envelope and initiate the 
receptor binding and membrane fusion. Due to the molecular features, this S protein has 
been known as a class I fusion protein that has a locked conformation generation to 
inhibit the premature triggering of the fusion mechanism then prepared for the proteolytic 
process called priming. This results in a cleavage of S protein producing two functional 
protein domains, a soluble head domain that is responsible for receptor binding and a 
membrane bound subunit for the fusion process. A characteristic feature of the cleaved, 
fusion-ready subunit is an N-terminal fusion peptide. Proteolytic priming can occur in the 
extracellular environment, virus-producing cell or after contact of the virus with the 
target cell membrane. Priming of the PEDV S protein is generated by intestinal digestive 
enzymes [42]. 
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Pathogenesis and host responses to infection 
PEDV infects all pigs of different ages, but suckling pigs are the most severely 
affected. After fecal-oral transmission, PEDV replicates in intestinal enterocytes that 
express large amounts of the porcine aminopeptidase N receptor that is considered to be a 
receptor for PEDV. The PEDV S protein facilitates the binding process to the receptor 
which then cleaves into subunits S1 and S2, leading to a conformational change in the 
receptor and internalization of the virus by the cell [59]. 
Replication of PEDV in enterocytes leads to cell lysis, causing villous atrophy 
and subsequent destruction of the brush border. PEDV cell receptors play a critical role in 
digestion and nutrient absorption, so destruction caused by PEDV infection leads to 
malabsorption and severe, acute watery diarrhea within one week leading to higher viral 
shedding in infected pigs. Replicating virus is then shed in the feces where it is spread to 
other animals. Despite its ability to cause disease in swine of all ages, PEDV has notably 
higher mortality rates in suckling piglets. Physiological factors associated with the age of 
the pigs may play important roles, specifically the slower rate of enterocyte regeneration 
in young pigs. Although mortality is rare in older animals, there is still considerate 
morbidity associated with PEDV infection [65,66]. 
The PEDV incubation period varies according to the age of the pigs, for instance, 
it can be one day in 1-day old nursing piglets or 3-6 days in 3-week old weaned piglets. 
The characteristic clinical signs of PED are diarrhea and vomiting which can persist for 
5-10 days. Fecal shedding of PEDV often starts 1-3 days’ post infection (pi) and can be 
detected in feces for up to 24-30 days’ pi [47,65,67,68]. 
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The early detection of PEDV specific antibodies in serum varies between days 6 
and 14 pi [60]. Clearly, the antibody responses detected were against PEDV N and S 
proteins, which are considered the two major structural proteins of the virus. Neutralizing 
PEDV antibodies are first detected between days 7 and 14 pi, peaking on day 21 pi and 
persisting for at least 6 months’ pi [69]. 
PEDV Diagnostics  
After the first appearance of PEDV in the U.S in 2013. Several molecular 
biological and immunological techniques have been developed to diagnose PEDV. 
Highly specific virological and serological methods have been developed including real-
time and conventional PCR, enzyme-linked immunosorbent assays (ELISA), 
immunofluorescence assays (IFA), immunohistochemistry, 3’ isothermal amplification 
assays, and electron microscopy (EM) [70]. 
In April 2013, the Iowa State University Veterinary Diagnostic Laboratory was 
not able to differentiate between PEDV and TGEV in the initial case because of clinical 
symptoms that are consistent with TGEV.  Consequently, tissue samples from small 
intestines were collected and stained with hematoxylin and eosin for microscopic 
examination. The examination showed severe atrophy of villi in all segments of the small 
intestines and villus-epithelial syncytial cells. Negative-staining EM revealed presence of 
coronavirus-like particles in the feces and intestinal contents but PCR testing for TGEV 
was negative. A pan-CoV RT PCR was done and suggested a positive amplification of 
the S gene and the N gene of PEDV, which by sequence comparison showed high 
identity to known PEDV strains but negative of TGEV and PRCV [47]. 
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Virus isolation:  Vero cells are the most widely used cell line for isolation and 
propagation of PEDV. Replication in cell culture induces typical cytopathic effect (CPE) 
that is characterized by cell fusion, syncytia formation and eventually cell detachment 
[4,63,71]. One of the important requirements for PEDV replication in cell culture is the 
presence of exogenous trypsin in the cell culture medium. The proteolytic activity of 
trypsin triggers the cleavage of the S glycoprotein into the S1 and S2 subunits, leading to 
virus-to-cell and cell-to-cell fusion and increased virus infectivity and release from 
infected cells [42]. 
Direct and Indirect Immunofluorescence assay:  The direct FA has been used 
to confirm virus isolation and to detect PEDV antigens (antibody-antigen reaction) in cell 
culture [63,71]. The direct FA is to detect intracellular viral antigens using fluorophore-
conjugated PEDV-specific antibodies which can be visualized under a fluorescent 
microscope. The direct FA showed value to detect virus antigens in infected intestinal 
enterocytes in formalin fixed tissues [4,72,73]. Using the direct FA assay, the viral 
antigens can be detected in intestinal samples for up to 72 h after the onset of clinical 
signs [72,73,74]. 
The IFA is a serological assay and utilizes PEDV infected Vero cell cultures as 
antigen to detect PEDV specific antibodies found in serum samples of pigs suspected to 
be infected. If the sample is positive, the PEDV specific antibodies bind to the antigens 
and then these antibodies can be detected with fluorophore-labeled anti-porcine 
secondary antibodies and visualized with a fluorescence microscope [66]. The IFA assay 
is specific, less time consuming than other assays detecting antibody and easier to 
perform [5]. Moreover, IFA can be used for qualitative or quantitative evaluation of 
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PEDV-specific antibodies in serum. The titers of antibodies can be determined by 
incubation of serial two-fold dilutions of serum with PEDV infected Vero cells. The 
antibody titer is the reciprocal of the highest dilution of serum in which specific 
fluorescent signal is detected. Antibody can be detected from 7 to 14 days’ post-exposure 
by IFA and detected for at least 43 days’ pi after which the antibody titer starts to decline 
[75]. 
Polymerase chain reaction-based assays for detection of PEDV nucleic acid:  
PCR is a method in which an in vitro amplification of specific nucleic acid sequences can 
be done. The PCR rapidly and specifically produces more than a million copies of a 
target nucleic acid sequence through a simple three-step cycling process. The specificity 
of the assay depends mainly on the primers (oligonucleotides with ~18-24 nt in length). 
These primers are complementary and capable of hybridizing with opposite strands of the 
target region to be amplified [76].  
It is important to be able to differentiate PEDV from other related swine 
coronaviruses including TGEV and PDCoV when we design primers for PCR [63]. The 
structural proteins of the PEDV; N, M or S, have been used as diagnostic targets but 
consideration of their genetic variability is important [77,78]. For instance, the spike gene 
is the most variable and several strains all over the world are characterized by deletions in 
their spike gene so this may not represent a good diagnostic target [79]. 
PCR shows good sensitivity for the detection of the PEDV genome in feces, 
swabs, intestinal or rectal samples from infected pigs [65,71]. Also, oral fluid has been 
used in an RT-PCR based test [80].  In comparison to IFA and other diagnostic assays, 
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PCR is a more sensitive, specific and rapid method to detect viral nucleic acid, although 
it may be positive when no infectious virus is present in the clinical sample. 
Conventional RT-PCR:  Briefly, the conventional RT-PCR amplifies a target 
nucleic region of the PEDV genome using virus specific primers in RT-PCR reactions, 
followed by electrophoresis and visualization of amplicons in agarose gels [81,82,83]. 
Recently, multiplex RT-PCR assays have been developed for detection and 
differentiation of several porcine enteric viruses, including PEDV, TGEV and porcine 
rotaviruses [84,85,86,87]. 
Real-time reverse transcriptase PCR (rRT-PCR):  The detection of amplicons 
in rRT-PCR depends on two different methods; the first utilizes a nonspecific fluorescent 
probe that interacts with PEDV double stranded DNA, and the second depends on 
sequence-specific oligonucleotide probes that are labelled by a fluorescent reporter that 
hybridizes with the target sequence. The amount of fluorescent emission by the probe 
during the extension of the target sequence can be detected in real time by a 
thermocycler. The sequence-specific probe based rRT-PCR proves to be the best and 
most specific diagnostic molecular technique [88]. 
A multiplex rRT-PCR assay has been developed for detection of PEDV, TGEV, 
Group A rotaviruses, and porcine circovirus. This test serves as a rapid identification and 
differentiation between different strains of PEDV [89], and also with other enteric viral 
pathogens of swine, including the closely related coronaviruses, TGEV and PDCoV 
[89,90].  At the South Dakota State University Animal Disease Research and Diagnostic 
Laboratory, a multiplex rRT-PCR assay for simultaneous detection of PEDV, PDCoV 
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and TGEV has been used routinely since July 2014. Since then, more than 50,000 
samples from more than 25 US states have been tested (Clement, T., personal 
communication). 
There are two rRT-PCR assays developed recently targeting the N and the S gene 
of PEDV. The detection limit of these rRT-PCRs were 10-6 and 10-5 for the N and S 
assays, corresponding to a virus suspension containing ~10-2.2 and ~10-0.2 TCID50/mL of 
PEDV, respectively. The S assay performed better than the N-based assay [78]. 
Virus neutralization assays:  Virus neutralization (VN) is the reduction of the 
viral infectivity mediated by antibodies, specifically neutralizing antibodies. The basics 
of the test are the binding of the antibodies to the virions, so if the sample is positive, the 
antibodies will either block the entry of the virus, prevent binding to the receptors, or 
restrict the uncoating cycle [91]. Originally, the test depended on the ability to read 
reduction of CPE when neutralizing antibody was present [92]. A difficulty arises when 
trying to determine CPE on cells infected with PEDV due to importance of adding trypsin 
to the PEDV culture media in order for the virus to grow. It is difficult to differentiate 
between the cell rounding and detachment that occurs because of virus infection or the 
effect trypsin has on cell monolayers. Recently, a modification of the VN test was 
developed called a fluorescent focus neutralization (FFN) for rapid PEDV neutralizing 
antibody detection [60,66]. The PEDV infectivity is assessed by using an anti-PEDV 
fluorophore-conjugated antibody and the neutralizing antibody titers are determined as 
the reciprocal of the highest serum dilution resulting in 90% or greater reduction in 
fluorescent foci relative to negative control samples [60]. The neutralizing antibodies 
have been detected by 7-14 days’ pi in experimentally infected animals and can be 
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detected for at least 6 months post natural PEDV infection. The FFN assay has been 
optimized and validated for the detection and quantitation of PEDV neutralizing Abs in 
serum, colostrum and milk samples [69,75]. 
Antibody ELISAs:  Since 2013, after the first appearance of PEDV in U.S. swine 
farms, different PEDV diagnostic ELISAs have been developed. The PEDV indirect 
ELISA has been developed based on different antigens; for instance, whole virus 
preparation [66] or recombinant structural proteins expressed in bacteria, such as the N 
protein [60] and S protein [93,94,95,96]. The indirect ELISA immobilizes antigen on a 
solid phase and then is incubated with the test sample to allow the antibody-antigen 
complex formation. An enzyme-linked secondary antibody coupled with a colorimetric 
substrate detection system is used to develop the test [97]. 
PEDV blocking ELISAs or competitive ELISAs have been developed based on 
using PEDV-specific monoclonal or polyclonal antibodies [60,98]. In these assays, the 
labeled antibodies are added to the antigen coated microplates together with the test 
sample allowing competition between the antibodies present in the serum and labeled 
monoclonal antibodies for the antigen immobilized in the wells [97]. The reaction is also 
developed as for the indirect ELISA. The blocking ELISA is characterized by a greater 
specificity than the indirect ELISA [98].  
Fluorescent microsphere immunoassay:  The FMIA basically depends on a 
fluidic fluorescent microsphere laser scanning system. The FMIA has several advantages 
compared to the ELISA, including higher sample throughput, sensitivity, and the ability 
to multiplex or detect antibodies specific to multiple pathogens simultaneously [99].  The 
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FMIA can be done by coupling a specific viral antigen to fluorescent microspheres, then 
antigen-specific antibodies are detected using a biotin/streptavidin/fluorophore detection 
system. The results are expressed as median fluorescent intensity (MFI) in which a dual-
laser instrument (i.e. Bio-Plex 200, Bio-Rad) can detect the florescent emission of the 
antigen-antibody reactions. PEDV N-specific antibodies were developed and specifically 
able to detect the antibody level as early as 6 days’ pi with peak antibody levels detected 
on day 21 pi [60]. 
Immunohistochemistry:  Immunohistochemistry is a highly specific and 
sensitive test used for the detection of PEDV antigens in intestinal tissues [47,68]. The 
test involves immunological (antibody-antigen) and chemical (enzyme-substrate) 
reactions [100]. PEDV-specific antibodies, which can be polyclonal or monoclonal, are 
able to detect the viral antigen early, prior to the appearance of clinical signs. The assay 
allows the visualization of target cells and the antigen in the intestinal tissue during the 
course of infection starting one-day pi to 14 days’ pi. [68,101]. One more advantage of 
immunohistochemistry is that archived fixed samples can be tested. 
Isothermal amplification assays:  Loop-mediated isothermal amplification 
(LAMP) is a nucleic acid amplification method characterized by simple, specific and 
cost-effective techniques. It has been recently applied for infectious disease diagnosis, 
including disease due to PEDV [102,103,104]. In the assay, 4-6 primers are used to 
recognize six to eight regions of target DNA associated with the Bst DNA polymerase. 
This acts as a strand-displacement activity. The amplification step is performed under a 
single temperature (isothermal), leading to the synthesis of large amounts of nucleic acid 
[102,103]. The amplification reactions can be simply performed using inexpensive 
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equipment (i.e. water bath), without using thermocyclers [102,105]. Addition of a 
fluorescent dye in the reaction mix can be done and allows the assessment of the results 
by simple visual inspection [106]. 
Ren and Li [103] designed the RT-LAMP to amplify the N gene of PEDV with a 
detection limit lower than that of the RT-PCR. Recently a real-time RT-LAMP for the 
detection of PEDV has been developed, in which five sets of primers targeting the M 
gene of PEDV have been used followed by a detection of the amplified target sequence 
using a loop amp real-time turbid meter. The sensitivity and specificity of RT-LAMP-
based assays associated with the low cost and efficiency make this method an alternative 
for PEDV diagnosis [104]. 
Antigenic cross-reactivity among swine enteric coronaviruses 
Swine hyperimmune antisera against TGEV (Miller strain) cross-reacted with 
PEDV in the cell culture IFA, however swine antisera against PEDV did not cross-react 
with TGEV by the same test. This one-way antigenic cross-reactivity could be due to a 
single epitope on the N-terminal region of PEDV/TGEV [107]. Another study showed 
that the PEDV whole virus-based ELISA and S1 protein-based ELISAs did not cross-
react to swine antisera against PDCoV, PRCV, or TGEV Purdue strain [108]. 
Prevention and Vaccines  
Development of vaccines for enteric pathogens like PEDV are still considered a 
major challenge, especially because of the requirement for lactogenic immunity. The 
crudest strategies to prevent PEDV infection was the exposure of pregnant sows to live, 
infectious virus in which older animals are not susceptible to PEDV associated mortality 
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and will recover from the disease [70]. Subsequently, sows exposed to PEDV are able to 
transfer PEDV specific antibodies passively to their offspring in the colostrum. The 
maternal antibodies effectively protect the piglets from disease. Specific IgG and IgA are 
secreted in colostrum, with 60% being IgG. In addition, subsequent immunity to PEDV 
can be achieved by exposing animals to feces or minced intestines of infected animals 
[109]. Infecting healthy animals results in inconsistent immunity and has several negative 
implications, as well as the inherent dangers of its spread to other animals and farms.  
The proper sanitary and hygienic precautions to prevent spread of the highly infectious 
virus are considered the best strategies for preventing PEDV. 
Since PEDV emergence, initially in Europe, then Asia, the most current PEDV 
vaccines have been developed for different strains circulating in Asia [110]. In 1977, 
PEDV CV777 strain was used as a vaccine in either inactivated or attenuated forms in 
Europe. Attenuated vaccines were developed by multiple passages in cell culture, leading 
to significant mutation in the viral genome. The Korean KPEDV-1 strain and the 
Japanese P-5V strain were successfully attenuated by passaging the virus many times in 
Vero cells. Both vaccines are moderately effective producers of lactogenic immunity, and 
are capable of passive immunization of suckling piglets [111]. 
Porcine Deltacoronavirus 
Epidemiology 
Initially, porcine deltacoronavirus was first recognized in 2009 during a molecular 
surveillance study in pig samples collected in Hong Kong [8]. In February 2014, PDCoV 
emerged in U.S. swine and the virus rapidly spread in the U.S. [7,112,113]. Shortly after 
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the emergence of PDCoV in US, the virus was detected in the South Korean pig farms 
[114] followed by emergence in mainland China and Thailand [115,116]. 
Genomic Structure 
Like other coronaviruses, PDCoV is an enveloped, positive-sense, single-
stranded, RNA virus characterized by a genome of about 25 kb in length. The genomic 
organization is in the order of:  5 UTR, ORF1a/1b, S, E, M, nsp6, N, nsp7, and 3 UTR 
region. PDCoV protein functions are unknown. However, like other CoVs, the replicase 
polyproteins 1a (pp1a) and pp1ab are cleaved by virus-encoded proteases producing 15-
16 nsps involved in viral transcription and replication [22]. The spike glycoprotein of 
CoVs is the key protein for receptor binding, cell membrane fusion and entry; moreover, 
the S protein harbors the neutralizing epitopes.  
In the whole genome sequences, the S and the N gene sequences of PDCoV have 
been used for phylogenetic analysis [115,117]. The S, M and N protein genes of PDCoV 
also have been used for the development of virological and serological diagnostic assays 
[50,118,119]. 
Clinical signs and disease 
Similar to the other swine enteric pathogens like PEDV and TGEV, PDCoV 
clinical manifestations are diarrhea, vomiting, dehydration and mortality in neonatal 
piglets, but generally milder than PEDV infection [116,120]. The histopathological 
lesions presented are primarily atrophic enteritis [121]. Conventional and gnotobiotic 
piglets inoculated with PDCoV showed mild to severe diarrhea, gross and microscopic 
intestinal lesions in experimental infection studies [122].  
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Clinical studies were performed by inoculating 10 to 19 day-old gnotobiotic pigs 
with cell culture-adapted PDCoV isolates and/or PDCoV positive intestinal contents. The 
inoculated pigs showed diarrhea and vomiting from 24 -72 hr post inoculation and the 
diarrhea persisted for 72–120 hr pi. The viral RNA was detected in feces from 24 hr pi 
and lasted to 72–120 hr pi [50,65]. A second study in which 5-day-old conventional pigs 
were inoculated experimentally by 3*104 TCID of cell culture adapted PDCoV isolates 
showed diarrhea starting 5 days’ post inoculation and maintained to day 7 pi. The viral 
RNA shedding in feces lasted from 2-7 days’ pi [118]. In another study, inoculation of 
four 10-day-old conventional pigs were done orally using 5ml of virus containing 106 
PFU of PDCoV. The diarrhea occurred on 1 day pi and persisted for 7–10 days. All of the 
inoculated pigs recovered from disease by 10 day pi. The fecal viral RNA shedding was 
detected on 1–2 days’ pi, increased to the peak on 7 day pi, then gradually declined after 
10 day pi [50].  
Diagnosis of PDCoV  
PDCoV diagnostic samples:  Individual fecal swabs, pen-based oral fluids, and 
pen-based feces can be collected and used for PDCoV PCR and/or virus isolation (VI) 
assays. Due to the transient viremia caused by PDCoV infection and the low level of 
virus in the serum, serum is not the best choice for PCR or VI [118]. The small intestinal 
tissues, especially the jejunum and ileum, are considered good samples for PCR and VI 
during the acute infection from 1-10 days’ pi. The tissue samples should be collected 
fresh and placed in 10% buffered formalin for histology and immunohistochemistry 
examinations [50,65]. 
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Virological methods for PDCoV detection 
The virological methods for PDCoV include detection of virus particles using 
EM, detection of viral nucleic acid using different RT-PCRs and in situ hybridization, 
detection of viral antigen by immunofluorescence staining and immunohistochemistry, 
and detection of viable virus through the virus isolation and swine bioassay techniques.  
Virus Isolation: The National Veterinary Services Laboratories under USDA has 
isolated PDCoV USA/IL/2014 strain and Michigan/8977/2014 strain in a swine testicular 
cell line [50,118]. Hu et al. [123] reported successful isolation and propagation of 
PDCoV OHFD22 strain in the LLC-pig kidney 1 (PK1) cell line and the swine testicle 
(ST) cell line. PDCoV cytopathic effects (CPE) in LLC-PK1 and ST cells can be seen as 
enlarged, rounded, granular cells followed by cell detachment. In addition, PDCoV 
OHFD22 replicated in LLC-PK1 cells in the absence of trypsin with 10,000-fold less 
virus titer than with trypsin. Moreover, the addition of small intestinal contents from 
gnotobiotic pigs together with trypsin or pancreatin to the culture medium resulted in low 
PDCoV titer of 7 log10 PFU/ml compared to the trypsin only. Interestingly, trypsin did 
not support PDCoV OH-FD22 propagation in ST cells; but, PDCoV propagated 
efficiently in ST cells when 10% pig swine intestinal content or 1% pancreatin was added 
[123]. 
A high concentration of virus and the use of the fresh samples are the critical 
factors for success of VI in cell culture. PDCoV VI is not a reliable assay to determine 
whether infectious virus is present in a clinical specimen due to the low success rate of 
PDCoV VI in cell culture. 
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Electron microscopy: Electron microscopy is considered a first step in the 
diagnosis of many viruses. Although EM cannot identify viruses to the related species 
and is a less sensitive test that needs at least 105–6 virions per milliliter and a highly 
skilled microscopist, it allows direct examination and visualization of the virus particles. 
There are two EM techniques commonly used in diagnostic laboratories: negative-stain 
EM that detects virus particles in a fluid matrix, and ultrathin-section EM for detection of 
virus particles in fixed tissues or cells. The PDCoV characteristic morphology and size of 
virus particles seen under EM identify it as coronavirus-like particles.  
Polymerase chain reaction-based assays: RT-PCR is the in vitro amplification 
of specific nucleic acid sequences to produce a billion copies of target sequences by 35–
40 cycles of three-step process denaturation, annealing, and extension within a few hours. 
A number of specimen types such as feces, intestinal tissue, rectal swabs, contents, oral 
fluid, environmental samples, and feed can be tested for presence of PDCoV RNA by 
RT-PCR. Magnetic bead-based reagents and automated extraction on different magnetic 
particle processors like Qiagen BioSprint, Thermo KingFisher, and Life Technologies 
MagMAX Express have been used for high throughput nucleic acid extraction with 
optimization required based on specimen types.  
Pan-coronavirus RT-PCR: A pan-coronavirus one step RT-PCR targeting a 
conserved region of about 251 bp of the CoV polymerase gene has been developed to 
confirm the identity as coronaviruses [124]. Using electron microscopy together with 
pan-coronavirus RT-PCR followed by genetic sequencing were critical keys in 
identifying PEDV and PDCoV during the early stage infection in the United States. Pan-
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coronavirus RT-PCR is not PEDV- or PDCoV-specific and that makes the test not 
suitable for routine PDCoV diagnostic testing [47,120]. 
Standard PDCoV-specific RT-PCR: Conventional or gel-based one-step RT-
PCR or nested RT-PCR assays have been developed for the specific detection of PDCoV 
[7,116]. They target a conserved region of PDCoV M or N genes for PCR amplification, 
electrophoresis on agarose gels and then visualization of amplicons under UV light. The 
nested RT-PCR is at higher risk of contamination due to the two steps of reaction set up, 
which explains why the test has not been widely used. 
Real-time RT-PCR for PDCoV detection: The real-time RT-PCR remains the 
method of choice for PDCoV detection and is commonly used by veterinary diagnostic 
laboratories. A variety of probe-based real-time RT-PCR assays have been developed for 
the specific detection of PDCoV [118,125,126]. These assays target the conserved 
regions of PDCoV M or N genes with the limit of detection of 2 viral RNA copies and 
LOD of 0.056 TCID50 per reaction. Zhang et al. [126] developed a duplex real-time 
PEDV/PDCoV RT-PCR targeting M genes for simultaneous detection and differentiation 
between the two viruses. The limit of detection of this duplex rRT-PCR is 7 RNA copies 
per reaction for PEDV and 14 RNA copies per reaction for PDCoV. 
Reverse transcription-insulated isothermal PCR: Recently, a point-of-need 
PCR detection platform accompanied by the insulated isothermal PCR technology and a 
field-deployable device (POCKITTM Nucleic Acid Analyzer) has been developed and 
validated for diagnostic testing and automatic detection in which the interpretation of 
PCR results can be done within one hour [126,127]. This assay has a limit of detection of 
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9 RNA copies per reaction for PDCoV and is considered a potentially useful tool for on-
site detection. 
Immunofluorescence staining: Immunofluorescence staining is a method for 
viral antigen detection using virus-specific monoclonal or polyclonal antibodies. These 
antibodies are either fluorophore-conjugated which is used directly, or unconjugated in 
which a fluorophore-conjugated secondary antibody is needed. The immunofluorescence 
staining is a viable test conducted on PDCoV-infected cell culture for confirmation of 
virus isolation [123], or performed on cryosections of tissues for determining the location 
of viral antigen in tissues [65]. The visualization of the viral antigens requires using a 
fluorescent microscope. 
Immunohistochemistry: Immunohistochemistry is a method to detect viral 
antigen in formalin fixed paraffin-embedded tissues labeled by virus-specific monoclonal 
or polyclonal antibodies followed by development of the reaction using an enzyme-linked 
secondary antibody and chemical substrate; the results can be visualized under a light 
microscope [50,118]. M peptide-specific rabbit antiserum or polyclonal antiserum against 
PDCoV generated in pigs has been used for PDCoV immunofluorescence staining and 
immunohistochemistry [50,65,123]. PDCoV N protein-specific monoclonal antibody has 
been recently developed by South Dakota State University and is available commercially 
through Medgene Labs. 
In situ hybridization: In situ hybridization is a technique in which the viral 
nucleic acid present in fixed tissues can be detected using a labeled complementary DNA, 
RNA or modified nucleic acid strand (e.g. probe). In contrast to PCR, in situ 
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hybridization detects viral nucleic acids that are not going through an amplification 
process [65]. 
Serological methods for PDCoV detection 
Indirect fluorescent antibody assay: The IFA assay primarily requires PDCoV-
infected ST or LLCPK1 cell plates which are then fixed at the appropriate time points. 
Double-fold serial dilutions of the tested serum samples are added to the plates to bind to 
the virus antigen followed by adding a fluorophore-conjugated anti-swine secondary 
antibody, then visualization under a fluorescence microscope. IFA can be used in a 
qualitative manner or in a quantitative manner for detection of PDCoV antibody. 
Antibody isotyping can be determined using different types of secondary antibody; 
however, commonly it has been used to determine IgG antibody. The IFA is not 
automated and is subjective with respect to result reading and reporting. To date, the 
dynamics of PDCoV IFA antibody has not been well defined and correlations of PDCoV 
IFA antibody to other serological assays are not determined [50]. 
Virus neutralization assays: In the VN assay, heat-inactivated serum samples 
are serially twofold diluted and incubated with a fixed amount of PDCoV (between 100–
200 TCID50) at 37 ◦C for 1–2 h., then the virus-serum mixture is added to a confluent 
monolayer of ST or LLC-PK1 cells and incubated at 37 ◦C. The endpoint determination 
of neutralizing antibody can be based on either conventional methods using viral CPE 
development or based on fluorescence staining called an FFN assay. The conventional 
CPE-based VN test needs enough time to allow a viral CPE which has fully developed in 
the virus control wells which may take 3-4 days. However, the serum cytotoxicity can be 
35 
 
 
 
 
mistaken as viral CPE. For the FFN assay, the confluent cell monolayer plates inoculated 
with virus-serial diluted serum mixture are incubated for 24–48 h and then stained with a 
FITC-conjugated monoclonal antibody against PDCoV N protein (Medgene Labs). 
Results are read as the reciprocal of the highest serum dilution resulting in >90% 
reduction of fluorescent staining compared to the negative serum control [60,66]. The 
assays are labor intensive and need manual reading and interpretation of the results. It 
also detects neutralizing antibody activities with no determination the antibody isotypes. 
To date, there have been no publications describing dynamics of PDCoV VN antibody 
production and duration.  
Enzyme linked immunosorbent assays: Subsequent to the first occurrence of 
PDCoV in the United States, different indirect ELISAs have been developed for the 
detection of PDCoV antibodies. These type of ELISAs include a eukaryotic expressed 
PDCoV S1 protein-based ELISA which was validated using 210 field serum samples. 
The test showed a diagnostic sensitivity of 90.6% and a diagnostic specificity of 94.8% 
depending on the clinical exposure history and PDCoV PCR testing on fecal samples to 
reflect the true PDCoV serological status [119].  
Another PDCoV N protein-based ELISA expressed in a prokaryotic system was 
validated using 62 serum samples and revealed high a sensitivity of 100% and a 
specificity of 90.4% when compared to the Western blot results on the same 62 serum 
samples [128]. 
Moreover, the PDCoV whole virus-based ELISA was validated using a few 
immune sera originated from gnotobiotic pigs that were immunized intramuscularly twice 
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with inactivated PDCoV. The diagnostic sensitivity and specificity were not provided in 
the paper [122]. The optical density (OD) of ELISA is measured using an ELISA plate 
reader and the sample to-positive (S/P) ratios are then calculated. The ELISA is 
considered a high throughput assay and is more suitable for testing a large number of 
samples. In addition, the ELISA has the ability to measure antibody isotypes (e.g. IgG, 
IgA, and IgM) in various specimen types [94].  
Fluorescent microsphere immunoassay: The FMIA is a microsphere bead 
(magnetic or non-magnetic)-based fluidic assay that showed a high sensitivity and 
specificity result for serologic testing of animal infectious diseases [99,129,130]. Up to 
100 color-coded fluorescent microspheres bead sets are used in which each bead set can 
be conjugated to individual antigens for the detection of antibodies in biological samples. 
The variation of the beads allows simultaneous detection of antibodies to multiple 
pathogens found in a single sample. A FMIA based on PDCoV N protein has recently 
been developed for the detection of PDCoV antibody in serum samples [129]. 
Antigenic cross-reactivity among swine enteric coronaviruses 
The antigenic relationships between PDCoV, PEDV and TGEV are considered a 
concern and motivate developing specific immunoassays for each virus. It has been 
shown that although the similar conserved N protein among PEDV and PDCoV, the 
swine PDCoV antisera was not able to neutralize PEDV and the pig PEDV antisera did 
not cross-neutralize PDCoV either [122]. Moreover, the PDCoV serological tests 
including IFA, S1 protein-based ELISA, and N protein-based ELISA assays specifically 
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detected the antibodies against PDCoV with no cross-reaction to antisera against PEDV 
or TGEV [122,128]. 
Influenza D Virus 
Etiology and evolution  
Influenza D virus is an enveloped virus recently placed in the family 
Orthomyxoviridae. The main difference between ICV and IDV is the hemagglutinin-
esterase (HE) fusion protein. The difference between IDV and the other influenza viruses 
is the spike glycoproteins found on the surface of both IAV and IBV contain 
hemagglutinin (H) and neuraminidase (N) separately. The HE protein is the main factor 
and plays the major role in receptor recognition, viral fusion, and binding of the host 
receptor in IDV [131]. Moreover, ICV and IDV contain seven genomic segments, while 
IAV and IBV each contain eight [10]. 
Influenza viruses are characterized by formation of new antigenic progenies able 
to evade the host immune systems. Antigenic drift occurs through mutation and antigenic 
shift occurs through reassortment within recombination of viral genetic material in 
different strains among a genus. The influenza genome’s division into segments aids 
reassortment between strains especially in case of the concurrent infection with more than 
one virus strain [132]. 
IBV and ICV diverged from IAV, in which ICV as a genus is suggested to have 
evolved before the split between IAV and IBV. A recent study of IBV and ICV 
reassortants with IAV show that they are unable to produce viable progeny due to the 
genomic RNA sequence variation [133].  
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The matrix (M1) protein and nucleoprotein (NP) share only a 20–30% homology 
and are the antigens used to distinguish between the influenza viruses. The novel IDV 
shares only 50% amino acid homology with human ICV, similar to the level of 
divergence between IVA and IVB [10]. Analysis of the most conserved influenza viral 
protein, the polymerase protein (PB1), revealed that this new virus is more closely related 
to ICV than to IAV or IBV. The PB1 segments of ICV and IDV share a 72% identity, 
while the segment containing HE has diverged to 53% [12]. 
In vitro reassortment and serological studies indicate that the virus is antigenically 
distinct from human ICV and unable to produce viable reassortants. However, an isolate 
of IDV from swine and another from bovine were found to frequently reassort with each 
other [134]. 
Survival and inactivation 
Influenza viruses are susceptible to pH extremes, heat, dryness, and are unstable 
in the environment (Kapoor et al., 2014). The ideal temperature for IDV replication is 
33˚C and the variation in the HE protein is responsible for virus-cell fusion at various 
temperatures [11]. 
Influenza viruses can be inactivated by sunlight, disinfectants, and detergents. 
Also glutaraldehyde, formaldehyde, beta propiolactone, and binary ethylenimine in the 
presence of organic matter can inactivate the viruses. Without organic matter, destruction 
of the virus can be achieved with phenolics, 5.25% sodium hypochlorite, quaternary 
ammonium compounds, 4% sodium carbonate dilute acids, 2% sodium hydroxide and 
hydroxylamine [135]. 
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Zoonotic potential 
According to the serological studies carried out in Japan and China, the ICV 
infect pigs with the probability of interspecies transmission of ICV between pigs and 
humans. Human ICV isolates were able to replicate in experimentally infected pigs but 
the role of pigs as a potential animal reservoir host for human ICV has not been proven. 
[136]. Little is currently known about the epidemiology of IDV, but it is monitored as a 
potential zoonotic pathogen. It has been transmitted by contact and can cause clinical 
disease in ferrets, the preferred animal model for human influenza studies [137]. 
In Florida’s cattle industry, cow-calf operations pose a greater risk of IDV 
transmission to humans than operations housing adolescent and adult cattle. Whereas it is 
still unknown whether IDV causes disease in humans, IDV is a zoonotic risk and is 
considered an emerging pathogen among cattle-exposed workers because of the high 
seroprevalence (94–97%) among the bovine population [138]. 
Transmission  
In both humans and animals, the major route of influenza transmission is through 
nasopharyngeal exposure by direct contact. Also, it can be transmitted through direct and 
indirect contact with contaminated surfaces and aerosol transmission. In pigs, influenza 
viruses replicate in the upper and lower respiratory tracts. The infection is maintained by 
recurrent infections among populations [21].  
Intensive farming practices and close contact can facilitate the spread of the IDV. 
There is no evidence of IDV being spread through consumption of meat from infected 
animals. IDV can spread among the herd in few days and may be spread to adjacent 
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farms through wild boars or other wild animals. The infection can be maintained for 25 
days’ pi [20].  
Diagnosis   
Serological surveys revealed that cattle are considered the species with the highest 
seroprevalence and the highest antibody titers for IDV [11]. It has been experimentally 
shown that IDV can also infect guinea pigs and ferrets, replicating in their respiratory 
tract [139]. The antibodies specific for IDV have been detected in sera of small ruminants 
in North America [140]. In spite of the apparent generally low seroprevalence in humans 
[10], a recent study has demonstrated that 94–97% of cattle-exposed workers in some 
states have specific antibodies against IDV, confirming the concerns of a possible 
zoonotic risk [13,138].  
PB1 is one of the most, if not the most, conserved region of IDV genome, based 
on phylogenetic analysis of 14 PB1 sequences of IDV from GenBank (GenBank 
accession numbers: JQ922306, KM392469, KM392476, KM392483, KM392490, 
KM392497, KM392504, KF425653, KF425660, KF425667, KM015492, KM015499, 
KM015506, LN559121) [12,16]. A recent real-time PCR, specific for IDV was 
developed in which target sequences of primers and probe are the PB1. The investigators 
used in silico by BLAST, and in vitro with a wide panel of common swine and bovine 
respiratory pathogens to confirm the specificity of the method. The sensitivity of the RT 
PCR was determined using synthetic RNA molecules with a limit of detection that was 
about 20 copies/µL [141]. 
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Samples: Influenza viruses replicate in the epithelial cells of the upper and lower 
respiratory tract, so the infectious virus can be isolated from nasal mucosa, trachea, 
ethmoid, tonsils, lungs, bronchoalveolar lavage, oropharyngeal swabs and regional lymph 
nodes [21]. Lung tissue and nasal swabs have successfully been used for real time RT-
PCR in detection of IDV [10].  
Primarily, clinical diagnosis of influenza has been achieved by virus isolation but 
potentially low viral loads may require more sensitive methods [132]. Virus isolation has 
been successfully achieved by inoculation of 8-10 day old embryonated chicken eggs 
[142,143,144]. The propagation of the virus can be done using Madin-Darby canine 
kidney (MDCK) and the supplementation of MDCK cells with high concentrations of 
trypsin increases their susceptibility to IDV infection [145,146]. Human hepatocarcinoma 
cell (HuH7), [147] and human malignant melanoma (HMV-II) cells have been used for 
creating and obtaining in vitro reassortant viruses [148] in addition to African green 
monkey kidney (Vero) cells and human embryonic kidney (293T) cells [131]. Moreover, 
IDV can be readily isolated and cultured in ST cells [10].  
Hemagglutination inhibition:  Hemagglutination inhibition (HI) assays are the 
major assay used to identify unknown influenza viruses by their antigenic cross-reactivity 
and sort isolates into antigenic groups [10]. Antigenic variation among ICV isolates can 
be evaluated with anti-HE monoclonal antibodies [149,150,151]. ICV causes 
agglutination in chicken and turkey erythrocytes, but not in guinea pig erythrocytes [148]. 
Conventional reverse transcription polymerase chain reaction:  RT-PCR can 
be used for detection of viral RNA in infected supernatants [134]. The test has also been 
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used in detection of IVA, IVB [152] and ICV [153] as well as the recent IDV [12,16]. 
Multiplex PCRs have been one of the assays used for detection of human ICV, 
rhinovirus, and coronavirus [147]. Another multiplex PCR has been developed for 
simultaneous detection of IVA, IVB, ICV, adenovirus, and both A and B respiratory 
syncytial viruses [154]. 
Electron microscopy: Electron microscopy can identify orthomyxoviruses in cell 
cultures while enzymatic assays can detect a particular genus of influenza. With these 
methods, RT-PCR is typically used for definitive diagnosis [10].  
Antibody detection serological assays: Antibody based assays are valuable 
diagnostic tools for the differentiation of newly identified influenza viruses [11]. Some 
enzyme-linked immunosorbent assays (ELISA) detecting the antibodies against ICV 
virion proteins have been described [155]. There is a good correlation between the HI test 
and SVN test [156]. Although the sensitivity of ELISA is similar or slightly higher than 
HI, a positive result in both assays is sufficient confirmation of infection and the results 
can also be confirmed by Western blotting [157]. 
Prevention and Control  
Cattle farm workers, veterinarians, and meat processing workers with increased 
exposure to bovine, swine and poultry and represent a high risk for potential zoonotic 
influenza infection and viral reassortment (Lade et al., 2011). So utilizing personal 
protective equipment when in close contact (at least within six feet) with infected animals 
can help to decrease the risk of infection [158]. Biosecurity and appropriate disinfection 
protocols between animal groups or farms can limit spread of this virus.  
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Vaccines:  Seasonal human vaccines are available in the United States for both IVA 
and IVB. There are inactivated trivalent and quadrivalent vaccines, recombinant trivalent 
vaccines, and live-attenuated quadrivalent vaccines; administered through intramuscular 
injection, intradermal injection, or nasal spray. There are no bovine or licensed modified 
live swine vaccines are currently available [132]. Up to this date, antibody cross-
reactivity has not observed between ICV and IDV isolates [12]. 
The immune response to influenza in animals includes cell mediated immunity 
and the production of antibodies [21]. The response can vary according to the inoculated 
strains of the virus [159]. Immunity against the specific strain causing the infection may 
last several years based on previous human studies, suggesting that the infection does not 
induce sufficient protective immunity in all individuals [160]. 
 
  
44 
 
 
 
 
References for Chapters 1 and 2 
1. Holmes, KV. 2001. Coronaviruses. In: Knipe DM, Howley PM, Griffin DE. eds. Fields 
Virology. Lippincott Williams & Wilkins, Philadelphia, pp. 1187-1197. 
 
2. Alvarez J, Sarradell J, Morrison R, Perez A. 2015. Impact of porcine epidemic diarrhea 
on performance of growing pigs. PLoS One 10, e0120532. 
doi:10.1371/journal.pone.0120532 
 
3. Annamalai T, Saif LJ, Lu Z, Jung K. 2015. Age-dependent variation in innate immune 
responses to porcine epidemic diarrhea virus infection in suckling versus weaned 
pigs. Vet. Immunol. Immunopathol. 168:193–202. 
doi:10.1016/j.vetimm.2015.09.006 
 
4. Jung K, Saif LJ. 2015. Porcine epidemic diarrhea virus infection: Etiology, 
epidemiology, pathogenesis and immunoprophylaxis. Vet. J. 204(2):134-143. 
 
5. Lee C. 2015. Porcine epidemic diarrhea virus: An emerging and re-emerging epizootic 
swine virus. Virol. J. 12:193. doi:10.1186/s12985-015-0421-2 
 
6. Song D, Park B. 2012. Porcine epidemic diarrhoea virus: a comprehensive review of 
molecular epidemiology, diagnosis, and vaccines. Virus Genes 44(2):167-175.  
 
7. Wang L, Byrum B, Zhang Y. 2014a. Detection and genetic characterization of 
deltacoronavirus in pigs, Ohio, USA, 2014. Emerg. Infect. Dis. 20:1227–30. 
doi:10.3201/eid2007.140296 
 
8. Woo PC, Lau SK, Lam CS, Lau CC, Tsang AK, Lau JH, Bai R, Teng JL, Tsang CC, 
Wang M, Zheng BJ, Chan KH, Yuen KY. 2012. Discovery of seven novel 
Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat 
coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian 
coronaviruses as the gene source of gammacoronavirus and deltacoronavirus. J. 
Virol. 86 (7):3995–4008. 
 
9. Vitosh-Sillman S, Loy JD, Brodersen BW, Kelling CL, Doster AR, Topliff CL, Nelson 
EA, Bai J, Schirtzinger E, Poulsen E, Meadors B, Anderson J, Hause B, Anderson 
G, Hesse R. 2016.  Experimental infection of conventional nursing pigs and their 
dams with Porcine deltacoronavirus. Papers in Veterinary and Biomedical Science. 
Paper 232 
 
10. Hause BM, Ducatez M, Collin EA, Ran Z, Liu R, Sheng Z, Armien A, Kaplan B, 
Chakravarty S, Hoppe AD, Webby RJ, Simonson RR, Li F. 2013. Isolation of a 
novel swine influenza virus from Oklahoma in 2011 which is distantly related to 
human influenza C viruses. Plos Pathog. 9(2):e1003176. doi:10.1371/journal.ppat 
1003176. 
 
11. Hause BM, Collin EA, Liu R, Huang B, Sheng Z, Lu W, Wang D, Nelson EA, Li F. 
45 
 
 
 
 
2014. Characterization of a novel influenza virus in cattle and swine: Proposal for a 
new genus in the Orthomyxoviridae family. mBio 5(2):e00031-14. 
doi:10.1128/mBio.00031-14 
 
12. Collin EA, Sheng Z, Lang Y, Ma W, Hause BM, Li F. 2015. Cocirculation of two 
distinct genetic and antigenic lineages of proposed influenza D virus in cattle. J. 
Virol. 89(2):1036-1042. 
 
13. Ferguson L, Eckard L, Epperson WB, Long L, Smith D, Huston C, Genova S, Webby 
R, Wan X. 2015. Influenza D virus infection in Mississippi beef cattle. Virology 
486:28–34. 
 
14. Ng TF, Kondov NO, Deng X, Van Eenennaam A, Neibergs HL, Delwart E. 2015. A 
metagenomics and case-control study to identify viruses associated with bovine 
respiratory disease. J. Virol. 89:5340–5349. 
 
15. Jiang WM, Wang SC, Peng C, Yu JM, Zhuang QY, Hou GY, Liu S, Li JP, Chen JM. 
2014. Identification of a potential novel type of influenza virus in bovine in China. 
Virus Genes 49:493–496. http://dx.doi.org/10.1007/ s11262-014-1107-3 
 
16. Ducatez MF, Pelletier C, Meyer G. 2015. Influenza D virus in cattle, France, 2011–
2014. Emerg Infect Dis. 21:368–71.  
 
17. Chiapponi C, Faccini S, De Mattia A, Baioni L, Barbieri I, Rosignoli C, Foni E. 2016. 
Detection of Influenza D Virus among Swine and Cattle, Italy. Emerging Infectious 
Diseases 22(2):352–354. doi.org/10.3201/eid2202.151439 
 
18. Mitra N, Cernicchiaro N, Torres S, Li F, Hause B. 2016. Metagenomic 
characterization of the virome associated with bovine respiratory disease in feedlot 
cattle identified novel viruses and suggests an etiologic role for influenza D virus J. 
Gen. Virol. 97(8):1771-1784. doi:10.1099/jgv.0.000492 
 
19. Murakami S, Endo M, Kobayashi T, Takenaka-Uema A, Chambers JK, Uchida K, 
Nishihara M, Hause B, Horimoto T. 2016. Influenza D Virus Infection in Herd of 
Cattle, Japan. Emerg. Infect. Dis. 22(8):1517–1519. 
doi.org/10.3201/eid2208.160362 
 
20. Lade K, Sawant S, Singh M. 2011. Review of influenza with special emphasis on 
swine flu. Int. J. Curr. Pharm. Res. 3(1):97-107. 
 
21. Van Reeth K, Brown I, Olsen C. 2012. Influenza Virus. In: Zimmerman J, Karriker L, 
Ramirez A, Schwartz K, Stevenson G, eds. Diseases of Swine. 10th ed. Ames, IA: 
John Wiley & Sons, Inc.  pp. 557-571. 
 
22. Masters P, Perlman S. 2013. Coronaviridae D. Knipe, P. Howley, eds. Fields 
Virology, Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia.  pp. 
46 
 
 
 
 
825–858. 
 
23. Sjaak de Wit JJ, Cook JK, van der Heijden HM. 2011. Infectious bronchitis virus 
variants: a review of the history, current situation and control measures. Avian 
Pathol. 40(3):223-235. 
 
24. Belouzard S, Millet JK, Licitra BN, Whittaker GR. 2012. Mechanisms of Coronavirus 
cell entry mediated by the viral spike protein viruses 4:1011-1033. 
doi:10.3390/v4061011 
 
25. Pensaert MB, de Bouck P. 1978. A new coronavirus-like particle associated with 
diarrhea in swine. Arch. Virol. 58:243–247. doi:10.1007/BF01317606 
 
26. de Groot RJ, Baker SC, Baric RS, Brown CS, Drosten C, Enjuanes L, Fouchier RAM, 
Galiano M, Gorbalenya AE, Memish ZA, Perlman S, Poon LLM, Snijder EJ, 
Stephens GM, Woo PCY, Zaki AM, Zambon M, Ziebuhr J. 2013. Middle East 
Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the 
Coronavirus Study Group. J. of Virol. 87(14):7790-7792. doi:10.1128/JVI.01244-
13. 
 
27. Brian DA, Baric RS. 2005. Coronavirus genome structure and replication. Curr. Top. 
Microbiol. Immunol. 287:1–30. 
 
28. Perlman S, Netland J. 2009. Coronaviruses post-SARS: Update on replication an 
pathogenesis. Nature Reviews Microbiology. 7(6):439-450. 
doi:10.1038/nrmicro2147. 
 
29. Kamitani W, Huang C, Narayanan K, Lokugamage KG, Makino S. 2009. A novel 
twopronged strategy to suppress host protein synthesis by SARS coronavirus nsp1 
protein. Nat. Struct. Mol. Biol. 16:1134-1140 
 
30. Graham RL, Sims AC, Brockway SM, Baric RS, Denison MR. 2005. The nsp2 
replicase proteins of murine hepatitis virus and severe acute respiratory syndrome 
coronavirus are dispensable for viral replication. J. Virol. 79(21):13399-13411. 
 
31. Ziebuhr J, Snijder EJ, Gorbalenya AE. 2000. Virus-encoded proteinases and 
proteolytic processing in the Nidovirales. J. Gen. Virol. 81:853-879. 
 
32. Han YS, Chang GG, Juo CG, Lee HJ, Yeh SH, Hsu JT, Chen X. 2005. Papain-like 
protease 2 (PLP2) from severe acute respiratory syndrome coronavirus (SARS-
CoV): Expression, purification, characterization, and inhibition. Biochemistry 
44(30):10349-10359. 
 
33. Deming DJ, Graham RL, Denison MR,  Baric RS. 2007. Processing of open reading 
frame 1a replicase proteins nsp7 to nsp10 in murine hepatitis virus strain A59 
replication. J. Viro.l 81(19):10280-10291. 
47 
 
 
 
 
 
34. Knoops K, Kikkert M, van den Worm SHE, Zevenhoven-Dobbe JC, van der Meer Y, 
Koster AJ, Mommaas AM, Snijder EJ. 2008. SARS-coronavirus replication is 
supported by a reticulovesicular network of modified endoplasmic reticulum. Plos 
Biol 6(9):1957-1974. 
 
35. Velthuis AJWT, van den Worm SHE, Snijder EJ. 2012. The SARS-coronavirus 
nsp7+nsp8 complex is a unique multimeric RNA polymerase capable of both de 
novo initiation and primer extension. Nucleic Acids Res. 40(4):1737-1747. 
 
36. Bouvet M, Lugari A, Posthuma CC, Zevenhoven JC, Bernard S, Betzi S, Imbert I, 
Canard B, Guillemot JC, Lecine P, Pfefferle S, Drosten C, Snijder EJ, Decroly E, 
Morelli X. 2014. Coronavirus Nsp10, a Critical Co-factor for Activation of Multiple 
Replicative Enzymes. J. Biol. Chem. 289(37):25783-25796. 
 
37. Sturman LS, Holmes KV. 1983. The molecular biology of coronaviruses. Adv. Virus 
Res. 28:35-122. 
 
38. Fang SG, Shen HY, Wang JB, Tay FPL, Liu DX. 2008. Proteolytic processing of 
polyproteins 1a and 1ab between non-structural proteins 10 and 11/12 of 
Coronavirus infectious bronchitis virus is dispensable for viral replication in 
cultured cells. Virology 379(2):175-180. 
 
39. Ivanov KA, Hertzig t, Rozanov M, Bayer S, Thiel V, Gorbalenya AE, Ziebuhr 
J. 2004. Major genetic marker of nidoviruses encodes a replicative 
endoribonuclease. Proc Natl Acad Sci USA 101:12694–12699. 
 
40. Bosch BJ, Bartelink W, Rottier PJM. 2008. Cathepsin L functionally cleaves the 
severe acute respiratory syndrome coronavirus class I fusion protein upstream of 
rather than adjacent to the fusion peptide. J. Virol. 82(17):8887-8890. 
 
41. Li WH, Zhang C, Sui J, Kuhn JH, Moore MJ, Luo S, Wong SK, Huang IC, Xu K, 
Vasilieva N, Murakami A, He Y, Marasco WA, Guan Y, Choe H, Farzan M. 2005. 
Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. 
EMBO J. 24(8):1634-1643. 
 
42. Wicht O, Li W, Willems L, Meuleman TJ, Wubbolt, RW, van Kuppeveld FJM, 
Bosch BJ. 2014. Proteolytic activation of the porcine epidemic diarrhea coronavirus 
spike fusion protein by trypsin in cell culture. J. Virol. 88(14):7952–7961.  
 
43. Huang QL, Yu L, Petros AM, Gunasekera A, Lin Z, Xu N, Hajduck P, Mack J, Fesik 
SW, Olejniczak ET. 2004. Structure of the N-terminal RNA-binding domain of the 
SARS CoV nucleocapsid protein. Biochemistry 43(20):6059-6063. 
 
44. Kopecky-Bromberg SA, Martinez-Sobrido L, Frieman M, Baric RA, Palese P. 2007. 
severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 
48 
 
 
 
 
6, and nucleocapsid proteins function as interferon antagonists. J. Virol. 81(2):548-
557. 
 
45. Ding Z, Fang L, Jing H, Zeng S, Wang D, Liu L, Zhang H, Luo R, Chen H, Xiao S. 
2014. Porcine Epidemic Diarrhea Virus Nucleocapsid Protein Antagonizes Beta 
Interferon Production by Sequestering the Interaction between IRF3 and TBK1. J. 
Virol. 88(16):8936-8945. 
 
46. Angelini MM, Akhlaghpour M, Neuman BW, Buchmeier MJ. 2013. Severe Acute 
Respiratory Syndrome Coronavirus nonstructural proteins 3, 4, and 6 induce double 
membrane vesicles. Mbio 4(4), e00524-13. doi:10.1128/mBio.00524.13  
 
47. Stevenson GW, Hoang H, Schwartz KJ, Burrough ER, Sun D, Madson D, Cooper 
VL, Pillatzki A, Gauger P, Schmitt BJ, Koster LG, Killian ML, Yoon KJ. 2013. 
Emergence of Porcine epidemic diarrhea virus in the United States: clinical signs, 
lesions, and viral genomic sequences. J. Vet. Diagn. Invest. 25:649–54. 
doi:10.1177/1040638713501675 
 
48. Marthaler D, Jiang Y, Otterson T, Goyal S, Rossow K, Collins J. 2013. Complete 
genome sequence of porcine epidemic diarrhea virus strain USA/colorado/2013 
from the United States.  Genome Announc. 1 (1) e00555–613. 
 
49. Li Y, Zhen, F, Fan B, Muhammad HM, Zou Y, Jiang P. 2015. Development of an 
indirect ELISA based on a truncated S protein of the porcine epidemic diarrhea 
virus. Can. J. Microbiol. 61:811–7. doi:10.1139/cjm-2015-0213 
 
50. Ma Y, Zhang Y, Liang X, Lou F, Oglesbee M, Krakowka S, Li J. 2015. Origin, 
evolution, and virulence of porcine deltacoronaviruses in the United States. MBio 6 
(2):e00064. 
 
51. Park SJ, Song DS, Ha GW, Park BK. 2007. Cloning and further sequence analysis of 
the spike gene of attenuated porcine epidemic diarrhea virus DR13. Virus Genes 
35:55-64. doi:10.1007/s11262-006-0036-1 
 
52. Chen J, Wang C, Shi H, Qiu H, Liu S, Chen X, Zhang Z, Feng L. 2010. Molecular 
epidemiology of porcine epidemic diarrhea virus in China. Arch. Virol. 155:1471–6. 
doi:10.1007/s00705-010-0720-2 
 
53. Sun D, Wang X, Wei S, Chen J, Feng L. 2015. Epidemiology and vaccine of porcine 
epidemic diarrhea virus in China: a mini-review. J. Vet. Med. Sci. 78(3):355–363. 
doi:10.1292/jvms.15-0446 
 
54. Ojkic D, Hazlett M, Fairles J, Marom A, Slavic D, Maxie G, Alexandersen S, Pasick 
J, Alsop J, Burlatschenko S. 2015. The first case of porcine epidemic diarrhea in 
Canada.  Can. Vet. J. 56(2):149–152. 
 
49 
 
 
 
 
55. Yamamoto T, Suzuki T, Ohashi S, Miyazaki A, Tsutsui T. 2016. Genomic motifs as a 
novel indicator of the relationship between strains isolated from the epidemic of 
porcine epidemic diarrhea in 2013-2014. PLoS One 11: e0147994. 
doi:10.1371/journal.pone.0147994 
 
56. Wang YW, Yu, H, Fang W, Huang YW. 2015. Complete genome sequence of 
porcine deltacoronavirus strain CH/Sichuan/S27/2012 from mainland China. 
Genome Announc. 3 (5).  
 
57. Egberink H, Ederveen J, Koolen M, Lutz H, Horzineck MC, Diergeneeskunde TV. 
1988. Infections with feline T-lymphotropic lentivirus. Europe PMC 113(17):937-
943. 
 
58. Bosch BJ, van der Zee R, de Haan CA, Rottier PJ. 2003. The coronavirus spike 
protein is a class I virus fusion protein: structural and functional characterization of 
the fusion core complex. J. Virol. 77(16):8801-11. 
 
59. Huang YW, Dickerman AW, Piñeyro P, Li L, Fang L, Kiehne R, Opriessnig T, Meng 
XJ. 2013. Origin, evolution, and genotyping of emergent porcine epidemic diarrhea 
virus strains in the United States. MBio 4:e00737–13. doi:10.1128/mBio.00737-13 
 
60. Okda F, Liu X, Singrey A, Clement T, Nelson J, Christopher-Hennings J, Nelson EA, 
Lawson S. 2015. Development of an indirect ELISA, blocking ELISA, fluorescent 
microsphere immunoassay and fluorescent focus neutralization assay for serologic 
evaluation of exposure to North American strains of Porcine Epidemic Diarrhea 
Virus. BMC Vet. Res. 11:180. doi:10.1186/s12917-015-0500-z 
 
61. Du LY, He Y, Zhou Y, Liu S, Zhen BJ, Jiang S. 2009. The spike protein of SARS-
CoV - a target for vaccine and therapeutic development. Nat. Rev. Microbiol. 
7(3):226-236. 
 
62. Xing Y, Chen J, Tu J, Zhang B, Chen X, Shi H, Chen Z. 2013. The papain-like 
protease of porcine epidemic diarrhea virus negatively regulates type I interferon 
pathway by acting as a viral deubiquitinase. J. Gen. Virol. 94(Pt 7):1554–1567. 
http://doi.org/10.1099/vir.0.051169-0 
 
63. Oka T, Saif LJ, Marthaler D, Esseili MA, Meulia T, Lin CM, Vlasova AN, Jung K, 
Zhang Y, Wang Q. 2014. Cell culture isolation and sequence analysis of genetically 
diverse US porcine epidemic diarrhea virus strains including a novel strain with a 
large deletion in the spike gene. Vet. Microbiol. 173:258–69. 
doi:10.1016/j.vetmic.2014.08.012 
 
64. Liu C, Tang J, Ma Y, Liang X, Yang Y, Peng G, Qi Q, Jiang S, Li J, Du L, Li F. 
2015. Receptor usage and cell entry of porcine epidemic diarrhea coronavirus. J. 
Virol. 89:6121–6125. doi:10.1128/JVI.00430-15 
 
50 
 
 
 
 
65. Jung K, Hu H, Eyerly B, Lu Z, Chepngeno J, Siaf LJ. 2015.  Pathogenicity of 2 
porcine deltacoronavirus strains in gnotobiotic pigs.  Emerg. Infect. Dis. 21(4):650-
654. doi: 10.3201/eid2104.141859.  
 
66. Thomas JT, Chen Q, Gauger PC, Giménez-Lirola LG, Sinha A, Harmon KM, 
Madson DM, Burrough ER, Magstadt DR, Salzbrenner HM, Welch MW, Yoon KJ, 
Zimmerman JJ, Zhang J. 2015. Effect of porcine epidemic diarrhea virus infectious 
doses on infection outcomes in naïve conventional neonatal and weaned pigs. PLoS 
One 10: e0139266. doi:10.1371/journal.pone.0139266 
 
67. Madson DM, Magstadt DR, Arruda PHE, Hoang H, Sun D, Bower LP, Bhandari M, 
Burrough ER, Gauger PC, Pillatzki AE, Stevenson GW, Wilberts BL, Brodie J, 
Harmon KM, Wang C, Main RG, Zhang J, Yoon KJ. 2014. Pathogenesis of porcine 
epidemic diarrhea virus isolate (US/Iowa/18984/2013) in 3-week-old weaned pigs. 
Vet. Microbiol. 174:60-68. doi:10.1016/j.vetmic.2014.09.002 
 
68. Madson DM, Arruda PHE, Magstadt DR, Burrough ER, Hoang H, Sun D, Bower 
L.P, Bhandari M, Gauger PC, Stevenson GW, Wilberts BL, Wang C, Zhang J, Yoon 
KJ. 2016. Characterization of porcine epidemic diarrhea virus isolate 
US/Iowa/18984/2013 Infection in 1-day-old cesarean-derived colostrum-deprived 
piglets. Vet. Pathol. 53:44–52. doi:10.1177/0300985815591080 
 
69. Ouyang K, Shyu D-L, Dhakal S, Hiremath J, Binjawadagi B, Lakshmanappa YS, Guo 
R, Ransburgh R, Bondra KM, Gauger P, Zhang J, Specht T, Gilbertie A, Minton W, 
Fang Y, Renukaradhya GJ. 2015. Evaluation of humoral immune status in porcine 
epidemic diarrhea virus (PEDV) infected sows under field conditions. Vet. Res. 
46:140. doi:10.1186/s13567-015-0285-x. 
 
70. Diel DG, Lawson S, Okda F, Singrey A, Clement T, Fernandes MHV, Christopher-
Hennings J,  Nelson EA. 2016. Porcine epidemic diarrhea virus: an overview of 
current virological and serological diagnostic methods. Virus Res. 226 doi: 
10.1016/j.virusres.2016.05.013 
 
71. Chen Q, Li G, Stasko J, Thomas JT, Stensland WR, Pillatzki AE, Gauger PC, 
Schwartz KJ, Madson D, Yoon KJ, Stevenson GW, Burrough ER, Harmon KM, 
Main RG, Zhang J. 2014. Isolation and characterization of porcine epidemic 
diarrhea viruses associated with the 2013 disease outbreak among swine in the 
United States. J. Clin. Microbiol. 52, 234–43. doi:10.1128/JCM.02820-13 
 
72. Debouck P, Pensaert M, Coussement W. 1981. The pathogenesis of an enteric 
infection in pigs, experimentally induced by the coronavirus-like agent, CV 777. 
Vet. Microbiol. 6:157–165. doi:10.1016/0378-1135(81)90007-9 
 
73. Jung K, Wang Q, Scheuer KA, Lu, Z, Zhang Y, Saif LJ. 2014. Pathology of US 
porcine epidemic diarrhea virus strain PC21A in gnotobiotic pigs. Emerg. Infect. 
Dis. 20:662–665. doi 10.3201/eid2004.131685 
51 
 
 
 
 
 
74. Guscetti F, Bernasconi C, Toble, K, Van Reeth K, Pospischil A, Ackermann M. 1998. 
Immunohistochemical detection of porcine epidemic diarrhea virus compared to 
other methods. Clin. Diagn. Lab. Immunol. 5:412–414. 
 
75. Clement T, Singrey A, Lawson S, Okda F, Nelson J, Diel D, Nelson EA, Christopher-
Hennings J. 2016. Measurement of neutralizing antibodies against porcine epidemic 
diarrhea virus in sow serum, colostrum, and milk samples and piglet serum samples 
after feedback. J. Swine Health Prod. 24:1–10. 
 
76. Templeton NS. 1992. The polymerase chain reaction history, methods, and 
applications. Diagn. Mol. Pathol. 1:58–72. 
 
77. Jarvis MC, Lam HC, Zhang Y, Wang L, Hesse RA, Hause BM, Vlasova A, Wang Q, 
Zhang J, Nelson MI, Murtaugh MP, Marthaler D. 2016. Genomic and evolutionary 
inferences between American and global strains of porcine epidemic diarrhea virus. 
Prev. Vet. Med. 123:175–84. doi:10.1016/j.prevetmed.2015.10.020 
 
78. Miller LC, Crawford KK, Lager KM, Kellner SG, Brockmeier SL. 2016. Evaluation 
of two real-time polymerase chain reaction assays for Porcine epidemic diarrhea 
virus (PEDV) to assess PEDV transmission in growing pigs. J. Vet. Diagn. Invest. 
28, 20–9. doi:10.1177/1040638715621949 
 
79. Zhang X, Pan Y, Wang D, Tian X, Song Y, Cao Y. 2015. Identification and 
pathogenicity of a variant porcine epidemic diarrhea virus field strain with reduced 
virulence. Virol. J. 12:88. doi:10.1186/s12985-015-0314-4 
 
80. Yoon, KJ. 2015. Oral fluid testing for efficient PEDV surveillance and control 
[WWW Document]. URL https://www.aasv.org/news/story.php?id=8120 (accessed 
1.1.16). 
 
81. Ishikawa K, Sekiguchi H, Ogino T, Suzuki S. 1997. Direct and rapid detection of 
porcine epidemic diarrhea virus by RT-PCR. J. Virol. Methods 69:191–5. 
 
82. Kubota S, Sasaki O, Amimoto K, Okada N, Kitazima T, Yasuhara H. 1999. Detection 
of porcine epidemic diarrhea virus using polymerase chain reaction and comparison 
of the nucleocapsid protein genes among strains of the virus. J. Vet. Med. Sci. 
61:827–830. 
 
83. Kweon CH, Lee JG, Han MG, Kang YB. 1997. Rapid diagnosis of porcine epidemic 
diarrhea virus infection by polymerase chain reaction. J. Vet. Med. Sci. 59:231–232. 
 
84. Ben Salem AN, Chupin Sergei A, Bjadovskaya Olga P, Andreeva Olga G, Mahjoub 
A, Prokhvatilova Larissa B. 2010. Multiplex nested RT-PCR for the detection of 
porcine enteric viruses. J. Virol. Meth. 165:283–93. 
doi:10.1016/j.jviromet.2010.02.010 
52 
 
 
 
 
 
85. de Arriba ML, Carvajal A, Pozo J, Rubio P. 2002. Isotype-specific antibody-secreting 
cells in systemic and mucosal associated lymphoid tissues and antibody responses in 
serum of conventional pigs inoculated with PEDV. Vet. Immunol. Immunopathol. 
84:1–16. 
 
86. Jung K, Kim J, Kim O, Kim B, Chae C. 2003. Differentiation between porcine 
epidemic diarrhea virus and transmissible gastroenteritis virus in formalin-fixed 
paraffin-embedded tissues by multiplex RT-nested PCR and comparison with in situ 
hybridization. J. Virol. Methods 108:41–47. 
 
87. Kim O, Choi C, Kim B, Chae C. 2000. Detection and differentiation of porcine 
epidemic diarrhoea virus and transmissible gastroenteritis virus in clinical samples 
by multiplex RT-PCR. Vet. Rec. 146:637–640. 
 
88. Arya M, Shergill IS, Williamson M, Gommersall L, Arya,N, Patel NR. 2005. Basic 
principles of real-time quantitative PCR. Expert Rev. Mol. Diagn. 5:209. 
doi:http://dx.doi.org/10.1586/14737159.5.2.209 
 
89. Zhao P, Bai J, Jiang P, Tang T, Li Y, Tan C, Shi X. 2014. Development of a 
multiplex TaqMan probe-based real-time PCR for discrimination of variant and 
classical porcine epidemic diarrhea virus. J. Virol. Methods 206:150–5. 
doi:10.1016/j.jviromet.2014.06.006 
 
90. Song DS, Kang BK, Oh JS, Ha GW, Yang JS, Moon HJ, Jang YS, Park BK. 2006. 
Multiplex reverse transcription-PCR for rapid differential detection of porcine 
epidemic diarrhea virus, transmissible gastroenteritis virus, and porcine group A 
rotavirus. J. Vet. Diagn. Invest. 18:278–281. doi: 10.1177/104063870601800309.  
 
91. Klasse PJ. 2014. Neutralization of Virus Infectivity by Antibodies: Old Problems in 
New Perspectives. Adv. Biol. 24. doi.org/10.1155/2014/157895 
 
92. Paudel S, Park JE, Jang H, Hyun BH, Yang DG, Shin HJ. 2014a. Evaluation of 
antibody response of killed and live vaccines against porcine epidemic diarrhea 
virus in a field study. Vet. Q. 34:194–200. doi:10.1080/01652176.2014.973999 
 
93. Fan JH, Zuo YZ, Shen XQ, Gu WY, Di JM. 2015. Development of an enzyme-linked 
immunosorbent assay for the monitoring and surveillance of antibodies to porcine 
epidemic diarrhea virus based on a recombinant membrane protein. J. Virol. Meth. 
225:90–4. doi:10.1016/j.jviromet.2015.07.021 
 
94. Gerber PF, Opriessnig T. 2015. Detection of immunoglobulin (Ig) A antibodies 
against porcine epidemic diarrhea virus (PEDV) in fecal and serum samples. 
MethodsX 2:368–373. doi:10.1016/j.mex.2015.10.001 
 
95. Gerber PF, Gong Q, Huang YW, Wang C, Holtkamp D, Opriessnig T. 2014. 
53 
 
 
 
 
Detection of antibodies against porcine epidemic diarrhea virus in serum and 
colostrum by indirect ELISA. Vet. J. 202:33–6. doi:10.1016/j.tvjl.2014.07.018 
 
96. Paudel S, Park JE, Jang H, Shin HJ. 2014b. Comparison of serum neutralization and 
enzyme-linked immunosorbent assay on sera from porcine epidemic diarrhea virus 
vaccinated pigs. Vet. Q. 34:218–23. doi:10.1080/01652176.2014.979512 
 
97. Aydin S. 2015. A short history, principles, and types of ELISA, and our laboratory 
experience with peptide/protein analyses using ELISA. Peptides 72:4–15. 
doi:10.1016/j.peptides.2015.04.012 
 
98. Carvajal A, Lanza I, Diego R, Rubio P, Cármenes P. 1995. Evaluation of a blocking 
ELISA using monoclonal antibodies for the detection of porcine epidemic diarrhea 
virus and its antibodies. J. Vet. Diagn. Invest. 7:60–4. 
 
99. Christopher-Hennings J, Araujo KP, Souza CJ, Fang Y, Lawson S, Nelson EA, 
Clement T, Dunn M, Lunney JK. 2013. Opportunities for bead-based multiplex 
assays in veterinary diagnostic laboratories. J. Vet. Diagn. Invest. 25 (6):671–691. 
 
100. Ramos-Vara JA. 2011. Principles and methods of immunohistochemistry. Methods 
Mol. Biol. 691:83–96. doi:10.1007/978-1-60761-849-2_5 
 
101. Duraiyan J, Govindarajan R, Kaliyappan K, Palanisamy M. 2012. Applications of 
immunohistochemistry. J. Pharm. Bioallied Sci. 4(6):307–9. doi:10.4103/0975-
7406.100281 
 
102. Notomi T, Mori Y, Tomita N, Kanda H. 2015. Loop-mediated isothermal 
amplification (LAMP): principle, features, and future prospects. J. Microbiol. 53:1–
5. doi:10.1007/s12275-015-4656-9 
 
103. Ren X, Li P. 2011. Development of reverse transcription loop-mediated isothermal 
amplification for rapid detection of porcine epidemic diarrhea virus. Virus Genes 
42:229–35. doi:10.1007/s11262-011-0570-3 
 
104. Yu X, Shi L, Lv X, Yao W, Cao M, Yu H, Wang X, Zheng S.. 2015. Development 
of a real-time reverse transcription loop-mediated isothermal amplification method 
for the rapid detection of porcine epidemic diarrhea virus. Virol. J. 12:76. 
doi:10.1186/s12985-015-0297-1 
 
105. Oura CAL, Edwards L, Batten CA. 2013. Virological diagnosis of African swine 
fever--comparative study of available tests. Virus Res. 173:150–8. 
doi:10.1016/j.virusres.2012.10.022 
 
106. Tomita N, Mori Y, Kanda H, Notomi T. 2008. Loop-mediated isothermal 
amplification (LAMP) of gene sequences and simple visual detection of products. 
Nat. Protoc. 3:877–82. doi:10.1038/nprot.2008.57 
54 
 
 
 
 
 
107. Lin CM, Annamalai T, Liu X, Gao X, Lu Z, El-Tholoth M, Hu H, Saif LJ, Wang Q. 
2015. Experimental infection of a US spike-insertion deletion porcine epidemic 
diarrhea virus in conventional nursing piglets and cross-protection to the original US 
PEDV infection. Vet. Res. 46:134. doi: 10.1186/s13567-015-0278-9. 
 
108. Chen Q, Thomas JT, Giménez-Lirola LG, Hardham, JM, Gao Q, Gerber PF, Zhang 
J. 2016. Evaluation of serological cross-reactivity and cross-neutralization between 
the United States porcine epidemic diarrhea virus prototype and S-INDEL-variant 
strains. BMC Vet. Res. 12:70. http://doi.org/10.1186/s12917-016-0697-5 
 
109. Hain KS, Joshi LR, Okda F, Nelson J, Singrey A, Lawson S, Martins M, Pillatzki 
A, Kutish G, Nelson EA, Flores EF, Diel DG. 2016. Immunogenicity of a 
Recombinant Parapoxvirus Expressing the Spike Protein of Porcine Epidemic 
Diarrhea Virus. J. Gen. Virol. 24. doi: 10.1099/jgv.0.000586. 
 
110. Cruz DJM, Kim CJ, Shin HJ. 2006. Phage-displayed peptides having antigenic 
similarities with porcine epidemic diarrhea virus (PEDV) neutralizing epitopes. 
Virology 354:28-34. doi.org/10.1016/j.virol.2006.04.027. 
 
111. Usami Y, Yamaguchi O, Kumanomido K, Matsumura Y. 1998. Antibody response 
of pregnant sows to porcine epidemic diarrhea virus live vaccine and maternally-
derived antibodies of the piglets. J. Jpn. Vet. Med. Assoc. 51:652-655. 
 
112. Wang L, Byrum B, Zhang Y. 2014b. Porcine coronavirus HKU15 detected in 9 US 
states, 2014. Emerg. Infect. Dis. 20 (9):1594–1595.  
 
113. Wang L, Zhang Y, Byrum B. 2014c. Complete genome sequence of porcine 
Coronavirus HKU15 strain IN2847 from the United States. Genome Announc. 2 (2).  
 
114. Lee S, Lee C. 2014. Complete genome characterization of korean porcine 
deltacoronavirus strain KOR/KNU14-04/. Genome Announc. 2 (6), e01191-14. 
 
115. Janetanakit T, Lumyai M, Bunpapong N, Boonyapisitsopa S, Chaiyawong S, 
Nonthabenjawan N, Kesdaengsakonwut S, Amonsin A. 2016. Porcine 
deltacoronavirus, Thailand, 2015. Emerg. Infect. Dis. 22 (4):757–759. 
 
116. Song D, Zhou X, Peng Q, Chen Y, Zhang F, Huang T, Zhan, T, Li A, Huang D, Wu 
Q, He H, Tang Y. 2015. Newly emerged porcine deltacoronavirus associated with 
diarrhoea in swine in China: identification, prevalence and full-length genome 
sequence analysis. Transbound. Emerg. Dis. 62(6):575–580. 
 
117. Homwong N, Jarvis MC, Lam HC, Diaz A, Rovira A, Nelson M, Marthaler D. 2016. 
Characterization and evolution of porcine deltacoronavirus in the United States. 
Prev. Vet. Med. 123:168–174. 
 
55 
 
 
 
 
 
118. Chen Q, Gauger P, Stafne M, Thomas J, Arruda P, Burrough E, Madson D, Brodie 
J, Magstadt D, Derscheid R, Welch M, Zhang J. 2015.  Pathogenicity and 
pathogenesis of a United States porcine deltacoronavirus ceell culture isolate in 5-
day-old neonatal piglets.  Virology 482:51-59. doi:10.10/1016/j.virol.2015.03.024 
 
119. Thachil A, Gerber PF, Xiao CT, Huang YW, Opriessnig T. 2015. Development and 
application of an ELISA for the detection of porcine deltacoronavirus IgG 
antibodies. PLoS One 10(4): e0124363. 
 
120. Li G, Chen Q, Harmon KM, Yoon KJ, Schwartz K, Hoogland MJ, Gauger PC, Main 
RG, Zhang J. 2014. Full-Length genome sequence of porcine deltacoronavirus strain 
USA/IA/2014/8734. Genome Announc. 2 (2), e00278-14. 
 
121. Wang L, Hayes J, Sarver C, Byrum B, Zhang Y. 2016. Porcine deltacoronavirus: 
histological lesions and genetic characterization. Arch. Virol. 161:171–175. 
 
122. Ma Y, Zhang Y, Liang X, Oglesbee M, Krakowka S, Niehaus A, Wang G, Jia A, 
Song H, Li J. 2016. Two-way antigenic cross-reactivity between porcine epidemic 
diarrhea virus and porcine deltacoronavirus. Vet. Microbiol. 186:90–96. 
 
123. Hu H, Jung K, Vlasova AN, Chepngeno J, Lu Z, Wang Q, Saif LJ. 2015. Isolation 
and characterization of porcine deltacoronavirus from pigs with diarrhea in the 
United States. J. Clin. Microbiol. 53 (5):1537–1548. 
 
124. Moes E, Vijgen L, Keyaerts E, Zlateva K, Li S, Maes P, Pyrc K, Berkhout B, van 
der Hoek L, Van Ranst M. 2005. A novel pancoronavirus RT-PCR assay: frequent 
detection of human coronavirus NL63 in children hospitalized with respiratory tract 
infections in Belgium. BMC Infect. Dis. 5(1):6. doi: 10.1186/1471-2334-5-6 
 
125. Marthaler D, Raymond L, Jiang Y, Collins J, Rossow K, Rovira A. 2014. Rapid 
detection, complete genome sequencing, and phylogenetic analysis of porcine 
deltacoronavirus. Emerg. Infect. Dis. 20(8):1347–1350. 
 
126. Zhang J. 2016. Porcine deltacoronavirus: Overview of infection dynamics, 
diagnostic methods, prevalence and genetic evolution. Virus Res. 226:71-84. 
 
127. Jianqiang Zhang, Yun-Long Tsai, Pei-Yu Alison Lee, Qi Chen, Yan Zhang, Cheng-    
Jen Chiang, Yu-Han Shen, Fu-Chun Li, Hsiao-Fen Grace Chang, Phillip C. Gauger, 
Karen M. Harmon, Hwa-Tang Thomas Wang, Evaluation of two singleplex reverse 
transcription-Insulated isothermal PCR tests and a duplex real-time RT-PCR test for 
the detection of porcine epidemic diarrhea virus and porcine deltacoronavirus, 
Journal of Virological Methods, Volume 234, August 2016, Pages 34-42, ISSN 
0166-0934, http://doi.org/10.1016/j.jviromet.2016.03.016. 
 
128. Su M, Li C, Guo D, Wei S, Wang X, Geng Y, Yao S, Gao J, Wang E, Zhao X, 
56 
 
 
 
 
Wang Z, Wang J, Wu R, Feng L, Sun D. 2015. A recombinant nucleocapsid protein-
based indirect enzyme-linked immunosorbent assay to detect antibodies against 
porcine deltacoronavirus. J. Vet. Med. Sci. 78(4):601–606. 
 
129. Okda F, Lawson S, Liu X, Singrey A, Clement T, Hain K, Nelson J, Christopher-
Hennings J, Nelson EA. 2016. Development of monoclonal antibodies and 
serological assays including indirect ELISA and fluorescent microsphere 
immunoassays for diagnosis of porcine deltacoronavirus. BMC Vet Res. 12:95. doi: 
10.1186/s12917-016-0716-6. 
 
130. Langenhorst RJ, Lawson S, Kittawornrat A, Zimmerman JJ, Sun Z, Li Y, 
Christopher-Hennings J, Nelson EA, Fang Y. 2012. Development of a fluorescent 
microsphere immunoassay for detection of antibodies against porcine reproductive 
and respiratory syndrome virus using oral fluid samples as an alternative to serum-
based assays. Clin. Vaccine Immunol. 19(2):180–189. 
 
131. Crescenzo-Chaigne B, van der Werf S. 2007. Rescue of influenza C virus from 
recombinant DNA. J. Virol. 81:11282–11289. doi: 10.1128/JVI.00910-07. 
 
132. Speranskaya AS, Melnikova NV, Belenkin MS, Dmitriev AA, Oparina N, 
Kudriavtseva AV. 2012. Genetic diversity and evolution of the influenza C virus. 
Genetika. 48:797-805. 
 
133. Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y. 1992. Evolution 
and ecology of influenza A viruses. Microbiol. Mol. Biol. Rev. 56(1):152. 
 
134. Mukherjee TR, Mukherjee A, Mullick S, Chawla-Sarkar M. 2013. Full genome 
analysis and characterization of influenza C virus identified in Eastern India. Infect. 
Genet. Evol. 16(0):419-425. 
 
135. Kapoor S, Dhama K. 2014. Properties of Influenza Viruses. In: Dhama K, ed. 
Insight into Influenza Viruses of Animals and Humans. 1st ed. Switzerland: 
Springer International Publishing; pp. 7-14. 
 
136. Kimura H, Abiko C, Peng G, Muraki Y, Sugawara K, Hongo S, Kitame F, Mizuta 
K, Numazaki Y, Suzuki H, Nakamura K. 1997. Interspecies transmission of 
influenza C virus between humans and pigs. Virus Res. 48(1):71-79. 
 
137. Sheng Z, Ran Z, Wang D, Hoppe AD, Simonson R, Chakravarty S, Hause BM, Li F. 
2014. Genomic and evolutionary characterization of a novel influenza-C-like virus 
from swine. Arch Virol. 159(2):249-255. 
 
138. White SK,  Ma W, McDaniel CJ, Gray GC, Lednicky JA. 2016. Serologic evidence 
of exposure to influenza D virus among persons with occupational contact with 
cattle. J. Clin. Virol. 81:31-33 
 
57 
 
 
 
 
139. Sreenivasan C, Thomas M, Sheng Z, Hause BM, Collin EA, Knudsen DE, Pillatzki 
A, Nelson E, Wang D, Kaushik RS, Li F. 2015. Replication and transmission of the 
novel bovine Influenza D Virus in a guinea pig model.  J. Virol. 89:11990–12001. 
 
140. Quast M, Sreenivasan C, Sexton G, Nedland H, Singrey A, Fawcett L, Miller G, 
Lauer D, Voss S, Pollock S, Cunha CW, Christopher-Hennings J, Nelson E, Li F. 
2015. Serological evidence for the presence of influenza D virus in small ruminants. 
Vet. Microbiol. 180:281–285. 
 
141. Faccini S, Mattia AD, Chiapponi C, Barbieri I, Boniotti MB, Rosignoli C, Franzini 
G, Moreno A, Foni E, Nigrelli AD. 2017. Development and evaluation of a new 
Real-Time RT-PCR assay for detection of proposed influenza D virus. J. Virol. 
Meth. 243:31-34. doi.org/10.1016/j.jviromet.2017.01.019 
 
142. Nishimura H, Hara M, Sugawara K, Kitame F, Takiquchi K, Umetsu Y, Tonosaki A, 
Nakamura K. 1990. Characterization of the cord-like structures emerging from the 
surface of influenza C virus-infected cells. Virol. 179:179-188. doi:10.1016/0042-
6822(90)90287-2 
 
143. Alamgir AS, Matsuzaki Y, Hongo S, Tsuchiya E, Sugawara K, Muraki Y, 
Nakamura K. 2000. Phylogenetic analysis of influenza C virus nonstructural (NS) 
protein genes and identification of the NS2 protein. J. Gen. Virol. 81(8):1933-1940. 
 
144. Muraki Y, Hongo S. 2010. The molecular virology and reverse genetics of influenza 
C virus. Jpn. J. Infect. Dis. 63(3):157. 
 
145. Yamaoka M, Homma M, Hotta H. 1995. MDCK cell cultures supplemented with 
high concentrations of trypsin exhibit remarkable susceptibility to influenza C virus. 
Arch. Virol. 140:937–944. 
 
146. Greenbaum E, Morag A, Zakay-Rones Z. 1998. Isolation of Influenza C virus during 
an outbreak of Influenza A and B viruses. J. Clin. Microbiol. 36(5):1441–1442.  
 
147. Gouarin S, Vabret A, Dina J, Petitjean J, Brouard J, Cuvillon-Nimal D, Freymuth F. 
2008. J. Med. Virol. 80(8):1441-1446. 
 
148. Moriuchi H, Oshima T, Nishimura H, Nakamura K, Katsushima N, Numazaki Y. 
1990. Human malignant melanoma cell line (HMV-II) for isolation of influenza C 
and parainfluenza viruses. J. Clin. Microbiol. 28:1147–50. 
 
149. Matsuzaki Y, Mizuta K, Sugawara K, Tsuchiya E, Muraki Y, Hongo S, Suzuki H, 
Nishimura H. 2003. Frequent reassortment among influenza C viruses. J. Virol. 77: 
871–881. 
 
58 
 
 
 
 
150. Odagiri T, Matsuzaki Y, Okamoto M, Suzuki A, Saito M, Tamaki R, Lupisan SP, 
Sombrero LT, Hongo S, Oshitani H. 2015. Isolation and characterization of 
influenza C viruses in the Philippines and Japan. J. Clin. Microbiol. 53:847–858. 
 
151. Matsuzaki Y, Sugawara K, Abiko C, Ikeda T, Aoki Y, Mizuta K, Katsushima N, 
Katsushima F, Katsushima Y, Itagaki T, Shimotai Y, Hongo S, Muraki Y, 
Nishimura H. 2014. Epidemiological information regarding the periodic epidemics 
of influenza C virus in Japan (1996–2013) and the seroprevalence of antibodies to 
different antigenic groups. J. Clin. Virol. 61:87–93. doi:.10.1016/j.jcv.2014.06.017 
 
152. Kauppila J, Ronkko E, Juvonen R, Saukkoriipi A, Saikku P, Bloigu A, Vainio O, 
Ziegler T. 2014. Influenza C virus infection in military recruits-symptoms and 
clinical manifestation. J. Med. Virol. 86(5):879-885. 
 
153. Pabbaraju K, Wong S, Wong A, May‐Hadford J, Tellier R, Fonseca K. 2013. 
Detection of influenza C virus by real time RT‐PCR assay. Influenza Other Respir. 
Viruses 7:954–960. 
 
154. Coiras MT, Pérez-Breña P, García ML, Casas I. 2003. Simultaneous detection of 
influenza A, B, and C viruses, respiratory syncytial virus, and adenoviruses in 
clinical samples by multiplex reverse transcription nested-PCR assay. J. Med. 
Virol. 69:132–144. 
 
155. Salez N, Mélade J, Pascalis H, Aherfi S, Dellagi K, Charrel RN, Carrat F, de 
Lamballerie X. 2014. Influenza C virus high seroprevalence rates observed in 3 
different population groups. J. Infect. 69:182–189. 
 
156. Yamaoka M, Hotta H, Itoh M, Homma M. 1991. Prevalence of antibody to influenza 
C virus among pigs in Hyogo prefecture Japan. J. Gen. Virol. 72:711–714. 
 
157. Manuguerra JC, Hannoun C, Aymard M. 1992. Influenza C virus infection in 
France. J. Infect. 24:91-99. 
 
158. Center for Disease Control and Prevention. Influenza (flu). 2015. 
http://www.cdc.gov/flu/index.htm. Accessed July 2, 2015. 
 
159. Yuanji G, Desselberger U. 1984. Genome analysis of influenza C viruses isolated in 
1981/82 from pigs in China. J. Gen. Virol. 65:1857–1872. 
 
160. Matsuzaki Y, Abiko C, Mizuta K, Sugawara K, Takashita E, Muraki Y, Suzuki H, 
Mika M, Shimada S, Sato K, Kuzuya M, Takao S, Wakatsuki K, Itagaki T, Hongo 
S, Nishimura H. 2007. A nationwide epidemic of influenza C virus infection in 
Japan in 2004. J. Clin. Microbiol. 45:783-788. 
  
59 
 
 
 
 
Chapter 3 
 
Development of an indirect ELISA, blocking ELISA, fluorescent microsphere 
immunoassay and fluorescent focus neutralization assay for serologic evaluation of 
exposure to North American strains of Porcine Epidemic Diarrhea Virus 
 
Faten Okda1,2, Xiaodong Liu1, Aaron Singrey1, Travis Clement1, Julie Nelson1, Jane 
Christopher-Hennings1, Eric Nelson1, and Steven Lawson1 
 
1Animal Disease Research and Diagnostic Laboratory, Department of Veterinary and 
Biomedical Sciences, South Dakota State University, Brookings, 57007, SD, USA. 
2National Research Center, Giza, Egypt. 
 
This paper is published in BMC Veterinary Research (2015) 11:180 DOI 
10.1186/s12917-015-0500-z 
 
Abstract 
Background:  Recent, severe outbreaks of porcine epidemic diarrhea virus (PEDV) in 
Asia and North America highlight the need for well-validated diagnostic tests for the 
identification of PEDV infected animals and evaluation of their immune status to this 
virus. PEDV was first detected in the U.S. in May 2013 and spread rapidly across the 
country. Some serological assays for PEDV have been previously described, but few 
were readily available in the U.S. Several U.S. laboratories quickly developed indirect 
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fluorescent antibody (IFA) assays for the detection of antibodies to PEDV in swine 
serum, indicating prior exposure. However, the IFA has several disadvantages, including 
low throughput and relatively subjective interpretation. Different serologic test formats 
have advantages and disadvantages, depending on the questions being asked, so a full 
repertoire of tests is useful. Therefore, the objective of this study was to develop and 
validate multiple improved serological assays for PEDV, including an indirect ELISA 
(iELISA); a highly specific monoclonal antibody-based blocking ELISA (bELISA); 
fluorescent microsphere immunoassays (FMIA) that can be multiplexed to monitor 
exposure to multiple antigens and pathogens simultaneously; and a fluorescent focus 
neutralization assay (FFN) to measure functional virus neutralizing antibodies. 
Results:  A recombinant North American nucleoprotein (NP) based iELISA was 
developed and validated along with a bELISA using newly developed PEDV-NP specific 
biotinylated monoclonal antibodies (mAbs) and an FMIA using magnetic beads coupled 
with expressed NA PEDV-NP. Receiver operating characteristic (ROC) analysis was 
performed using swine serum samples (iELISA n=1486, bELISA n=1186, FMIA 
n=1420). The ROC analysis for the FMIA showed estimated sensitivity and specificity of 
98.2% and 99.2%, respectively. The iELISA and bELISA showed a sensitivity and 
specificity of 97.9% and 97.6%; and 98.2% and 98.9%, respectively. Inter-rater (kappa) 
agreement was calculated to be 0.941 between iELISA and IFA, 0.945 between bELISA 
and IFA and 0.932 between FMIA and IFA. Similar comparative kappa values were 
observed between the iELISA, bELISA and FMIA, which demonstrated a significant 
level of testing agreement among the three assays. No cross-reactivity with the closely 
related coronaviruses, transmissible gastroenteritis virus (TGEV) or porcine respiratory 
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coronavirus (PRCV) was noted with these assays. All three assays detected 
seroconversion of naïve animals within 6-9 days’ post exposure. The FFN assay allows 
relative quantitation of functional neutralizing antibodies in serum, milk or colostrum 
samples. 
Conclusion: Well-validated iELISA, bELISA and FMIA assays for the detection of 
PEDV antibodies were developed and showed good correlation with IFA and each other. 
Each assay format has advantages that dictate how they will be used in the field. Newly 
developed mAbs to the PEDV-NP were used in the bELISA and for expediting FFN 
testing in the detection and quantitation of neutralizing antibodies. In addition, these 
PEDV mAbs are useful for immunohistochemistry, fluorescent antibody staining and 
other antigen-based tests. Measurement of neutralizing antibody responses using the FFN 
assay may provide a valuable tool for assessment of vaccine candidates or protective 
immunity. 
 
Keywords:  porcine epidemic diarrhea virus (PEDV), serology, ELISA, fluorescent 
microsphere immunoassay (FMIA), Fluorescent Focus Neutralization (FFN) 
 
Background 
Porcine epidemic diarrhea virus (PEDV) was first described in Europe in the 
1970s with more recent and severe outbreaks in Asia [1,2]. The virus was identified in 
the United States in May 2013, causing severe diarrhea and vomiting in pigs across age 
groups, with high mortality of up to 90%-95% in suckling pigs [3]. PEDV is an 
enveloped, single stranded RNA virus belonging to the Coronaviridae family. The 
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coronaviruses taxonomically form a subfamily (Coronavirinae) within the order 
Nidovirales. Recently, the International Committee on Taxonomy of Viruses (ICTV) 
recognized four genera within the Coronavirinae subfamily: Alphacoronavirus, 
Betacoronavirus, Gammacoronavirus, and Deltacoronavirus [4]. PEDV belongs to the 
genus Alphacoronavirus along with other swine viruses including transmissible 
gastroenteritis virus (TGEV) and porcine respiratory coronavirus (PRCV). 
 The genome is composed of a large ~28 Kb molecule consisting of a 5’ 
untranslated region (UTR), a 3’ UTR, and at least seven open reading frames (ORFs) 
encoding three nonstructural proteins: ORF1ab (pp1a and pp1ab) and ORF3, an 
accessory protein. The four major structural proteins of the mature virion include the 
spike (S) glycoprotein (Mr 150-220 kDa), the nucleoprotein (NP) (Mr 45-57 kDa) that is 
associated with the positive stranded RNA providing integral support for its helical 
structure, the glycosylated membrane protein (M) (Mr 20-30 kDa), and the glycosylated 
envelope protein (E) (Mr 7kDa) [5,6,7].  
 Coronaviruses are taxonomically assigned to different genera based on their 
rooted phylogeny and calculated evolutionary distance for seven highly conserved 
genomic domains within ORF 1ab [8]. The genetic diversity of coronaviruses may be due 
to their high frequency of recombination [9]. The heterogeneity among coronavirus 
subfamilies is well documented [7], and the factors that contribute to PEDV’s ability to 
gain or lose parts of its transcriptome are believed to have contributed to quasispecies 
with novel traits that are able to adapt to new hosts, ecological niches and zoonotic 
events. The exact origin of PEDV in North America is not entirely clear, but there is 
evidence of genetic similarities to Chinese PEDV strains [10].  
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Recently, a novel NA PEDV recombinant strain was identified (S INDEL) 
containing both insertions and deletions within the N-terminal domain of the ORF 3 and 
S1 genes. Specifically, sequence alignment indicated spike gene nucleotide deletions at 
positions 164-169 that correspond to amino acid deletions at positions 55 and 56 in 
addition to substitutions at positions 23 (I), 31 (H), 57 (K), and 59 (E) as compared to the 
CV777strain [10,11].  
The relatedness of several PEDV strains circulating in China was evaluated by Li 
et al. [5] using phylogenic analysis of the NP gene and no insertions or deletions were 
noted. Sequence comparison with other European and Korean PEDV strains obtained 
from GenBank indicated that the NP genes were highly conserved (94.7%- 97.7%) even 
though these strains originated from different geographic regions [5]. In addition to being 
highly conserved among PEDV variants, the NP is the most abundant viral protein 
expressed in PEDV infected cells [12,13]. In contrast, the spike protein is presented on 
the viral surface and subject to various host immune pressures, which predisposes it to a 
greater range of genetic heterogeneity including insertions and deletions. Because the NP 
protein is highly abundant in virus infected cells, it provides an attractive target for the 
development of antigen-based serological assays. Taken together, this evidence provided 
rationale for using it as our antigen of choice for the iELISA, bELISA and FMIA.  
 In response to the recent outbreaks of highly virulent PEDV in North America 
(NA), PCR assays were quickly developed to detect the presence of PEDV RNA in 
intestine or fecal material. These assays provide an important tool in control of the virus; 
however, well-validated, high-throughput assays to detect antibodies following infection 
would provide additional valuable diagnostic tools for the swine industry. The ability to 
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detect and evaluate antibody responses using serologic tests is important in efforts to 
answer basic production related questions. These questions may include whether a 
production site is naïve or has historically experienced a PEDV exposure, even though a 
producer has not seen obvious clinical signs; the level of immune response sows may 
have in relation to vaccination, initial wild-type virus infection or intentional feedback 
exposure; and whether sow immunity is inadequate when clinical infection occurs in 
individual litters after initial PEDV exposure in a herd. 
 One of the most pressing issues of PEDV disease is maintaining herd site 
biosecurity through exclusion measures to prevent viral entrance into swine units. 
However, PEDV infection may not always be obvious in finishing pigs so the widespread 
transport of these animals may represent additional risks. Thus, sensitive serological tests 
provide a valuable tool in the detection of recent infection to avoid the introduction of 
these animals into naïve herds.   
 Since PEDV was widespread in Europe in the 1970s and 1990s and more recently 
in Asia, various serologic tests have been developed and subjected to varying degrees of 
validation [14,15,16,17,18,19,20]. However, few assays have been developed using 
antigens associated with contemporary strains currently circulating across NA. The need 
to develop more sensitive serological assays has become paramount in order to address 
questions regarding PEDV infections and epidemiological transmission patterns, as well 
as to analyze disease progression.  
 Currently, serum virus neutralization (SVN) tests are the most widely employed 
serological assays used to detect PEDV antibodies. It is a test that is highly specific and 
useful for screening of antibody titer post vaccination [1,16]. However, the test is 
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expensive and labor intensive, requiring manual reading and interpretation of virus 
induced cytopathic effect (CPE) endpoints. Moreover, serum cytotoxicity can be 
mistaken for viral CPE, giving rise to false interpretations at lower serum dilutions.   
 Several laboratories have generated in-house indirect ELISAs using either virus 
derived antigen or recombinant structural proteins. Early indirect ELISAs were 
developed using Vero cell derived, whole virus preparations [15,21] or Vero cell 
expressed viral proteins [16]. These methods may be problematic because serum from 
animals vaccinated with cell culture derived PEDV may cross-react with cellular 
components of ELISA antigen, causing low specificity and high background. Other 
groups have used recombinantly expressed, purified, structural S and NP proteins for 
iELISA serodiagnosis, but because low numbers of experimentally derived samples were 
used to evaluate the performance of the assay, full validation of the diagnostic 
sensitivities and specificities could not be assessed [19,20].  
Both the iELISA and bELISA formats have proven useful for the serodiagnosis of 
experimental and natural infections. Blocking or competitive ELISAs have been shown to 
be especially useful where a higher level of specificity is required. The increased 
specificity has been shown to be dependent on both the isotype and on the target 
specificity of the monoclonal or polyclonal antibodies [6,17,22]. Various laboratories 
have developed sensitive blocking ELISAs, and Carvajal et al. [17] demonstrated their 
bELISA was able to detect an antibody response 3 to 5 days earlier than IFA, which 
suggested higher sensitivity of the bELISA. In addition, the bELISA is valuable as a 
confirmatory test where unexpected positive results appear in presumably negative herds. 
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 The fluorescent microsphere immunoassay is based on fluidic, particle array 
technology (Luminex Corp., Austin, TX) and has become increasingly standardized and 
accepted in applications involving the serologic diagnosis of autoimmune and animal 
infectious diseases [23,24]. There are distinct advantages of the FMIA over the ELISA, 
which include higher sensitivity, higher sample throughput analysis, and the ability to 
multiplex and monitor exposure to multiple pathogens simultaneously in a single sample. 
In addition, multiple bead sets in the FMIA could be added to a standardized assay 
against newer virus subtypes that continue to emerge in the field or to assess 
antigenic/phylogenetic differences between genera of coronaviruses.   
 In this study, we report the adaptation of a recombinant, highly purified, NA 
PEDV-NP antigen to the development of iELISA, bELISA and FMIA platforms for the 
detection of PEDV antibodies in serum. These assays provide high throughput serological 
tests designed to address PEDV disease diagnostics. They were fully validated using a 
large number of serum samples of known status, and validation of the tests was detailed 
using methods for the validation of serological assays for the diagnosis of infectious 
diseases previously described by Jacobson for the Office International des Epizooties 
[25]. In addition, a fluorescent focus neutralization (FFN) assay was developed for the 
rapid evaluation of neutralizing antibody responses. 
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Methods 
 
Animal samples for assay validation and time-course serological evaluation  
For time course studies, serum samples from experimentally infected animals 
were obtained courtesy of Dr. Richard Hesse (Kansas State University Veterinary 
Diagnostic Laboratory, National Pork Board Grant #13-228). Thirty-three PEDV naïve 3-
week-old feeder pigs were obtained from a private, high-health status swine production 
farm. Of the 33 pigs, 23 were inoculated with PEDV at 4 weeks of age via intranasal and 
oral routes with a pool of gut derived intestinal contents that had been used as “feedback” 
inocula for controlled exposure of a sow herd. Serum was collected prior to challenge and 
at days 0, 6, 9, 14, 21, 28, 35 and 43 days’ post-infection (DPI). Multiple aliquots of all 
samples collected were shared with requesting laboratories to expand diagnostic testing 
and vaccine development capabilities.  
To accurately assess the diagnostic sensitivity and specificity of the assays, 
samples of known serostatus for PEDV were used. This included sera from multiple 
animal populations including experimentally infected animals and serum samples from 
animals with known historical exposure to PEDV that were submitted to the South 
Dakota Animal Disease Research and Diagnostic Laboratory (ADRDL). PEDV negative 
sample sets included samples from PEDV negative control pigs used in experimental 
studies and selected high biosecurity herds with no history of PEDV. In addition, 
archived serum samples collected prior to the emergence of PEDV in the U.S., including 
samples testing positive for the related swine coronaviruses TGEV and PRCV (n=>50), 
were used. The exact number of positive and negative sera used for sensitivity and 
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specificity calculations per assay with statistical testing agreement calculations based on 
serum numbers is listed in Table 3.1. The majority of these sera were identical among 
assays, but limited serum volume did not allow for use of all sera samples among all 
assays.  
 
Antigen production, expression of recombinant PEDV-NP protein 
The development and validation of the iELISA and bELISA made use of a 
recombinantly expressed full length NA PEDV-NP. The NP open reading frame (ORF) 
of PEDV was amplified from RNA extracted directly from intestinal contents by RT-
PCR from a case submitted to the South Dakota ADRDL. It was subsequently 
directionally cloned into the E. coli, pET 28a(+), plasmid expression vector (Novagen, 
Madison, WI), then transformed into BL21-Codon Plus (DE3)-RP competent cells 
(Stratagene, La Jolla, CA) for protein expression. Primers used for the amplification of 
the full length (1323bp) nucleoprotein were: PEDV-NP-fwd (5’-
CGCGGATCCATGGCTTCTGTCAGTTTTCAG-3’); PEDV-NP-rev (5’- 
CACACTCGAGATTTCCTGTGTCGAAGATCTC-3’). Next, 20µl of transformed cells 
were plated onto Luria-Bertani agar plates containing 50µg of kanamycin/ml and 
incubated overnight. The following morning, colonies from the agar plates were added to 
1L of pre-warmed 2X yeast extract tryptone (YT) culture medium containing 50µg 
kanamycin/ml and allowed to grow to an OD600 of 0.5 at 37 ºC. PEDV-NP expression 
was induced using isopropyl -D-1-thiogalactopyranoside (IPTG) at a final 
concentration of 1.0 mM to induce transcription of the Lac operon, and the E. coli was 
allowed to incubate for an additional 8 hours at 37 ºC with shaking at 200 RPM. The agar 
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was strained out and bacteria pelleted by centrifugation at 12,000 g for 10 minutes at 4°C. 
The pellet was resuspended in 40 ml of lysis buffer solution (B-PER, Pierce, Rockford, 
IL), incubated for 15 minutes at 20-22 ºC, then centrifuged at 12,000 g to separate the 
soluble from insoluble proteins. The PEDV-NP recombinant protein was expressed as 
insoluble periplasmic inclusion bodies. The resulting 441 amino acid recombinant protein 
was denatured using 8M urea, subsequently purified three times using nickel-NTA 
affinity column chromatography and refolded back to its native conformational state. 
Individual affinity column elutions were collected, pooled and confirmed by SDS-PAGE, 
then aliquoted/frozen at -80 ºC. The correct nucleotide sequence was confirmed by 
sequence and restriction endonuclease analysis. The average protein yield produced by 
the pET28a-PEDV-NP plasmid construct was calculated to be 11 mg PEDV-NP per liter 
of 2XYT under the aforementioned conditions. The recombinant protein was detected 
and a predicted molecular weight of 51 kDa confirmed via Western Blotting using 
convalescent sera, a 6X histidine-specific mAb (Novagen, Madison, WI) and a PEDV-NP 
specific mAb (Figure 3.1 and 3.2).   
 
mAb production and biotinylation 
Two separate mAbs were developed in our laboratory (SD6-29 and SD17-103) 
that recognize both the native conformation of the PEDV-NP and the full length, linear, 
recombinant protein used in all antibody capture assays. Hybridomas were produced as 
previously described [26].  Immunoglobulin isotyping of the resulting mAbs was 
performed using a commercial lateral flow assay (Serotec, Raleigh, NC). Subsequently, 
mouse ascites fluid was produced in pristane-primed mice, and the antibodies were 
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purified and biotinylated for use as the detection moiety for the bELISA [23]. The 
conjugated antibody solution was quantified via the Lowry protein method, and carrier 
BSA was added to a final concentration of 10 mg/ml, then aliquoted and stored at −20 ºC. 
 
IFA 
Vero-76 cells (ATCC CRL-1587) were cultured with MEM + 10% FBS for 48-72 
hours until fully confluent in 96-well plates, then washed twice with MEM. 
Subsequently, alternating rows of 96-well plates were inoculated with the cell culture 
adapted PEDV NVSL-CO strain of PEDV (PEDV USA/Colorado/2013, GenBank 
accession number KF272920) at a multiplicity of infection (MOI) of 0.05 with MEM 
supplemented with 1.5 µg/ml trypsin (TPCK treated, bovine derived (Sigma, St. Louis, 
MO)). After incubation at 37 ºC for 20-24 hours, monolayers were fixed with 80% 
acetone for 20 minutes. Serum samples were initially serially diluted from 1:40 to 1:320 
with PBS in duplicate wells, and 100 µls of the diluted serum were added to each well. 
The plates were incubated at 37 ºC for 1 hour and then rinsed 3X with PBS. Next, 
fluorescein isothiocyanate (FITC)-conjugated goat anti-swine IgG (KPL, West Chester, 
PA) was prepared at a dilution of 1:15 with PBS and 50 µl added to each well. After 1 
hour of incubation at 37°C, plates were rinsed 3X with PBS and examined using 
fluorescent microscopy. For each individual test, each PEDV infected well was compared 
to its respective uninfected partner well, and a positive sample was indicated if a PEDV 
specific fluorescent signal was observed at a serum dilution of 1:40 or greater. All 
samples were tested in duplicate, and the antibody titer was expressed as the mean of all 
replicates.   
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iELISA 
The serological PEDV-NP indirect ELISA was performed by coating alternate 
wells of Immulon 1B, 96-well, microtiter plates (Thermo Labsystems, Franklin, MA) 
with 250 ng/well of purified, recombinantly expressed PEDV-NP antigen. The optimal 
dilution of the recombinant protein and secondary detection antibody was determined by 
a checkerboard titration that gave the highest signal to noise ratio. In addition, a single lot 
of pooled convalescent serum from PEDV infected pigs was used to generate quality 
control standards that gave high and low optical density (high OD = 2.0 to 2.5; low OD = 
0.5 to 1.0; and negative OD < 0.2). PEDV-NP recombinant protein was diluted to 2.5 
µg/ml in 15 mM sodium carbonate-35 mM sodium bicarbonate- antigen coating buffer 
(ACB) pH 9.6. Odd-numbered columns were coated with 100 µl of ACB plus antigen, 
while the even-numbered columns were coated with ACB without antigen, serving as 
background control. The plates were incubated for one hour at 37 ºC, then washed 3X 
with PBS plus 0.05% tween20 (PBST). Each well was then blocked with 200 µl of sample 
milk diluent (PBST plus 5% nonfat dry milk, (SMD)) and allowed to incubate overnight 
at 4 ºC. The following day, the plates were washed 3X with 300 µl of PBST. Test and 
control sera were diluted 1/50 in SMD, mixed, and 100 µl of the solution was added to 
each well. The plates were incubated for 1 hour at 20-22 ºC. Next, 100 µl of biotinylated, 
goat anti-swine detection antibody (Bethyl Laboratories, TX) was added at a 
concentration of 200 ng/ml of PBST and allowed to incubate at 20-22 ºC for 1 hour. The 
plate was washed 3X with 300 µl of PBST, then 100 µl of streptavidin-HRP conjugate 
(Pierce, Rockford, IL) was added and incubated for another hour at 20-22 ºC, then 
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washed and developed with 3,3’,5,5’- tetramethylbenzidine, peroxidase substrate (TMB) 
(Surmodics, Eden Prairie, MN). Color development progressed until the positive control 
attained a standard OD and was stopped using 2N H2SO4. Colorimetric development was 
quantified spectrophotometrically at 450 nm with a ELx800 microplate reader (BioTek 
Instruments Inc., Winooski, VT) controlled by XCheck software (Idexx Laboratories, 
Westbrook, ME). The raw data was normalized and transformed into an Excel 
spreadsheet. Sample to Positive (S/P) ratios were calculated using the following formula: 
S/P = optical density (OD) of sample - OD of buffer/OD of positive control - OD of 
buffer.  
 
bELISA 
The serological bELISA was performed using Immulon 1B, 96-well microtiter 
plates (Thermo Labsystems, Franklin, MA). Alternate wells of each plate were coated 
with 500 ng per well of expressed PEDV-NP antigen. The optimal dilution of the 
recombinant protein and mAb antibody was determined by a checkerboard titration that 
gave the highest signal to noise ratio with an OD reading of approximately 2.0, in the 
absence of swine serum/competitor antibody. First, PEDV-NP recombinant protein was 
diluted to 2.5 µg/ml of ACB. Odd-numbered columns were coated with 100 µl of ACB 
plus antigen, while the even-numbered columns were coated with ACB without antigen 
serving as background control. The plates were incubated for 1 hour at 37 ºC, washed 3 
times with PBST, then placed at 4 ºC overnight. The following day, each well was 
blocked with 300 µl of SMD and incubated one hour at 37 ºC. Plates were washed 3 
times with PBST, and 100 µl of test and control sera were diluted 1/3 with PBST + 0.1% 
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nonfat dry milk and added to each of the duplicate wells. Plates were incubated 1 hour at 
37 ºC. During sample incubation, PEDV-NP specific biotinylated, mAbs (SD6-29 and 
SD17-103) were adjusted to equal titers and mixed together in a 1:1 ratio. Next, 100 µl of 
a 1:40,000 dilution of the antibody detection mixture was added to the microtiter plate 
containing the competitive swine antibody, then swirled and incubated for an additional 
30 minutes at 37 ºC. The plates were washed 3 times, and 100 µl of high sensitivity, 
streptavidin-horseradish peroxidase conjugate (Pierce, Rockford, IL) was added to all 
wells of the microtiter plate for 1 hour at 37 ºC.  
Plates were washed 4 times with PBST, and 100 µl of TMB was added to all wells and 
gently swirled. After approximately15 minutes, color development progressed until the 
negative control attained a standard OD of approximately 2.0 and was subsequently 
stopped using 2N H2SO4. Colorimetric development was quantified 
spectrophotometrically at 450 nm with an ELx800 microplate reader (BioTek Instruments 
Inc., Winooski, VT) controlled by XCheck software (Idexx Laboratories, Westbrook, 
ME). The raw data was normalized and transformed into a Excel spreadsheet, and the 
percent inhibition (PI) ratio was calculated using the following formula: PI= 1-{(OD of 
sample - OD of buffer)/(OD of negative control – OD of buffer)} X 100. 
 
Preparation of PEDV-NP coupled microspheres for the FMIA  
A two-step carbodiimide coupling procedure was used to couple NA PEDV-NP 
protein to Luminex™ microspheres. Briefly, the coupling of fluorescent microsphere was 
performed by washing 3.125 x106 microspheres twice with 250 µl activation buffer 
(0.1MNaH2PO4, pH6.2) and sonicating them for 60 seconds after each wash. 
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Microspheres were activated for 20 minutes at 20-22 ºC in 500 µl activation buffer 
containing 2.5 mg N-hydroxysulfosuccinimide (sulfo-NHS) and 2.5 mg N-(3- 
dimethylaminopropyl)-N-ethylcarbodiimide (EDC) (Pierce Chemical, Rockford, IL). 
Activated microspheres were washed twice with PBS and sonicated. Coupling was 
initiated by the addition of 12.5 µg of recombinant NA PEDV-NP protein, brought to a 
final volume of 500 µl with PBS and incubated in the dark for 3 hours at 20-22 ºC with 
rotation. Coupled microspheres were washed once with 1 ml of PBS plus 0.05% NaN3 
and 1.0% bovine serum albumin (PBS-NB). Next, the microspheres were blocked with 1 
ml of PBS-NB for 30 minutes to reduce nonspecific binding. Microspheres were then 
washed twice with PBS-NB and resuspended in PBS-NB to a final concentration of 2.0 
x106 antigen-coupled microspheres/ml. 
 
FMIA  
A 96-well hydrophilic membrane filter plate was blocked for 2 minutes with 150 
µl of PBS-NB, and then the liquid was aspirated via vacuum manifold. The plates were 
wetted with 20 µl of PBS-NB buffer to prevent drying. Next, 50 µl of serum (diluted 1:50 
in PBS-NB) was added to duplicate wells of the filter plate along with 50 µl of PBS-NB 
containing 2.5 x103 antigen-coupled microspheres. Since the microspheres and reporter 
moieties are light sensitive, all incubations were performed in the dark by sealing the 
plate with foil. Subsequently, the FMIA plate was incubated at 20-22 ºC for 1 hour on a 
plate shaker rotating at 600 rpm. The plate was washed 3 times with 200 µl of PBST. 
Next, 50 µl of anti-swine, biotinylated IgA (heavy & light chain, diluted in PBS-NB; 
Bethyl Laboratories) or IgG-FC specific polyclonal antibodies (diluted 1:2,000 dilution in 
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PBS-NB; Bethyl Laboratories) were added to the filter plate and incubated at 20-22 ºC 
for 1 hour. NP IgM and IgG isotype-specific antibody levels were detected using PEDV-
NP coated microspheres, but speciated by means of individual and separate IgM and IgG-
specific secondary antibodies. Since validation was performed using serum, and because 
IgA is present in very low amounts, IgA specific secondary antibodies were not used at 
this step. After incubation with the secondary antibodies, 50 µl of streptavidin 
phycoerythrin (2.5 µg/ml in PBS-NB, Molecular Probes) was added to each well and 
incubated for 30 minutes at 20-22 ºC with shaking. The supernatant was aspirated, and 
the plate was washed 3 times with PBST. Finally, the microspheres were resuspended in 
125 µl of PBST per well and transferred to a clear 96-well polystyrene optical plate. 
Coupled microspheres were analyzed through a dual-laser Bio-Rad Bio-Plex 200 
instrument. The median fluorescent intensity (MFI) for 100 microspheres corresponding 
to each individual bead analyte was recorded for each well. All reported MFI 
measurements were normalized via F - F0, where F0 was the background signal 
determined from the fluorescence measurement of a test sample in uncoated beads and F 
was the MFI for a serological test sample using antigen-coated beads. 
 
Establishment of serological reference standards for ELISA and FMIA development 
 Four serological reference serum sets were constructed as standards termed 
high, medium, low and negative to serve as internal quality control standards and to 
mathematically normalize individual samples for objective comparisons between testing 
platforms. The high-labeled standard was designed to generate an OD above 2.0 for the 
iELISA and bELISA and an MFI of approximately 25,000 for the FMIA. The high 
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standard was used exclusively for the mathematical determination of the serological 
response (S/P ratio) of samples used for test validation. The medium standard generated a 
response of between 1.5 and 2.0 OD for the two ELISAs and approximately 10,000 MFI 
for the FMIA. The low standard was designed to deliver a signal slightly above threshold 
level for all 3 tests, and the negative serum generated an OD or MFI to a background 
level of less than 0.2 OD for the ELISAs and 600 MFI for the FMIA.  
 
Validation methods for the determination of diagnostic sensitivity, specificity, 
repeatability and threshold cutoff level  
To accurately assess the diagnostic sensitivity and specificity of the assays, 
samples of known serostatus for PEDV were used. This included sera from multiple 
animal populations including experimentally infected animals and serum samples 
submitted to the South Dakota ADRDL. PEDV negative sample sets included samples 
from selected high biosecurity herds with no history of PEDV and archived serum 
samples collected prior to the emergence of PEDV in the U.S., including samples testing 
positive for the related swine coronaviruses TGEV and PRCV. Known positive samples 
were collected from pigs that were naturally infected at least 3 weeks prior to collection 
and were previously positive by PCR. The negative-testing sample population 
(uninfected animals) consisted of maximally 980 PEDV negative serum samples, while 
the positive-testing (infected) population was composed of 516 serum samples. Receiver 
operating characteristic (ROC) analysis was calculated for each assay to assess diagnostic 
performance, which included determination of sensitivity, specificity and threshold cutoff 
using MedCalc version 11.1.1.0 (MedCalc software, Mariakerke, Belgium).   
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The repeatability of each assay was assessed by running the same internal quality 
control serum standards in multiple replicates within the same run or between runs. For 
the iELISA and the bELISA, the intra-assay repeatability was calculated for 48 replicates 
on 3 separate plates, then repeated over a 3-day period for inter-assay repeatability 
assessment. The values for each assay were expressed as a mean, standard deviation and 
percent coefficient of variation (CV%) for repeated measure. 
 
Measurement of statistical testing agreement   
 Multiple comparison, inter-rater agreement (kappa measure of association) was 
calculated among all four tests (bELISA, iELISA, FMIA and IFA) using IBM, SPSS 
version 20 software (SPSS Inc., Chicago, IL). The sample cohort used was a well-
characterized set of serum samples collected from “positive testing” experimentally 
infected pigs over time courtesy of Dr. Richard Hesse (n=158) and from archived 
experimental control uninfected PEDV “negative testing” animals. The interpretation of 
kappa can be rated as follows:  Kappa less than 0.0, “poor” agreement; between 0.0 and 
0.20, “slight” agreement; between 0.21 and 0.40, “fair” agreement; between 0.41 and 
0.60, “moderate” agreement; between 0.61 and 0.80, “substantial” agreement; and 
between 0.81 and 1.0, “almost perfect” agreement [28,29].   
 
FFN 
A PEDV virus neutralization assay using a FFN format was developed for rapid 
detection of neutralizing antibodies produced in response to PEDV infection. The FFN 
was evaluated using serum samples or rennet treated milk and colostrum samples. Heat-
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inactivated samples were diluted in a 2-fold dilution series starting at 1:10 in MEM plus 
1.5 µg/ml TPCK-treated trypsin in 96-well plates. An equal amount of cell culture 
adapted PEDV stock at a concentration of 100 foci forming units/100µl was added to 
each well and plates incubated for 1 hour at 37 ºC. The virus/sample mixture was then 
added to washed confluent monolayers of Vero-76 cells and incubated for 2 hours at 37 
ºC. Plates were washed again with MEM/TPCK-trypsin medium and incubated 20-24 
hours to allow for replication of non-neutralized virus. Plates were then fixed with 80% 
acetone and stained with FITC conjugated mAb SD6-29 to allow visualization of infected 
cells. Endpoint neutralization titers were determined as the highest serum, milk or 
colostrum dilution resulting in a 90% or greater reduction in fluorescent foci relative to 
controls. 
 
Results 
Expression of recombinant PEDV-NP antigen  
 As shown in Figure 3.1, the purity of the recombinant protein was assessed via 
SDS-PAGE and gave a band that migrated corresponding to the expected molecular mass 
of 51 kDa upon staining with Coomassie brilliant blue R250. The protein yield of the 
IPTG induced E. coli culture was calculated to be approximately 11 mg PEDV-NP/ liter 
of 2XYT medium with a purity of greater than 95%. The identity of the protein was 
further characterized by Western blot using convalescent swine serum, an anti-His mAb 
and an anti-PEDV-NP mAb (Figure 3.2). 
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Diagnostic sensitivity, specificity, repeatability and threshold cutoff level  
 To optimize the serologic assays, various antigen and serum dilutions were used 
to determine optimum concentrations. All 3 tests were optimized in a checkerboard 
fashion to maximize signal-to-noise ratios. It was determined by antigen titration that the 
optimal coating of Luminex™/FMIA microspheres was achieved at a concentration of 
12.5 µg protein per 3.125 x 106 microspheres. Similarly, the optimum coating of both the 
iELISA and bELISA plates was achieved at a concentration of 250 ng/well. In addition, 
to determine the optimum serum dilution for each of the testing platforms, a well-
characterized PEDV “high” positive serum standard was serially diluted in a log2 titration 
against antigen coated microspheres (FMIA) or antigen coated ELISA wells at a fixed 
concentration. Figure 3 shows concentration-dependent OD or MFI signals of various 
serum standards. Overall, sample absorbance increased inversely proportional to the 
serum dilution. However, based upon the highest signal-to-noise ratio, it was determined 
that the optimal serum dilution for the bELISA was 1/3, while the iELISA and FMIA 
each demonstrated an optimum dilution of 1/50 as indicated by arrows (Figure 3.3).   
ROC analysis to determine sensitivity, specificity and threshold cut-off levels was 
performed using large numbers of swine serum samples and demonstrated excellent 
agreement (>0.91 kappa scores) between assays with good intra and inter assay 
repeatability (Table 3.1). None of the known positive TGEV or PRCV samples tested 
was shown to cross-react.  
The optimal cutoff values and corresponding sensitivity and specificity of each 
individual test are presented in Figure 3.4. Specifically, ROC analysis for the iELISA and 
bELISA showed similar sensitivity and specificity of 97.9% and 97.6%; and 98.2% and 
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98.9%, respectively. The ROC analysis for the FMIA showed estimated sensitivity and 
specificity of 98.2% and 99.2%, respectively. Although the FMIA showed an identical 
sensitivity as the bELISA, it demonstrated the highest degree of specificity of all three 
assays at 99.2%. This observation was not surprising given that FMIA technology 
inherently imparts greater sensitivity and a larger dynamic range than the ELISA 
platform [30].   
 In addition to determining cutoff values, sensitivities and specificities, multiple 
comparison tests were performed to calculate the degree of agreement among the ELISA, 
FMIA and IFA tests. Specifically, the Kappa test demonstrated all diagnostic platforms 
had kappa values greater than 0.91, which demonstrates that all 4 tests are in “almost 
perfect” agreement with each other.    
 
Assessment of repeatability   
 The iELISA and bELISA demonstrated slightly lower %CVs than the FMIA 
with 3.7%, 6.8%, 10.7% intra-assay variability for bELISA, iELISA and FMIA 
respectively. Inter-assay %CVs were 5.0%, 5.6% and 7.7% for the bELISA, iELISA and 
FMIA respectively. Nonetheless, all the CVs were 10.7% or less, which demonstrated 
that the tests were highly repeatable in a diagnostic application.  
 
Evaluation of a kinetic PEDV antibody response 
 As shown in Figure 3.5, a mean antibody response to PEDV-NP could be 
detected as early as 9 DPI for both the iELISA and bELISA. The FMIA detected PEDV-
NP antibodies slightly earlier at 6 DPI. All 3 tests detected the duration of antibody out to 
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the 43 DPI time-point in this study but demonstrated a decline in detectable antibody 
after 21 DPI.  
 
Application of the FMIA to isotype PEDV-NP specific antibodies 
High levels of PEDV-NP specific IgM antibodies were observed at 7 DPI 
compared to IgG (Figure 3.6). However, the IgM antibodies decreased to barely 
detectable levels by 20 DPI. IgG continued to increase linearly to 20 DPI. There is a 
concomitant appearance of neutralizing antibodies by 14 DPI.  
 
FFN 
 The FFN assay was initially evaluated using sequential serum samples from 
experimentally inoculated piglets. Additional evaluation was conducted using 250 serum 
samples from known PEDV naïve herds and 250 samples from herds with documented 
PEDV exposure, collected at least 3 weeks after initial PCR diagnosis and whole herd 
feedback. Experimentally inoculated piglets demonstrated detectable seroconversion by 
14 DPI (Figure 3.6). Essentially all samples from PEDV naïve animals had serum FFN 
endpoint titers of <1:20 while most samples from the PEDV positive set had endpoint 
titers ranging from 1:40 to 1:1280 (data not shown). Further evaluation of the FFN 
included serum, milk and colostrum samples from 27 sows from a herd that had 
experienced an acute PEDV outbreak 6 to 7 weeks prior to farrowing. All animals were 
exposed to live virus twice within the first week of the outbreak, followed by one dose of 
Harrisvaccines Porcine Epidemic Diarrhea Vaccine, RNA (Harrisvaccines, Inc., Ames, 
IA) at 1 week pre-farrow. Serum and colostrum samples were tested at the time of 
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farrowing, followed by serum and milk samples at 1 week and 2 weeks later. As shown in 
Figure 3.7, mean colostrum titers were approximately 4-fold higher than serum titers at 
the time of farrowing. At later time-points, serum and milk titers were similar in 
magnitude, although substantial animal to animal variation was apparent.  
 
Discussion  
 Overall, this repertoire of assays is useful for initial identification and efficient, 
high throughput quantitation of PEDV antibodies. We evaluated all three diagnostic 
platforms against a well characterized IFA and compared the individual serum IgM and 
IgG kinetic antibody responses in an FMIA to the appearance of neutralizing antibody as 
detected by the FFN assay. Each of the antibody-capture assays was validated using a 
large number of serum samples (n >1,100) based upon the assay validation methods of 
Jacobson, which is supported by the Office International des Epizooties [25].   
 Since PEDV was first identified in the U.S. in May 2013, it has spread rapidly 
to at least 33 states (www.aasv.org) and has been reported in Mexico and Canada [31]. 
The virus causes severe gastroenteritis, destroying villus enterocytes in pigs of all ages, 
and is characterized by vomiting and diarrhea, leading to subsequent dehydration, high 
mortality rates and economic losses, particularly in nursery piglets [3,32]. A variety of 
serological tests have been developed against PEDV, but they vary by antigen used and 
in the degree of validation. In addition, few have used North American NP based antigens 
or compared the array of serologic assays described here. In the current study, four tests 
(IFA, bELISA, iELISA, FMIA) showed strong correlation. Each has advantages, which 
dictate how they will be used in the field. In addition, newly developed NP mAbs were 
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used in the bELISA and for expediting FFN testing in the detection of neutralizing 
antibodies.  
In the development of the ELISAs and FMIA, the full length NA PEDV-NP gene 
was amplified directly from RNA extracted from PEDV-infected ileal tissue. Multiple 
sequence alignment analysis showed that the amplified NP gene shared a 100% 
nucleotide homology with that of the US Colorado strain isolated in 2013 (Genbank 
accession no. 13-019349). Several authors confirm that the NP carries multiple antigenic 
determinants that are conserved among the Coronaviridae [33,34]. However, we 
performed one-way cross-reactivity testing using serum from TGEV and PRCV, and no 
antibody cross-reactivity was detected within any of our assays. In addition to being 
highly conserved among various PEDV variants, the NP is the most abundant viral 
protein expressed in PEDV infected cells, making it an attractive target antigen [12,13]. 
Using Western blotting experiments, we confirmed the finding of Hou et al. [19], in 
which they observed the level of expression of NP protein to be significantly higher than 
the level of the spike protein. Our study demonstrated that it is possible to achieve a 
protein yield of over 10 mg per liter of culture with a purity of greater than 95%.  
 The recombinant NP has previously been identified as a useful antigen in other 
ELISAs developed to detect antibodies in pigs located in China and Korea [19]. In a 
study by Hou et al. [19], the authors showed similar sensitivities and specificities of their 
iELISA compared to the iELISA described in this study. However, smaller numbers of 
known positive and negative samples were evaluated than in the current study.   
Since no test has 100% specificity, a bELISA was developed that is useful for 
confirmatory testing due to its higher inherent specificity than the iELISA [35]. Blocking 
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or competitive ELISAs have been constructed using monoclonal antibodies in PEDV 
serodiagnosis, and the specific methodology can affect the overall specificity and 
performance of the assay. Our method was based upon coating plates with highly purified 
NA PEDV-NP, then using a combination of two separate NA, anti- PEDV-NP specific, 
biotinylated, monoclonal antibodies as the blocking/competitive detection step. This 
allows the capture of anti-NP antibodies at higher quantities and those with a greater 
range of antigen specificities. The analytical specificity of the NP-based bELISA is also 
dependent on the affinity of the mAbs used. The antibodies used in this study are directed 
against conserved epitopes on the nucleocapsid protein without any evidence of cross-
reactivity to any other genera of Alphacoronavirus tested. A previous assessment of 
antigenic cross-reactivity was performed using these same mAbs against different strains 
of PEDV and TGEV [7]. In that study, the authors reported that both mAbs used in the 
bELISA reacted with all PEDV strains tested, namely the homologous US isolate PC22A 
and the heterologous strains S INDEL IOWA 106, S 197DEL PC177 and CV777, at 
similar titers. Neither of the PEDV-NP mAbs cross-reacted with either the TGEV Miller 
or Purdue strains. Not only were the bELISA mAbs tested for heterologous cross-
reactivity, but all three diagnostic platforms were evaluated in their ability to capture 
antibody against TGEV and PRCV, and there was no cross-reactivity to either 
heterologous virus. 
Serology testing with IFA, iELISA, bELISA or FMIA is useful in determining 
whether pigs were previously infected with PEDV, or if piglets have acquired antibodies 
through colostrum (eg. passive antibody transfer). However, tests that evaluate the 
functionality of the antibodies such as the FFN are needed to determine if the detected 
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immune response could be helpful in providing protection to nursing piglets. Neutralizing 
antibodies may be protective through actions including blocking uptake of the virus into 
cells, preventing virus binding to receptors on cells, preventing uncoating of the virus 
genomes in endosomes and/or causing aggregation of virus particles. For enveloped 
viruses, such as PEDV, lysis of the virus may also occur when antiviral antibodies and 
serum complement disrupt the viral membrane. For these reasons, an FFN-based virus 
neutralization assay was developed to assess levels of PEDV neutralizing antibodies in 
serum, milk or colostrum samples. The FFN provides a more rapid determination of 
neutralizing antibody levels than is possible with traditional virus neutralization assays 
that rely on visualization of virus-induced CPE after three or more days’ incubation to 
allow for full development of PEDV CPE. The direct observation of fluorescent stained 
infected cells, or lack of stained infected cells in the case of virus neutralization, allows 
for simple endpoint determination. This feature is particularly valuable when dealing with 
a fastidious, trypsin-dependent virus such as PEDV where CPE-based endpoints may not 
be obvious or may be confused with trypsin-induced CPE in the cell monolayer. 
Although neutralizing antibodies present in the serum would not be expected to provide 
direct protection from a strictly enteric infection such as PEDV, our data suggest a 
correlation between detectable neutralizing antibody levels in the serum and those present 
in milk and colostrum of previously exposed or vaccinated sows. 
Some correlation between PEDV neutralization results and ELISA results exists 
as described in the literature. One study performed a comparative analysis between a 
whole-virus antigen ELISA and a serum neutralization test for the serodiagnosis of 
PEDV [21]. The presence of antibodies was confirmed by each test, and an overall testing 
86 
 
 
 
 
agreement of 84.2% was demonstrated using 1,024 field serum samples. Furthermore, a 
pairwise correlation was performed that showed corrected cutoff values between the 
ELISA OD and SN titers having an R value of 0.837, indicating that the CPE-based 
neutralization test had roughly the same reliability as the ELISA test [21].  
 Newer technologies such as the FMIA are useful for the detection of antibodies 
against multiple antigens simultaneously for surveillance purposes. FMIA are bead based 
assays for simultaneous high throughput detection of antibodies to multiple antigens. The 
FMIA differs from the ELISA since it involves a fluid incubation step with “beads 
suspended in solution, which allows for higher surface area exposure in 3 dimensions” 
[30]. Therefore, there is a shorter diffusion path to antibody binding sites on the antigen 
coated beads resulting in rapid reaction times. Instead of a method using an enzymatic 
reaction such as with the ELISA, the FMIA detection is with laser technology, which 
results in a shorter detection time. This PEDV antigen specific bead set can be “mixed” 
with additional coated beads to other antigens, such as SIV, PCV2, PRRSV or other 
pathogens, for simultaneous detection of antibodies to these antigens. In addition, an 
FMIA could be developed for differentiation of wild-type infected vs vaccinated animals 
(DIVA) if proteins used in the vaccine were different from those produced in a wild-type 
infection.   
Individual kinetic serum IgG and IgM levels were measured by FMIA in 
experimentally infected animals over time. The appearance of the IgM subclass is 
considered an immunological parameter of early infection and generally appears prior to 
the appearance of IgG, and this was confirmed in our study. This was in contrast to the 
data of Woo et al., 2004, which was unable to detect IgM antibodies using their NP-based 
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indirect ELISA [36]. IgG antibodies may be more easily detected as they are 
characterized by higher antigen affinity but lower avidity than IgM [37]. Further 
understanding of various antibody profiles will provide important information on the 
ability of vaccines to stimulate a protective immune response.   
 
Conclusions  
These well-validated NA PEDV iELISA, bELISA, FMIA and FFN assays are 
useful for a range of serological investigations. They can serve as a complement to 
nucleic acid detection and determine the PEDV status of asymptomatic individuals for 
cost-effective tools in management strategies and monitoring virus exposure within the 
herd. The FMIA will be useful for isotyping the antibody responses and in multiplexing 
for determining exposure to multiple pathogens simultaneously. In addition, the FFN is 
useful for determining whether the antibodies measured are providing a biological 
function of blocking virus infectivity. Work is ongoing to further validate these assays on 
other sample matrices such as milk and colostrum for measuring passive transfer of 
antibodies and oral fluids for pen-based surveillance. 
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Table 3.1. Evaluation of statistical agreement among serological testing platforms. 
Multiple comparison, inter-rater agreement (kappa association) was calculated among all 
four tests. Kappa values shown represent a statistical measure of test agreement and were 
calculated using MedCalc version 11.1.1.0.   
 
 
  
 FMIA bELISA Indirect ELISA IFA 
IFA 0.932 0.945 0.941 1 
iELISA 0.919 0.923 1 0.941 
bELISA 0.941 1 0.923 0.945 
FMIA 1 0.941 0.919 0.932 
Number Positive 
Serum Samples 
158 158 158 158 
Number Negative 
Serum Samples 
361 361 361 361 
Total Serum 
Samples Tested 
519 519 519 519 
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Figure 3.1. Purification of antibody capture antigen SDS-PAGE / Coomassie blue 
staining of E. coli expressed and purified NA PEDV-NP antigen used to coat ELISA 
microtiter plates and FMIA microspheres. Molecular weight ladder (MW) PEDV-NP (51 
kDa). 
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Figure 3.2. Antigen/antibody specificity. Western blot analysis showing detection of 
recombinant expressed NA PEDV-NP protein and specificity of the monoclonal antibody 
used in the bELISA.  
L- Molecular weight ladder. 
A- anti-PEDV-NP mAb 6-29. 
B- anti-polyhistidine mAb.  
C- anti PEDV-NP convalescent swine serum.  
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Figure 3.3. Serum dilution optimization for both ELISA assays and FMIA. 
Reference serum standard was titrated 2-fold in antigen coated wells at a fixed 
concentration in order to gauge a maximum signal-to-noise ratio for each assay (A) 
bELISA, (B) iELISA, (C) FMIA. Arrows show the optimum dilution of swine serum 
from which the highest signal to noise ratio was achieved.   
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Figure 3.4. Receiver operator characteristic (ROC) validation and determination of 
diagnostic sensitivity and specificity of the PEDV-NP iELISA, bELISA and FMIA 
assays. Diagnostic sensitivity and specificity were calculated using serum samples from a 
known PED-uninfected and PED-infected population. ROC analysis was performed using 
MedCalc version 11.1.1.0 (MedCalc software, Mariakerke, Belgium). In each panel, the 
dot plot on the left represents the negative testing population, and the dot plot on the right 
represents the positive population.  The horizontal line bisecting the dot plots represents 
the cutoff value that gives the optimal diagnostic sensitivity and specificity. (A) Serum 
iELISA, (B) Serum bELISA, (C) Serum FMIA. 
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Figure 3.5. Kinetic time course antibody evaluation. Antibody time course kinetics 
were calculated for each of the ELISAs and FMIA using serum samples from 
experimentally infected pigs collected at weekly intervals. The horizontal line indicates 
the diagnostic cutoff for each test. All three tests demonstrate similar kinetic curve 
responses via their calculated S/P values. (A) Antibody kinetic time course via iELISA, 
(B) Antibody kinetic time course via bELISA, (C) Antibody kinetic time course via 
FMIA.  
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Figure 3.6. FFN antibody and FMIA isotype time course evaluation. Using serum 
collected over time from experimentally infected pigs, the FMIA demonstrates the kinetic 
nucleoprotein-directed, isotype-specific response of IgG and IgM in serum. In addition, 
the data show a concomitant appearance of neutralizing antibodies as soon as 14 DPI. 
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Figure 3.7: Assessment of neutralizing antibody titers in different sample matrices 
following PEDV exposure. FFN titers were detected in various sample matrices 
including colostrum (n=25), milk (n=23) and serum (n=27) collected at the time of 
farrowing and weekly for two weeks post-farrowing. Error bars indicate a 95% confident 
interval for mean titers indicated by horizontal lines.   
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Abstract 
Background:  A novel porcine deltacoronavirus (PDCoV), also known as porcine 
coronavirus HKU15, was reported in China in 2012 and identified in the U.S. in early 
2014. Since then, PDCoV has been identified in a number of U.S. states and linked with 
clinical disease including acute diarrhea and vomiting in the absence of other identifiable 
pathogens. Since PDCoV was just recently linked with clinical disease, few specific 
antibody-based reagents were available to assist in diagnosis of PDCoV and limited 
serological capabilities were available to detect an antibody response to this virus. 
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Therefore, the overall objective of this project was to develop and validate selected 
diagnostic reagents and assays for PDCoV antigen and antibody detection. 
 
Results:  The nucleoprotein of PDCoV was expressed as a recombinant protein and 
purified for use as an antigen to immunize mice for polyclonal, hyperimmune sera and 
monoclonal antibody (mAb) production. The resulting mAb were evaluated for use in 
fluorescent antibody staining methods to detect PDCoV infected cells following virus 
isolation attempts and for immunohistochemistry staining of intestinal tissues of infected 
pigs. The same antigen was used to develop serological tests to detect the antibody 
response to PDCoV in pigs following infection. Serum samples from swine herds with 
recent documentation of PDCoV infection and samples from expected naïve herds were 
used for initial assay optimization. The tests were optimized in a checkerboard fashion to 
reduce signal to noise ratios using samples of known status. Statistical analysis was 
performed to establish assay cutoff values and assess diagnostic sensitivities and 
specificities. At least 629 known negative serum samples and 311 known positive 
samples were evaluated for each assay. The enzyme linked immunosorbent assay 
(ELISA) showed diagnostic sensitivity (DSe) of 96.1% and diagnostic specificity (DSp) 
of 96.2%. The fluorescent microsphere immunoassay (FMIA) showed a DSe of 95.8% 
and DSp of 98.1%. Both ELISA and FMIA detected seroconversion of challenged pigs 
between 8-14 days’ post-infection (DPI). An indirect fluorescent antibody (IFA) test was 
also developed using cell culture adapted PDCoV for comparative purposes.  
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Conclusion:  These new, specific reagents and serological assays will allow for 
improved diagnosis of PDCoV. Since many aspects of PDCoV infection and transmission 
are still not fully understood, the reagents and assays developed in this project should 
provide valuable tools to help understand this disease and to aid in the control and 
surveillance of porcine deltacoronavirus outbreaks.  
 
Keywords:  porcine deltacoronavirus (PDCoV), monoclonal antibodies, serology, 
ELISA, fluorescent microsphere immunoassay (FMIA) 
 
Background 
Coronaviruses are enveloped, positive sense RNA viruses divided among several 
genera, including Alphacoronavirus, Betacoronavirus, Gammacoronavirus and the 
recently described genus Deltacoronavirus. A novel porcine deltacoronavirus (PDCoV) 
was reported in China in 2012 and designated HKU15 [1]. Other important porcine 
coronaviruses include porcine epidemic diarrhea virus (PEDV), transmissible 
gastroenteritis virus (TGEV) and porcine respiratory coronavirus (PRCV); members of 
the genus Alphacoronavirus [2]. In February 2014, the Ohio Department of Agriculture 
announced the identification of PDCoV in swine feces at five farms in Ohio and 
associated with enteric disease similar to PEDV in the U.S. [3]. Since then, PDCoV has 
been identified in numerous U.S. states and Canada, linked with apparent clinical disease 
including acute diarrhea and vomiting in the absence of other identifiable pathogens. 
According to field observations in the U.S., PDCoV infections cause less severe clinical 
disease than PEDV, but analysis of the field data is complicated since co-infections with 
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PEDV or other pathogens are common. PDCoV is currently diagnosed by real time PCR 
and clinical symptoms [1, 4]. 
The severity of disease in both gnotobiotic and conventional piglets has further 
defined the pathogenicity and pathogenesis of the virus [5, 6, 7].  PDCoV causes diarrhea 
and vomiting in all age groups and mortality in nursing pigs but the mortality rates are 
less than that shown in cases of PEDV. Previously, there was little information about 
deltacoronavirus infections in pigs and only one surveillance study from Hong Kong 
reported its detection in pigs prior to its emergence in the U.S. The virus had not been 
reported to be associated with clinical disease in China. The newly emergent strain found 
on the Ohio farms, PorCoV HKU15 OH 1987, is closely related to the 2 strains from 
China, but it is unknown how this virus was introduced into the US [3].   
Recently, Jung et al. [7] developed in-situ hybridization and immunofluorescence 
staining techniques to demonstrate the areas of PDCoV replication in tissues of infected 
pigs. The OH-FD22 and OH-FD100 PDCoV strains were confirmed as causing an acute 
infection through the entire intestine, but primarily the jejunum and ileum, and clinically 
lead to severe diarrhea and vomiting. Clinical signs and pathological features of PDCoV-
infected pigs resemble those of PEDV and TGEV infections. Effective differential 
diagnosis between PDCoV, PEDV, and TGEV is important to control the diseases. 
Polymerase chain reaction (PCR) assays were quickly developed for the detection 
of PDCoV infections following the initial U.S. identification in 2014 but available 
serological assays are limited. Thachil et al. [8] developed an indirect anti-PDCoV IgG 
enzyme-linked immunosorbent assay (ELISA) based on the S1 portion of the spike 
protein. Although this assay was shown to be a highly sensitive (91%) and specific test 
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(95%), there is need for other ELISAs utilizing alternative antigen targets, such as the 
nucleoprotein of PDCoV, to serve as primary serological surveillance or confirmatory 
assays. As noted in Thachil’s research, several serum samples collected in 2010 were 
found positive for PDCoV antibody by their ELISA, but all those collected in 2011 and 
2012 tested negative by that assay. This finding is interesting since PDCoV was not 
thought to be circulating in North America prior to late 2013 [7, 9]. Therefore, 
availability of several serological assay formats targeting different viral antigens can be 
valuable as confirmatory assays in the investigation of unexpected laboratory findings. 
Since no specific antibody-based reagents were available to assist in diagnosis of 
PDCoV, one purpose of the current study was to develop readily available reagents for 
detection of PDCoV antigen in diagnostic tests, such as virus isolation, 
immunohistochemistry and fluorescent antibody techniques. Serological tests for the 
detection of antibody responses to PDCoV were also very limited. Therefore, another 
objective of this study was to develop and optimize several serological assays including 
an indirect ELISA, a fluorescent microsphere immunoassay (FMIA), and an indirect 
fluorescent antibody (IFA) test. 
Both specific antibody-based reagents and serological tests are essential for the 
further study and control of PDCoV and the differentiation of PDCoV infection from 
other related diseases such as PEDV or TGEV. The tools developed during the course of 
this study can be applied to many ongoing and future studies to better understand and 
control PDCoV. 
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Methods 
Serum Samples 
Samples used for optimization and validation of the PDCoV ELISA and FMIA 
assays included samples from a large PDCoV challenge study associated with National 
Pork Board (NPB) research project 14-182. These samples and samples from another 
group of 30 pigs which were collected near the time of initial field exposure to PDCoV 
and 28 days later were used in a time course study.  
For further validation and assessment of diagnostic sensitivity (DSe) and 
diagnostic specificity (DSp), samples of known PDCoV serostatus were used (n=940). 
The expected positive samples were submitted field serum samples (n=311) from herds 
previously testing PDCoV positive by PCR at least 3 weeks prior to sample collection. 
Expected negative samples included archived experimental serum collected prior to 2009 
(n=108) and field samples from high-health herds with no known history of PDCoV 
exposure (n=521). The total number of expected negative samples was 629. 
 
Viruses and cells 
Swine testicle (ST) cells were cultured in Eagle’s minimum essential medium 
(MEM; Gibco BRL Life Technologies) supplemented by 10% fetal bovine serum (FBS), 
and antibiotics (100 units/ml penicillin and 20 g/ml streptomycin). Cells were maintained 
at 37 °C in a humidified 5% CO2 incubator. Cell culture adapted PDCoV was provided 
by the National Veterinary Services Laboratories, designated porcine coronavirus 
HKU15 strain Michigan/8977/2014 (GenBank accession KM012168). PDCoV was 
propagated on ST cells utilizing 0.8 µg/ml trypsin (TPCK-treated, bovine derived 
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(Sigma, St. Louis, MO)) in the inoculation and maintenance media. Virus infected cells 
were harvested 24-48 hr after inoculation, when significant cytopathic effect (CPE) was 
noted. 
 
Antigen production 
The antigen used for the FMIA and indirect ELISA validation was a 
recombinantly expressed, full length, PDCoV nucleoprotein (NP). RNA isolated from 
semi-purified cultured virus corresponding to the PDCoV-NP was amplified by reverse 
transcriptase polymerase chain reaction (RT-PCR) and resulting DNA cloned into the 
pET-28a protein expression vector (Novagen). Primers used for amplification of the 
nucleocapsid region are described:  
PDCoV-NP fwd (5’-CGCGGATCCATGGCCGCACCAGTAGTC 3’);  
PDCoV-NP rev (5’-CACACTCGAGCGCGCTGCTGATTCCTGCTT- 3’).  
The NP gene was prokaryotically expressed as an insoluble 41 kDa, 6x 
polyhistidine-tagged, fusion protein then purified according to previously described 
methods [10]. Purified protein was analyzed by sodium dodecyl sulfate- polyacrylamide 
gel electrophoresis (SDS-PAGE) to determine purity and linear integrity. The expressed 
PDCoV NP was recognized in Western blotting by convalescent serum and two separate 
monoclonal antibodies developed in our laboratory were used to confirm the specificity 
of the proteins. 
 
Refolding of the PDCoV NP purified protein  
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The purified protein was refolded by first solubilizing the recombinant protein 
expressed as insoluble inclusion bodies in E. coli. Briefly, the protein was solubilized in 
50mM 3-(Cyclohexylamino)-1-propanesulfonic acid (CAPS buffer, pH 11.0) containing 
1.0% N-lauroylsarcosine and 1.0mM DTT. The protein was then dialyzed overnight at 
4oC in 20 mM Tris-HCL pH 8.5 containing 0.1 mM DTT to encourage correct disulfide 
bond formation and subsequent refolding of the protein. A second dialysis step was done 
in phosphate buffered saline (PBS) to remove excess reducing agent. Testing of the re-
folded NP-based ELISA and FMIA began with checkerboard titrations of both the 
antigen and PDCoV convalescent sera to determine optimum concentrations of each. 
Depending on the calculation of signal to noise ratios, optimum concentration of NP 
antigen was identified for coating of the ELISA plates and coupling FMIA beads. We 
also identified optimum test serum dilutions and blocking agents. 
 
Development and diagnostic application of rabbit antisera and monoclonal 
antibodies 
Rabbits and mice were immunized with selected recombinant PDCoV proteins for 
production of hyperimmune antisera and monoclonal antibodies (mAbs) as previously 
described [11, 12, 13]. Immunoglobulin isotyping of the resulting mAbs was performed 
using a commercial lateral flow assay (Serotec, Raleigh, NC).  
 
Indirect fluorescent antibody assay  
An IFA assay was developed for reference purposes using pig serum of known 
serostatus. ST cells were grown in cultures for 2 to 3 days to 80% confluence on 96-well 
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plates. Odd numbered lanes were infected with PDCoV (approximately 1000 50% tissue 
culture infective doses (TCID50)/ml) in MEM supplemented with 0.8 ug/ml TPCK-
treated trypsin. The plates were incubated for 18 to 24 h. then fixed with 50% (vol/vol) 
acetone/methanol for 20 min at -20 °C, air dried, and frozen with a desiccant at -20 °C 
until they were used. Serum dilutions of 1:20 and 1:40 were applied to infected and 
control wells of the IFA plates and incubated 1 hour. After washing three times with 300 
µl of phosphate buffered saline (PBS), 40 µl of fluorescein isothiocyanate (FITC)-labeled 
goat anti-swine immunoglobulin G (41.7 g/ml; KPL, West Chester, PA) was added to 
each well. The plates were incubated at 37 °C for 1 h and washed with PBS three times. 
The cells were examined for specific fluorescence with an inverted microscope and a UV 
light source (Nikon Eclipse TS100). Serum samples were considered positive if PDCoV 
specific fluorescence was observed at the 1:20 serum dilution.   
 
Antibody detection indirect ELISA  
The refolded PDCoV NP antigen-based indirect ELISA was performed using 
methods previously described in Okda et al. [13]. Briefly, alternate wells of Immulon 1B, 
96-well, microtiter plates (Thermo Labsystems, Franklin, MA) were coated for 1 hour at 
37 °C with 200 ng/well of purified, refolded PDCoV-NP antigen diluted in 15 mM 
sodium carbonate-35 mM sodium bicarbonate, antigen coating buffer (ACB) pH 9.6.  
Next, non-bound antigen was poured off and the plates washed 3X with PBS plus 0.05% 
tween-20 (PBST), then the remaining free-binding sites were blocked with 200 µl of 
sample milk diluent ((SMD)-PBST plus 5% nonfat dry milk) and incubated overnight at 
4 ºC. Test and control sera were diluted 1:50 in SMD, and 100 µl of the solution was 
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added to each well of a washed plate. The plates were incubated for 1 hour at 22 ºC. 
Next, 100 µl of biotinylated, FC-specific, goat anti-swine detection antibody (Bethyl 
Laboratories, Montgomery, TX) was diluted 1:4000 in PBST and allowed to incubate at 
22 ºC for 1 hour. Plates were washed 3X, then 100 µl of streptavidin-horseradish 
peroxidase conjugate (Pierce, Rockford, IL, diluted 1:4000) was added and incubated for 
1 hour at 22 ºC, then washed and developed using TMB (Surmodics, Eden Prairie, MN). 
Colorimetric development was stopped using 2N H2SO4, then OD’s were quantified 
spectrophotometrically at 450 nm with a ELx800 microplate reader (BioTek Instruments 
Inc., Winooski, VT).  The raw OD’s were normalized and the corrected S/P values were 
calculated as follows: S/P= (OD of sample - OD of buffer) / (OD of positive control - OD 
of buffer). 
The optimal dilution of the recombinant protein and secondary detection antibody 
was determined by a checkerboard titration that gave the highest signal to noise ratio. In 
addition, a single lot of pooled convalescent serum from PDCoV infected pigs was used 
to generate quality control standards that gave high, medium and low Sample to Positive 
(S/P) values. The negative, low and medium samples served as internal quality standards 
while the high standard served as a serum constant to mathematically calculate S/P values 
of individual unknowns. For the ELISA, a high positive S/P = 0.8-1.0; medium S/P= 0.6-
0.8; low S/P = 0.4-0.6; and negative S/P < 0.2. 
 
Microsphere coupling and FMIA procedure 
The coupling of purified, recombinant, refolded PDCoV-NP antigen to 
fluorescent microspheres was performed using a two-step, carbodiimide coupling 
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reaction as previously described [14].  Prior to performing large scale coupling reactions 
for test validation, the optimization of the amount of antigen used was obtained by 
performing a checkerboard titration of antigen-coupled microspheres against a two-fold 
titration of swine serum.  It was found that initiating a coupling reaction having 12.5ug of 
purified protein per 3.125 x 106 microspheres was optimal in obtaining the highest signal-
to-noise fluorescence ratio.  The performance of the FMIA test was described in detail 
previously by Okda et al. [11].  In the initial optimization of the FMIA test, we performed 
two-fold serial dilutions of swine serum and concluded that a dilution of 1:50 provided 
the highest signal-to-noise ratio.  For the generation of sample fluorescence, antigen-
coupled microsphere/antibody complexes were analyzed through a dual-laser Bio-Rad 
Bio-Plex 200 instrument. The median fluorescent intensity (MFI) for 100 microspheres 
corresponding to each individual bead analyte was recorded for each well. All reported 
MFI measurements were normalized by calculating individual S/P values using the 
following formula: S/P = MFI of sample - MFI of buffer control / MFI of high positive 
control - MFI of buffer control. The buffer control equated to the background signal 
determined from the fluorescence measurement of antigen-coated beads. Lastly, a single 
lot of pooled convalescent serum from PDCoV infected pigs was used to generate quality 
control standards that gave high, medium and low S/P values. The negative, low and 
medium samples served as internal quality standards while the high standard served as a 
serum constant to mathematically calculate S/P values of individual unknowns. For the 
FMIA, a high positive S/P = 0.8-1.0; medium S/P= 0.6-0.8; low S/P = 0.4-0.6; and 
negative S/P < 0.2, is consistent with the data of the ELISA standards.    
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Antibody capture efficacy comparison between refolded vs linear PDCoV-NP 
antigen 
An antibody capture titration assay was employed to compare the efficacy of 
refolded vs. linear antigen to capture anti-PDCoV-NP specific antibody in swine serum. 
Wells of a 96-well microtiter plate were coated with 10-fold decreasing concentrations of 
either linearly expressed or refolded PDCoV-NP antigen in ACB, pH 9.6., then allowed 
to incubate for 1 hour at 37 °C. Each well was then blocked with 200 µl of SMD and 
allowed to incubate overnight at 4 ºC. The following day, the plates were washed 3X with 
300 µl of PBST. Well characterized positive control sera having a “high” positive OD 
was diluted 1/50 in SMD, mixed, and 100 µl of the solution was added to each well. The 
ELISA was continued pursuant to the stated protocol and the OD was recorded at each 
titration point, then a logarithmic regression curve was generated. Relative capture 
efficiencies for each antigen-coated well was determined by analyzing the OD at each 
dilution point and position under the linear portion of the curve. 
 
Assay validation 
(i) Cutoff determination, DSe and DSp. To accurately assess the DSe and DSp 
of the assays, the assays were validated using seronegative and seropositive samples from 
different distinct animal populations. The expected positive samples used were field 
serum samples submitted to the ADRDL from herds previously testing PDCoV positive 
by PCR. Expected negative samples included archived experimental serum collected 
prior to 2009 and field samples from high-health herds with no known history of PDCoV 
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exposure. Receiver operating characteristic (ROC) analysis was performed using 
MedCalc version 11.1.1.0 (MedCalc software, Mariakerke, Belgium). 
(ii) Measurement of repeatability. The repeatability of the FMIA and ELISA 
was assessed by running the same lot of internal quality control serum standards multiple 
times on the same plates and on different plates over time. The intra-assay repeatability 
was calculated for 36 replicates on a single plate and then repeated over a 3-day period 
for inter-assay repeatability assessment. Each assay was run in a single-plex format, and 
median fluorescence intensity values were expressed as median, standard deviations, and 
percent coefficients of variation (CV) for repeated measurements. Percent CV was 
calculated using a method described earlier [15]. 
 
Statistical analyses and Measurement of testing agreement 
Multiple comparison, inter-rater agreement (kappa measure of association) was 
calculated among all three tests (ELISA, FMIA and IFA) using IBM, SPSS version 20 
software (SPSS Inc., Chicago, IL). The sample cohort used included a set of archived 
serum samples collected from PDCoV “positive testing” experimentally infected pigs 
over time and from archived experimental control uninfected PDCoV “negative testing” 
animals. The interpretation of kappa can be rated as follows: Kappa less than 0.0, “poor” 
agreement; between 0.0 and 0.20, “slight” agreement; between 0.21 and 0.40, “fair” 
agreement; between 0.41 and 0.60, “moderate” agreement; between 0.61 and 0.80, 
“substantial” agreement; and between 0.81 and 1.0, “almost perfect” agreement [16]. 
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Validation of the tests was performed by ROC analysis using Medcalc statistical 
software. Correlations between the tests and scatterplots for seroconversion were 
performed using SPSS 20.   
 
Results  
Expression of recombinant full-length nucleoprotein 
The full-length NP of PDCoV was cloned and expressed in E. coli as a 
polyhistidine fusion protein. Antigen purity was then evaluated using SDS-PAGE in 
which the His-tagged recombinant NP migrated through the gel according to its predicted 
molecular mass of 41 kDa upon staining with Coomassie brilliant blue R250 (Figure 
4.1A). The recombinant protein was expressed in the form of insoluble inclusion bodies. 
It was purified by Nickel-NTA affinity column chromatography and yielded a calculated 
concentration of approximately 10mg PDCoV-NP /liter of 2XYT medium and having a 
purity greater than 95% as measured by the Lowry protein assay. The protein was 
subsequently refolded back to its soluble, conformational structure and its specificity was 
tested via Western blotting (Figure 4.1B). The figure illustrates the migration pattern and 
antigen specificity of the refolded PDCoV-NP/polyhistidine fusion protein as compared 
to the adjacent lane loaded with semi-purified, concentrated PDCoV. Both the rPDCoV-
NP and native virus are recognized with equal intensity by a PDCoV-NP-specific 
monoclonal antibody (SD55-197) developed in our laboratory. Also, the recombinant 
nucleocapsid protein is shown to have a higher molecular mass than the native virus 
nucleocapsid due to its dual amino and carboxy terminus polyhistidine tags.   
Experiments were conducted to assess the immunoreactivity of refolded vs non-
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refolded PDCoV-NP antigen used for both tests. Specifically, an antibody capture 
titration ELISA was employed to compare the ability of a refolded and non-refolded 
version of the antigen to capture antibodies within swine serum. The immunoreactivity of 
antigen was determined by end-point titration and relative absorbance values as we 
observed differences in immunoreactivity based upon the conformational state of antigen 
tested. Figure 2 demonstrates in a dose-dependent fashion, that as the concentration of 
each antigen coated well decreases, the refolded antigen imparts a greater degree of 
antibody capture efficacy of swine antibodies than the non-refolded version. Specifically, 
a 27 fold difference at the end of the linear portion of the curve was calculated, 
illustrating that the refolded protein maintained a marked enhancement of 
immunoreactivity resulting in a greater dynamic range of the assay.  
 
Fluorescent microsphere immunoassay and indirect ELISA development 
(i) Establishment of control standards:  ELISA and FMIA test reference 
standards for PDCoV were developed for each of the respective prototype assays (Figure 
4.3 A & B). A control high positive standard was established by pooling several lots of 
serum collected from convalescent, seropositive pigs, and used to mathematically 
calculate S/P values of each assay. The medium and low positive samples served as 
internal quality control standards. The negative standard was pooled from a set of known 
seronegative pigs from a herd with no known prior PDCoV infection that also tested 
negative by PDCoV IFA and virus neutralization.  
(ii) Test optimization:  A series of coupling processes were performed using a 
two-fold titration of antigen to determine the optimum coupling concentration. A total of 
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3.125 x106 beads, were incubated with various concentrations (100 µg, 50 µg, 25 µg, and 
12.5 µg) of purified NP. Based upon the highest signal-to-noise ratio reflecting the 
detection of PDCoV-specific antibodies in standard serum, 12.5 µg per reaction was the 
optimal concentration for microsphere coupling. ELISA microtiter plates were coated 
with an optimized concentration of 200 ng antigen per well. 
Testing the re-folded, NP antigen-based ELISA and FMIA began with 
checkerboard titration of both antigen and PDCoV convalescent and naïve swine serum 
to determine the optimum signal-to-noise ratio of each test. We also identified optimum 
test serum dilutions and blocking agents. The optimal serum dilution of each assay was 
determined by diluting serum samples two-fold in their respective blocking/detergent 
buffer diluent. For both the FMIA and ELISA, a serum dilution of 1:50 was shown to 
produce an optimal signal-to-noise ratio (Figure 4.3 C & D). Testing field samples of 
known serological status was performed to gauge initial sensitivity of the assay. Our 
results showed a positive to negative sample ratio (P/N) of greater than 16-fold with 
ELISA and a P/N of greater than 40-fold with FMIA. The P/N is a relative measure of 
PDCoV antibody concentration between seropositive and seronegative samples. Having a 
diagnostic P/N of greater than 10 is highly desirable with any serological assay. 
 
Assessment of test repeatability 
The intra-assay repeatability was calculated for 36 replicates on a single plate and 
then repeated over a 3-day period for inter-assay repeatability assessment. Internal 
control serum standards were used to determine the precision of each FMIA and ELISA. 
The inter-assay and intra-assay repeatability of each test demonstrated a coefficient of 
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variation of less than 8.6%. These results confirmed that the serological tests are highly 
repeatable in diagnostic applications.   
 
Validation methods and cutoff determination 
ROC analysis of both FMIA and ELISA was performed using MedCalc software 
to calculate an optimized cutoff value that maximizes the DSe and DSp of each assay. 
Using known seronegative and seropositive serum samples (n=940), the expected 
positive samples used were submitted as field serum samples (n=311) from herds 
previously testing PDCoV positive by PCR. Expected negative samples included 
archived experimental serum collected prior to 2009 (n=108) and field samples from 
high-health herds with no known history of PDCoV exposure (n=521). ROC analysis was 
performed and DSe and DSp were shown to be 96.1% and 96.2% respectively for the 
ELISA; and 95.8% and 98.1% respectively for the FMIA (Figure 4.4). The similar cutoff 
values of both assays confirm the utility of these new diagnostic tests to aid in the control 
and surveillance of PDCoV outbreaks.  
 
Evaluation of the kinetic swine antibody response in serum 
Once validated, the assays were used to evaluate the kinetic antibody response 
over time using serum collected from experimentally infected pigs over weekly intervals. 
Serological responses detected by the PDCoV ELISA and FMIA following challenge 
show seroconversion between days 8 and 14 DPI (Figure 4.5). Both assays demonstrate a 
similar dynamic range using the same serum samples and “high” positive standard from 
which the S/P values are calculated. However, the FMIA appears to detect a slightly 
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higher level of antibody over a longer period of time at days 35 and 42 post infection. 
Additional testing of seroconversion included serum samples collected from a group of 
30 piglets near the time of initial field exposure to PDCoV then 28 days later. Figure 4.6 
shows clear seroconversion to the naturally circulating virus within the 28 day time-
frame using the same diagnostic cutoff values previously determined by ROC analysis.  
 
Measurement of statistical testing agreement 
Multiple comparison, inter-rater (kappa) agreement is a statistical measure of 
testing agreement, and was calculated among all three tests (ELISA, FMIA & IFA) using 
629 positive testing and 311 negative testing serum samples. Statistical comparison 
calculated kappa values to be 0.940 between FMIA and IFA, 0.902 between ELISA and 
IFA, and 0.914 between ELISA and FMIA (Table 4.1). Because all three diagnostic 
platforms had kappa values above 0.81, it demonstrates that the tests are in “almost 
perfect” agreement with each other according to the interpretation of kappa by Landis et 
al. [16].    
 
Cross Reactivity 
Serological cross reactivity testing was performed between PDCoV and other 
closely related swine coronaviruses. There was no cross reactivity among the 93 TGEV 
positive serum samples, 20 PRCV positive serum samples, 167 PEDV field positive 
serum samples and 84 PEDV experimentally positive serum samples tested via ELISA 
and FMIA (Table 4.2). The data show mean OD and MFI readings from ELISA and 
FMIA tests, respectively. The lack of cross reactivity between PDCoV and 
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aforementioned alphacoronavirus species was also confirmed via western blotting using 
seropositive, convalescent sera from individual pigs (data not shown). 
 
Development of reagents for detection of PDCoV antigen in diagnostic tests 
Both denatured and refolded versions of the NP were used to immunize rabbits 
for hyperimmune serum and mice for monoclonal antibody production. Rabbit 
hyperimmune sera specifically recognize the NP and can be used in indirect fluorescent 
antibody staining at dilutions of 1:1000 to 1:5000. In addition, the polyclonal antisera 
was used successfully in immunohistochemical staining procedures for the detection of 
PDCoV antigen in intestinal tissues (Figure 4.7B). The resulting monoclonal antibodies 
all recognized native viral protein in infected ST cells demonstrated by bright 
cytoplasmic immunofluorescent staining (Figure 4.7A) and within intestinal enterocytes 
stained immunohistochemically (Figure 4.7C).  
 
Discussion 
As a recently identified pathogen, the impact of PDCoV on the swine industry is 
not yet fully understood. Field observations and recent research studies have suggested 
that the virus can cause substantial morbidity and mortality in nursing piglets [5, 6, 7, 
17]. Specific antibody-based reagents and serological tests are essential for the further 
study and control of PDCoV, as well as the differentiation of PDCoV infection from 
other related coronaviruses such as PEDV or TGEV.    
Therefore, the primary objective of this study was to develop an initial generation 
of antibody-based diagnostic reagents and serological assays for the further study of 
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PDCoV, including NP-based indirect ELISA and FMIA tests that were developed and 
validated for diagnostic applications. Specific antibody-based reagents were also not yet 
available for PDCoV so monoclonal antibodies against selected PDCoV structural 
proteins were developed. The tools developed during the course of this study can be 
applied to many ongoing and future studies to better understand and control PDCoV. 
The new monoclonal antibody reagents described here should be of substantial 
value in the detection of PDCoV antigen in a variety of applications including:  early 
verification of virus isolation attempts and virus titrations; immunohistochemistry 
staining of fixed tissues; development of neutralization assays; fluorescent antibody 
staining of fresh tissues; development of field-based antigen capture assays such as lateral 
flow devices; and ELISA applications (competitive ELISA and antigen capture). Through 
extensive testing via ELISA (over 364 samples) and Western blot analysis, we were not 
able to demonstrate any cross-reactivity with other major swine coronaviruses including 
PEDV, PRCV and TGEV. However, since many described deltacoronaviruses of other 
species have not yet been adapted to cell culture replication or fully characterized, we do 
not yet know if these reagents may cross-react with other members of the genus.  
Several new serological assays for detection of antibody responses to PDCoV 
were developed during the course of this study. The ELISA and FMIA tests were based 
on a recombinant nucleoprotein antigen since this protein is highly conserved among 
PDCoV isolates. In addition, the NP is known to be the most abundant viral protein 
within host cytoplasmic compartments [18]. The highly immunoreactive PDCoV-NP 
interacts with itself to form non-covalently linked oligomers and associates with the viral 
genome to serve as the architectural basis of the ribonucleoprotein complexes during 
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virus assembly [19]. These reasons provided the rationale for its utility as a target antigen 
for the serodiagnosis of PDCoV in indirect ELISA and FMIA platforms.  
Antibody responses to the nucleoprotein of coronaviruses are very robust and 
have been reported to appear as soon as 7-9 days’ post infection. We originally 
hypothesized that antibody reactivity to PDCoV may be conformationally dependent so 
we designed an experiment to determine whether NP specific immunodominant epitopes 
tend to be present in greater abundance on conformationally or linearly expressed 
antigen. A refolded version of the NP was used as an antigen in both assays as it was 
shown to impart a higher degree of immunoreactivity than its unfolded, linear 
counterpart. This phenomenon was also observed by Johnson et al. [20] whereby the 
authors compared reactivity differences among single point serum titrations to provide a 
surrogate measure of antibody titer. They showed that the enhancement of 
immunoreactivity of PRRSV-N and nsp1 was completely dependent on refolding, and the 
reactivity of nsp2P was enhanced by twofold. Furthermore, we confirmed their 
observations that there is a loss of immunoreactivity when the linear protein (solubilized 
in 8M urea) was dialyzed in PBS prior to coating on microtiter plates or used for coupling 
to FMIA microspheres. This may indicate that using an antigen in its more native 
conformational state may present a higher number of immunoreactive epitopes that are 
able to capture a larger percentage of PDCoV-NP antibodies. Therefore, the production 
of a well purified, refolded recombinant protein maintained in a near-native conformation 
was required for the production of an efficacious assay. 
Both assays provide the capability of high-throughput testing with reasonable DSe 
and DSp. ROC analysis was performed for both assays demonstrating DSe of greater 
122 
 
 
 
 
than 95%. The FMIA demonstrated good DSp of 98.1% while the ELISA showed a 
slightly lower DSp of 96.2%. Inter-rater (kappa) agreement, a statistical measure of test 
agreement demonstrated a significant level of agreement among the IFA, ELISA and 
FMIA. Furthermore, each of the antibody-capture assays was validated using a large 
number of well characterized serum samples (n=940) based upon the suggested 5-stage 
validation methods of Jacobson, which is supported by the office International des 
Epizooties [21].  
Although preliminary DSe and DSp determinations for the first generation 
serological assays described here were slightly less than ideal, these new assays should 
provide valuable tools for assessment of PDCoV exposure on a herd level. One 
explanation for the approximately 95-96% DSe values determined to date may be related 
to selection of the presumed positive field populations used for test validation.  In this 
case, the initial stages of validation relied on characterizing the assay using known serum 
samples from experimentally infected pigs.  Because this was the only sera of known 
serostatus we had at our disposal, we believe that the resulting initial ROC characteristics 
were of sufficient value to begin testing samples from other sources believed to not have 
been exposed to PDCoV and from field sources known to have seroconverted to PDCoV 
within a specific time frame.  By following the methodology outlined by Jacobson [21] in 
which he recommends the inclusion of these initial ROC cut-off values from 
experimentally infected pigs, we demonstrated similar assay characteristics on chosen 
field samples which substantiated our final cut-off value of the assay.  These sample sets 
were collected at approximately 3 weeks after initial diagnosis of PDCoV by PCR. It is 
possible that PDCoV may not move through a herd at the very rapid rate seen with 
123 
 
 
 
 
PEDV. Therefore, some animals in some herds may not have been infected until a week 
or more after initial detection in the population, resulting in delayed seroconversion in a 
percentage of the presumed positive population. Likewise, since the initial origination 
and distribution of PDCoV in the U.S. is not fully understood at this time, it is possible 
that a small percentage of our presumed seronegative population may have been subject 
to prior exposure. Many of the samples in our presumed negative population were 
archived samples collected prior to 2009. However, some originated from recent field 
submissions from high health, biosecure herds with no clinical or PCR evidence of prior 
PDCoV or PEDV exposure. The observed DSp values of approximately 98% for FMIA 
and 96% for indirect ELISA are within the expected range for first generation assays 
using these test formats. Apparent false positive reactions could also be due to an epitope 
on the expressed antigen having commonality with another low prevalence infectious 
agent or due to low levels of residual E. coli protein contaminants in the purified antigen 
preparations. 
Recently, Thachil et al. [8], developed an indirect anti-PDCoV IgG enzyme-
linked immunosorbent assay based on the putative S1 portion of the spike protein and 
evaluated it using a total of 968 tested serum samples. Although it is a reasonably 
sensitive (91%) and specific (95%) test, there is room for other ELISAs utilizing other 
target antigens, such as the NP of PDCoV, to serve as primary serological surveillance or 
confirmatory assays. As noted in Thachil’s research, serum samples collected in 2010 
were found positive for PDCoV antibody by their ELISA, but not those collected in 2011 
and 2012. This was controversial because PDCoV was not thought to be circulating in 
North America in pigs before its identification in late 2013 [9]. It will be very beneficial 
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to have confirmatory assays to validate this finding. Additional screening of archived 
historical swine serum samples using multiple serological assays may provide further 
insight into the origin and epidemiology of PDCoV in North America. 
 
Conclusions  
The monoclonal antibody reagents developed here provide important research and 
diagnostic tools for the industry. They are valuable for fluorescence and 
immunohistochemical staining methods associated with diagnostic and pathogenesis 
studies. The serological assays allow the detection of antibodies developed in response to 
PDCoV infection. The PDCoV indirect ELISA and FMIA will allow high-throughput 
screening of swine serum samples. These tests should be adequately optimized and 
validated for sero-surveillance on a herd level, but further improvement is needed for full 
confidence on an individual animal basis. The IFA or other tests may be required for 
confirmation of individual unexpected results. Work is ongoing to further validate these 
assays and to adapt them to different sample matrices such as milk or oral fluid samples. 
Since lactogenic immunity is likely critical for protection of nursing piglets, these assays 
will be modified for detection of IgA as well. 
 
Funding 
Funding for this work was provided by the National Pork Board through grant 
#14-184, the South Dakota Agricultural Experiment Station, USDA Hatch funding and 
the South Dakota Animal Disease Research and Diagnostic Laboratory. 
 
125 
 
 
 
 
Acknowledgements 
The authors thank Drs. Sabrina Swenson and Melinda Jenkins-Moore of the 
National Veterinary Services Laboratories for providing the cell culture adapted 
Michigan/8977/2014 isolate of PDCoV; Dr. Richard Hesse of the Kansas State 
University Veterinary Diagnostic Laboratory and Dr. Sarah Vitosh-Sillman and 
colleagues at the University of Nebraska-Lincoln for providing serum samples from 
PDCoV challenge studies; Dr. David Knudsen and Amanda Brock for 
immunohistochemistry; Dr. Volker Brozel for critical review of the manuscript and the 
South Dakota State University Animal Resource staff for animal assistance. The authors 
also thank numerous swine producers and practitioners for providing field samples and 
herd history information. 
  
126 
 
 
 
 
 
 
 
 
 FMIA Indirect ELISA IFA 
IFA 0.940 0.902 1 
Indirect  ELISA 0.914 1 0.902 
FMIA 1 0.914 0.940 
Number positive serum samples 311 311 315 
Number negative serum samples 629 629 625 
Total 940 940 940 
 
Table 4.1. Evaluation of statistical testing agreement among three serological testing 
platforms.  Multiple comparison, inter-rater agreement (kappa association) were 
calculated among all three tests, IFA, indirect ELISA and FMIA.  Kappa values shown 
represent a statistical measure of test agreement and were calculated using MedCalc 
version 11.1.1.0.  
 
  
127 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.2. Serological cross reactivity testing among related swine coronaviruses.  
Antigenic cross reactivity testing was performed among both ELISA and FMIA tests 
using convalescent swine serum positive for TGEV, PRCV and PEDV antibodies.  Mean 
ELISA OD’s and FMIA fluorescent values are reported for each test.  The ELISA OD 
and FMIA MFI values shown are well below the established diagnostic test cutoff 
threshold levels described in figure 4 for the validation of the assay (ELISA OD = 0.36; 
FMIA MFI = 0.32).   
 
  
 
       
TGEV         PRCV  PEDV 
ELISA Mean OD 0.097        0.132  0.074 
FMIA Mean FI 0.024       0.016          0.032 
Total No. serum 
samples tested 93           20            251 
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Figure 4.1.  Purification and antigen specificity of PDCoV-NP antibody capture 
antigen.  (A) Coomassie blue staining of E. coli expressed and purified PDCoV-NP 
antigen used to coat ELISA microtiter plates and FMIA microspheres.  Molecular weight 
ladder MW and PDCoV-NP (41kDa).  (B) Western blot showing antigen specificity of 
recombinant, refolded PDCoV-NP/polyhistidine fusion protein probed with mAb SD-55-
197 (Lane 1).  Lane 2 was loaded with semi-purified, concentrated PDCoV strain 
HKU15/Michigan/8977/2014 then probed with mAb SD-55-197.   
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Figure 4.2. Antibody capture efficacy comparison between refolded vs linear 
PDCoV-NP.  An ELISA antibody capture titration assay was employed to compare the 
ability of refolded vs. linear antigen to capture anti-PDCoV-NP specific antibody in 
swine serum.  Wells of a 96-well microtiter plate were coated with decreasing 
concentrations of either linearly expressed or refolded PDCoV-NP antigen.  Refolded 
antigen demonstrated greater dynamic range of the assay and capture efficacy of swine 
antibody.   
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Figure 4.3. Production and reactivity of serological reference standards and internal 
quality control standards for both ELISA (A) & FMIA (B).  Reference serum 
standards were titrated 2-fold in antigen coated wells at a fixed concentration [250 
ng/well] in order to gauge a maximum signal-to-noise ratios for each assay (C) ELISA, 
and (D) FMIA.  Arrows indicate the optimal serum dilution that resulted in the greatest 
positive to negative (P/N) ratio for the test.   
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C D
131 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. Receiver operator characteristic (ROC) validation and determination of 
diagnostic sensitivity (DSe) and specificity (DSp) of the PDCoV-NP ELISA and 
FMIA assays. DSe and DSp were calculated using serum samples from known PDCoV-
infected and known PDCoV-uninfected populations. ROC analysis was performed using 
MedCalc version 11.1.1.0 (MedCalc software, Mariakerke, Belgium).  In each panel, the 
dot plot on the left represents the negative population, and the plot on the right represents 
the positive population.  The horizontal line bisecting the dot plots for each figure 
represents the tentative cutoff value that gives the optimal DSe and DSp.    
 
  
Negative N = 629            Positive N = 311 
    Sens. = 96.1%, Spec. = 96.2%, Cutoff = 0.36 
   Negative N = 629            Positive N = 311  
 Sens= 95.8%; Spec= 98.1%, Cutoff = 0.32 
ELISA FMIA >.36 >.32 
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Figure 4.5.  Serum antibody kinetic time course evaluation.  Antibody kinetic 
responses were calculated for the ELISA and FMIA tests using serum collected weekly 
over six weeks from experimentally infected pigs. Serological responses detected by 
PDCoV ELISA and FMIA tests show seroconversion between 8 and 14 DPI.    
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Figure 4.6. ELISA (A) and FMIA (B) results from a group of 30 piglets sampled 
near the time of initial PDCoV field exposure then 28 days later.  Both assays show 
clear seroconversion to naturally circulating PDCoV. The horizontal line between both 
positive and negative testing samples shows the diagnostic cutoff value for each test 
previously determined by ROC analysis. 
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Figure 4.7.  Development of reagents used for indirect fluorescent antibody (IFA) 
testing and immunohistochemical (IHC) staining of PDCoV infected cells.  Indirect 
fluorescent antibody staining of PDCoV infected ST cells with PDCoV anti-
nucleoprotein monoclonal antibody SD-55-24 [(A), 100X magnification].  
Immunohistochemistry staining of intestinal enterocytes with PDCoV anti-nucleoprotein 
rabbit polyclonal hyperimmune sera [(B), 100X magnification].  Immunohistochemistry 
staining of intestinal enterocytes with PDCoV anti-nucleoprotein monoclonal antibody 
55-197 [(C), 100X magnification]. Uninfected control showing hematoxylin staining of 
luminal, intestinal brush-border cross section [(D), 100X magnification].   
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Abstract 
The porcine epidemic diarrhea virus (PEDV) spike (S) glycoprotein plays a key 
role in virus entry into target cells. It mediates the functions of receptor binding (S1 
subunit) and fusion (S2 subunit) of virus and cellular membranes during entry. Given its 
critical functions during entry the S protein is one of the main targets of host antibodies 
against PEDV. Here, immunodominant neutralizing epitopes of PEDV were identified 
using a panel of S-specific monoclonal antibodies (mAbs). When mice were immunized 
with inactivated whole PEDV preparations, ten mAbs against the S protein were 
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obtained. The reactivity and specificity of these mAbs was confirmed by 
immunofluorescence, western blots and ELISAs, and their neutralizing activity was 
assessed by fluorescent focus neutralization (FFN) and plaque reduction neutralization 
assays (PRN). Nine of the ten mAbs successfully neutralized PEDV infectivity in vitro. 
Epitope mapping by peptide ELISAs revealed that seven mAbs recognized linear 
neutralizing epitopes located in the N-terminus of the S2 glycoprotein subunit (amino 
acids [aa] 744-759, 747-774 and/or 756-771). Additionally, two mAbs recognized a 
neutralizing epitope located in the C-terminus of S2 (aa 1371-1377), while only one 
neutralizing mAb reacted against a region of the S1 glycoprotein subunit (aa 499-600). 
Notably, mAbs that recognized epitopes 744-759 and 747-774 within the S2 subunit 
presented the highest neutralizing activity against PEDV. These results indicate that the 
S2 glycoprotein subunit contains major antigenic determinants and, perhaps, the 
immunodominant neutralizing epitopes of PEDV.  
 
Key words: Porcine epidemic diarrhea virus (PEDV), spike, neutralizing antibodies. 
 
Introduction 
Porcine epidemic diarrhea virus (PEDV) is a member of the genus 
Alphacoronavirus of the family Coronaviridae. The virus replicates primarily in 
enterocytes of the small intestine causing villous atrophy and malabsorptive diarrhea 
which lead to electrolyte imbalance, metabolic acidosis and death [1,2]. The 
characteristic clinical signs of PEDV infection are watery diarrhea, vomiting, anorexia, 
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and dehydration which are followed by high mortality rates (50-100%) in suckling piglets 
or weight loss due to diarrhea in older pigs [3].  
The PEDV genome consists of a large (~28 Kb) single-stranded, positive sense 
RNA molecule which contains seven open reading frames (ORF1ab, and ORFs2-6) [4,5]. 
It is organized in a central coding region that is flanked by 5’- and 3’-untranslated regions 
(UTRs). The first gene ORF1ab encompasses approximately 2/3 of the viral genome and 
encodes large polyproteins (pp1a and pp1b), that are cleaved by viral encoded proteases 
into 16 non-structural proteins (nsp1-16) [4]. In addition, four structural proteins are 
encoded by ORFs2, -4, -5 and -6, including the S glycoprotein (180–220 kDa), 
membrane (M; 27– 32 kDa), envelope (E; 7 kDa), and the nucleocapsid proteins (N; 55–
58 kDa), respectively. ORF3 encodes for a non-structural accessory protein [4,6,7].  
The S protein is the major envelope glycoprotein responsible for virus attachment, 
receptor binding, cell membrane fusion and entry, [8,9,10]. The S protein is expressed as 
a 1,383 amino acid- (aa) precursor peptide (180-200 kDa) that is cleaved by host 
proteases into two major subunits:  the S1 subunit (residues 20–725) that mediates virus 
attachment to the cell surface receptor; and the S2 subunit (residues 726–1383) involved 
in virus and host cell membrane fusion. Like other coronavirus’ S proteins, the PEDV S 
is a type I membrane glycoprotein that forms homotrimeric projections (spikes) on the 
virion surface and contains an N-terminal signal peptide (residues 1-19), a large 
extracellular region, a single transmembrane domain (residues 1335–1358) and a short 
cytoplasmic tail (residues 1359–1385) (Li et al., 2016). The S1 subunit has been shown to 
have a modular architecture with four discrete domains, including an N-terminal domain 
(NTD; residues 19-233) that exhibits sialic acid binding activity and a C-terminal domain 
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(CTD; residues 477–629) that can interact with protein receptor(s) [11]. The S2 subunit 
presents the typical structural features found in class I fusion proteins, including a 
hydrophobic fusion peptide (residues 891–908), two heptad repeat regions (HR1, residues 
978–1117 and HR2, residues 1274–1313), and a C-terminal transmembrane domain 
(residues 1335–1358) [11]. The homotrimeric S proteins on the virion surface are 
uncleaved and undergo proteolytic processing required for fusion during entry [10,12].  
Given its critical functions during cell entry, it is not surprising that the PEDV S 
protein is the main target of host antibody responses against the virus [13]. Indeed, 
several studies have recently shown that immunization of pigs with full-length or 
truncated versions of the S protein elicits antibody responses and protection against 
PEDV [14,15,16]. Most importantly, various neutralizing epitopes have been identified in 
the S protein, with one of them mapping to a domain homologous to the collagenase 
resistant fragment (CO-26K) of TGEV S [17], thus being named “collagenase 
equivalent” (COE) in PEDV (residues 499-638) [18]. Another neutralizing epitope has 
been mapped to the S1D region (residues 636-789) of the S, and it spans the S1-S2 
junction [9], while a third neutralizing epitope has been found in the C-terminus of the S 
protein (residues 1371-1377) [8]. It is important to note that neutralizing antibodies 
directed against the S protein are thought to be major effectors of protection against 
PEDV. 
Here we have shown that immunization of BALB/c mice with purified and 
inactivated whole virus preparations of PEDV followed by somatic cell fusion resulted in 
hybridoma cell lines secreting mAbs specific for the S protein that exhibited marked 
neutralizing activity against PEDV in vitro. Epitope mapping of the resultant neutralizing 
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mAbs led to the identification of important antigenic determinants within the S protein. 
Notably, most mAbs obtained here reacted against linear epitopes within the S2 subunit, 
indicating that this region contains immunodominant neutralizing epitopes of PEDV.   
 
Results  
Selection and characterization of PEDV S-specific mAbs 
PEDV S-specific mAbs were generated by immunization of BALB/c mice with 
sucrose purified inactivated whole virion preparations of PEDV in a water-in-oil adjuvant 
emulsion. Following three intraperitoneal immunizations, mice splenocytes were fused to 
NS-1 myeloma cell lines using standard fusion protocols, and primary hybridomas 
secreting S-specific mAbs were selected based on the reactivity of the mAbs with full 
length PEDV S expressed by a recombinant viral vector (ORFV-PEDV-S) [14] (Figure 
5.1). Approximately 25 primary hybridomas secreting S-specific mAbs were obtained 
and their specificity was confirmed by immunofluorescence and Western blot assays 
(data not shown). The specificity of these mAbs was assessed against the prototype 
PEDV strain USA/Colorado/2013 [19] and the S-INDEL strain USA/Iowa106/2013 [20] 
(Figure 5.1). Additionally, their neutralizing activity was assessed by fluorescent focus 
neutralization (FFN) assay, with supernatants from nine hybridomas presenting 
neutralizing titers between 4 and 16 (data not shown). These hybridoma lines were 
subcloned by limiting dilution and further characterized in our study. One additional 
hybridoma cell line (SD33; Figure 5.1) secreting S-specific mAbs that did not neutralize 
PEDV and another line previously established at the ADRDL (SD37-11) (unpublished 
data) that showed neutralizing activity in our initial screening were also included in our 
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study. After subcloning one clone of each primary hybridoma line was selected and 
subjected to ascites production (Envigo, Inc.). A summary of the properties and 
characteristics of the mAbs generated here is presented in Table 5.1.   
All mAbs specifically recognized cells infected with the recombinant ORFV-
PEDV-S, expressing the full length PEDV S and cells infected with the PEDV strain 
CO13 (Figure 5.1; Table 5.1). Notably, seven out of eight mAbs recognized cells infected 
with the S-INDEL variant PEDV strain USA/IOWA/106/2013, with mAb SD125-2 not 
recognizing S-INDEL infected cells (Figure 5.1; Table 5.1).  
The specificity of the PEDV-S mAbs was also evaluated by western blots and 
ELISAs using whole virus preparations, and recombinant S- (amino acid [aa] 630-800 or 
aa 499-600) and N proteins expressed in E. coli. On Western blots, eight of nine mAbs 
recognized the full-length spike protein in whole PEDV preparations (Figure 5.2a) and 
the truncated S protein spanning the S1-S2 junction region (aa 630-800) (Figure 5.2a), 
with mAb SD37-11 not recognizing the full-length spike and mAb SD125-2 not 
recognizing the S1-S2 recombinant protein (aa 630-800) (Figure 5.2a). None of the mAbs 
reacted with the recombinant N protein (Figure 5.2a). The reactivity of the mAbs with the 
S protein under denaturing western blot conditions indicate that all mAbs recognize linear 
epitopes of the S protein, with most of them being specific for epitopes within the S1-S2 
junction (Figure 5.1b). When tested by ELISA, all mAbs reacted against PEDV strains 
CO13 (Figure 5.3a) and S-INDEL Iowa106 (Figure 5.2a and 5.2b). These results 
corroborate the findings of the IFA assays, confirming the specificity of the mAbs for 
PEDV.  
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 Next, we assessed the reactivity of the mAbs against truncated versions of the S 
protein (aa 499-600 and 630-800). Notably, nine mAbs reacted against the S1-S2 region 
(aa 630-800), while only one mAb (SD131-3) reacted against the product corresponding 
to aa 499-600, which contains the putative receptor binding domain of the S1 subunit 
(Fig 2d and 2e). These results confirmed the findings of Western blots, indicating that 
most mAbs developed here specifically recognize epitopes located in the S1-S2 junction 
of the S protein. It is important to note that, while mAb SD125-2 reacted with PEDV 
CO13 whole virus (Figure 5.2a) this mAb did not recognize the S1- nor the S1-S2 
truncated proteins (Figure 5.2d and 5.2e), suggesting that this mAb may be specific to 
another region of the S protein or, perhaps, it could recognize conformational epitopes.  
 
Neutralizing activity of PEDV S-specific mAbs 
The neutralizing activity of S-specific mAbs was assessed by FFN and plaque 
reduction neutralization (PRN) assays. For this, all mAbs were purified from ascites fluid 
and diluted to a working solution of 3 µg/mL. Two-fold serial dilutions of the mAbs' 
working stocks (1:20 - 1:1280) were tested in triplicate by FFN or PRN assays. Endpoint 
titers were considered the reciprocal of the highest mAb dilution capable of reducing 
PEDV infectivity by 90 (FFN) or 80% (PRN) in vitro. Nine out of ten mAbs presented 
neutralizing titers ranging from 1:40 to 1:640 against PEDV strain CO13 (Table 5.2, 
Figure 5.3a) and from 1:40 to 1:160 against PEDV S-INDEL variant strain (Table 5.2, 
Figure 5.3a). Similarly, PRN titers against PEDV strain CO13 ranged between 1:20 to 
1:640 (Table 5.2, Figure 5.3b). Consistent with the results of our preliminary screening, 
no neutralizing activity was observed for PEDV S-specific mAb SD33-1, whereas mAb 
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SD37-11 presented neutralizing titers of 1:40 and 1:80 in the PRN and FFN assays, 
respectively. A PRRSV specific mAb (SDOW17), which was used as negative control in 
our assays, did not present neutralizing activity against PEDV (data not shown). These 
results demonstrate the neutralizing activity of nine S-specific mAbs against PEDV in 
vitro. 
 
Neutralizing activity of S-specific mAbs correlates with their reactivity with the 
truncated S1-S2 (aa 630-800) protein 
The S1-S2 junction region of the S protein has been shown to contain major 
neutralizing epitopes [21]. Notably, most neutralizing mAbs developed here specifically 
recognized a truncated form of the S protein (aa 630-800) spanning the S1-S2 junction 
region (Figure 5.2a and 5.2d). To assess whether the neutralizing activity of the mAbs 
correspond to their ability to recognize this truncated protein, the correlation between 
endpoint FFN, PRNT and ELISA titers was determined. As shown in Figure 5.4a, 
endpoint neutralizing and S1-S2 ELISA titers were very similar for all mAbs, resulting in 
a strong positive correlation between FFN and ELISA (R2 = 0.8843; Fig 4b) and PRNT 
and ELISA (R2 = 0.9563; Fig 4c) test results. Importantly, neutralizing titers detected in 
convalescent polyclonal swine serum also presented a high correlation with antibody 
titers detected by the S1-S2 indirect ELISA (Figure 5.4a).   
 
Epitope mapping of S-specific mAbs 
To identify immunodominant neutralizing domains in the PEDV S, the epitope 
specificity of the neutralizing mAbs developed here was assessed by peptide ELISAs. 
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Three regions of PEDV S protein have been shown to be targets of neutralizing 
antibodies, including the RBD region (aa 499-600), the S1-S2 junction region (aa 639-
789) and a region in the carboxi terminus of the S protein [18,21,22]. A few linear 
epitopes within these regions have been shown to induce neutralizing antibodies against 
PEDV, including epitopes at aa positions 747-774 and 1371-1377 [8,21,23]. Initially, all 
mAbs were screened against epitope 747-774 (which encompasses epitope 756-771 and 
most aa of epitope 744-759) located in N-terminus of S2 and against epitope aa 1371-
1377 located at the C-terminus of S.  Notably, six mAbs (SD120-1, SD129-5, SD131-3, 
SD137-90, SD138-108, and SD142-2) recognized the epitope 747-774, while mAb 
SD125-2 specifically reacted against epitope 1371-1377 (Figure 5.5a & b).  
 To confirm the specificity of the mAbs and further dissect neutralizing epitopes 
within the S1-S2 junction region, all mAbs were screened against two smaller 
neutralizing epitopes contained almost entirely within the 747-774 epitope (744-759 and 
756-771). As shown in Figure 5.5c & d six mAbs recognized epitope 744-756 (SD37-11, 
SD121-1, SD129-5, SD137-90, SD138-108, and SD142-2), while only two mAbs 
recognized epitope 756-771 (SD120-5 and SD129-5). A summary of the epitope 
specificity of individual mAbs is presented in Table 5.2. Notably, two mAbs (SD37-11 
and SD121-1) specific to the S1-S2 region recognized only epitope 744-759, three mAbs 
(SD137-90, SD138-108 and SD142-2) recognized both epitopes 744-759 and 747-774, 
while two mAbs (SD120-1 and SD129-5) recognized epitopes 756-771, and 747-774. 
These results indicate that the amino terminus of the S2 subunit contains highly antigenic, 
perhaps, immunodominant neutralizing epitopes of PEDV.  
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Discussion 
Given its critical functions in cell entry, the coronavirus S protein is the main 
target of host humoral responses. Neutralizing antibodies directed against the S protein 
likely play a key role on protection against PEDV infection. A recent study demonstrated 
that neutralizing activity against PEDV in colostrum and milk correlated with levels of 
IgA antibodies to the S protein (S1 and S2 subunits) [13]. Notably, at least three 
neutralizing B-cell epitopes have been identified in the S protein [8,18,21], with one of 
the epitopes mapping to a domain in S1 that is homologous to the collagenase resistant 
fragment (CO-26 K) of TGEV S [17] (aa 499-638; named “collagenase equivalent” in 
PEDV, COE) [18]. A region spanning the S1-S2 junction (aa 638-789) in PEDV S 
contains another neutralizing epitope [21], with a third epitope mapping to the carboxy-
terminus of the S protein (aa 1371-1377) [8,23]. Results here showing the specificity of 
PEDV neutralizing mAbs for these domains in the S protein confirm that epitopes located 
in these regions are indeed responsible for eliciting neutralizing antibodies against PEDV. 
The fact that these mAbs were generated by immunization of mice with whole virus 
preparations indicates that these regions are highly antigenic, further suggesting that 
epitopes within these regions may represent immunodominant neutralizing epitopes of 
the PEDV S protein.    
While the amino-terminal region of S (S1, aa 1-725) is involved in virus 
attachment to cellular receptors, the carboxy-terminal region (S2, aa 726-1383) 
undergoes conformational changes after the attachment of S1 to facilitate fusion of the 
virus envelope with the host cell membrane, thus allowing entry of the viral genome into 
the host cell [11]. Notably, antibodies directed against both S subunits have been 
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correlated with neutralization of PEDV infectivity [13]. Immunization of mice with 
inactivated whole PEDV virion preparations followed by somatic cell fusion here 
resulted in production of hybridoma cell lines secreting mAbs specific for the PEDV S 
protein and capable of neutralizing the virus infectivity in vitro (titers ranging from 1:40 
to 1:640). Interestingly, epitope mapping ELISAs revealed that eight of nine mAbs 
specifically recognized neutralizing epitopes located within the S2 subunit (SD37-11, 
SD120-1, SD121-1, SD125-2, SD129-5, SD137-90, SD138-108 and SD142-2), while 
only one mAb (SD131-3) reacted with the S1 subunit. While UV- or formalin inactivated 
PEDV virions likely do not retain the exact antigen conformation and architecture of 
infective PEDV particles, our data suggest that the S2 subunit contains important-, 
perhaps, immunodominant antigenic determinants of PEDV. Results from a recent study 
showing higher levels of S2-specific IgG antibodies when compared to S1-specific 
antibodies in serum and colostrum of sows naturally infected with PEDV, further support 
this hypothesis [13]. Nevertheless, antibodies against the S1 subunit also play a critical 
role on immune responses against PEDV [13], and immunization with the recombinant 
S1 protein subunit have induced neutralizing antibodies and passive protection against 
infection [16]. Similar experiments would have to be performed with the S2 subunit to 
assess its immunogenicity and to determine the contribution of S2-specific antibodies on 
protection against PEDV. 
Infection with PEDV induces neutralizing antibody responses within 14 to 21 
days’ post-infection, with NA titers in convalescent polyclonal serum usually ranging 
between 1:20 to 1:320 [24,25]. As shown in Figure 5.2, most S-specific mAbs produced 
here (exception SD33-1) were capable of completely blocking PEDV infectivity (titers of 
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1:40 to 1:160), with a few of these mAbs (SD137-90, SD138-108 and SD142-2) 
presenting markedly higher neutralizing activity (titers up to 1:640) (Table 5.2). 
Considering the highly stringent endpoint criteria used in the in vitro neutralization 
assays (90% reduction in fluorescent focus-forming units or 80% reduction in plaque 
forming-units), and the fact that these are monospecific antibodies these titers represent 
remarkable neutralizing activities. It is important to note, that while these three mAbs 
specifically recognized two overlapping epitopes located in the amino-terminus of the S2 
subunit (aa 744-759 and 747-774), they did not react against epitope 756-771, which is 
also contained within the core neutralizing epitope aa 747-774 in S2. Together these 
results indicate that these mAbs either recognize aa 747-759 or, perhaps, a smaller 
epitope within this domain. The specificity of mAbs SD137-90, SD138-108 and SD142-2 
and their high neutralizing activity, suggest that their target epitope might represent an 
immunodominant neutralizing epitope of PEDV S. However, the possibility that these 
results reflect a higher avidity and/or affinity of these mAbs for the inducing epitope 
cannot be formally excluded.  
At least two genetically distinct strains of PEDV (prototype and S-INDEL variant 
strains) have been described in the US and in other parts of the world [20,24]. The S-
INDEL variant strains contain aa insertions, deletions and/or substitutions mainly in the 
N-terminus of the S1 protein subunit (first 350 aa). Despite the genetic and antigenic 
differences between prototype and S-INDEL strains, a recent study has shown that there 
is significant serological and neutralizing cross-reactivity between two representative 
strains obtained in the US [24]. Consistent with these findings, our results show that all 
mAbs developed here recognized both prototype (CO13) and S-INDEL (Iowa106) strains 
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in IFA and/or whole virus ELISAs. Most importantly, all mAbs presented neutralizing 
activity against both PEDV strains. These results are consistent with the fact that the 
target neutralizing epitopes of the mAbs developed here are highly conserved (100% aa 
id; data not shown) between the two PEDV strains used in our study.   
Recently, Song and collaborators have demonstrated a high correlation between 
the levels of neutralizing antibodies in serum, colostrum and milk of naturally infected 
sows with the levels of S1- and S2-specific antibodies in these samples [13]. Given that 
most neutralizing mAbs developed here are specific for epitopes located within the S1-S2 
junction region, we performed endpoint ELISA titrations with those mAbs using the 
recombinant S1/S2 protein (aa 630-800) and assessed the correlation between ELISA and 
neutralizing antibody titers. Notably, a strong positive correlation between the ELISA 
titers and FFN and PRNT titers was observed for all mAbs developed here. Similarly, 
neutralizing antibody titers detected on a convalescent swine serum sample used as 
positive control also matched the endpoint titers detected in the S1/S2 ELISA. Screening 
of additional serum samples is, however, required to determine whether this assay could 
potentially be used to determine neutralizing activity in clinical samples.  
In summary, by using a panel of PEDV S-specific neutralizing mAbs we have 
shown that an immunodominant neutralizing epitope of PEDV S maps to the amino-
terminus of the S2 subunit. While seven neutralizing mAbs generated after immunization 
of mice with whole virion preparations recognized a domain in S2, only one mAb reacted 
against S1. These results suggest that S2 subunit may contain important, perhaps, 
immunodominant neutralizing determinants of PEDV. This study provides important 
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information and tools that may lead to the development of improved prevention, control 
and/or diagnostic strategies for PEDV.   
 
Materials and Methods 
Cells and viruses 
Vero-76 (ATCC® CRL-1587™) and primary ovine fetal turbinate cells were 
cultured at 37oC with 5% CO2 in minimum essential medium (MEM) supplemented with 
10% fetal bovine serum (FBS), and 2 mM L-glutamine, and containing penicillin (100 
U/mL), streptomycin (100 µg/mL) and gentamicin (50 µg/mL). PEDV strain 
USA/CO/2013 (CO13; GenBank accession no: KF272920.1) was obtained from the 
National Veterinary Services Laboratory (NVSL). PEDV strains BIVI-1 and BIVI-2 were 
provided by Boehringer Ingelheim Vetmedica and PEDV S-INDEL-variant strain 
USA/IOWA/106/2013 (GenBank Accession No: KJ645695.1) was provided by Dr. 
Qiuhong Wang, The Ohio State University. All PEDV strains were propagated in Vero-
76 cells in the presence of 1.5 µg tosyl phenylalanyl chloromethyl ketone (TPCK) treated 
trypsin (Sigma Aldrich, St. Louis, MO). A recombinant Orf virus expressing the full 
length PEDV S (ORFV-PEDV-S) was recently developed in our laboratory [14] and was 
used here for screening of S-specific mAbs. 
 
Production of S-specific monoclonal antibodies 
Four-week-old female BALB/c mice were randomly allocated into three groups as 
follows: Group 1: PEDV CO13-immunized (n = 3), Group 2: PEDV BIVI-1-immunized 
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(n = 3), and Group 3: PEDV BIVI-2 immunized (n = 3). After a week of acclimation, 
mice were immunized with sucrose purified UV-(PEDV CO13) or formalin (BIVI-1 and 
BIVI-2) inactivated whole PEDV virions in a water-in-oil (W/O) adjuvant emulsion 
(Montanide ISA 50 V2; Seppic, France). After a series of three intraperitoneal 
immunizations (2-week intervals), splenic cells were fused with myeloma NS-1 cell lines 
and cultured in the presence of hypoxanthine-aminopterin-thymidine (HAT) medium for 
selection of hybridoma cells following standard protocols [26]. After 10-14 days of 
culture, hybridoma cell culture supernatants were screened for the presence of S-specific 
mAbs by indirect immunofluorescence assays. All animal experiments have been 
reviewed and approved by the SDSU Institutional Animal Care and Use Committee 
(IACUC; protocol approval no. 14-087A). 
 
Immunofluorescence assay (IFA) 
The supernatant of hybridoma cell cultures was screened for the presence of S-
specific mAbs by using IFA. For this, primary ovine fetal turbinate cells infected with the 
recombinant ORFV-PEDV-S, expressing the full-length PEDV S [14], were incubated 
with the hybridoma cell culture supernatants for 1 h at 37oC. Unbound antibodies were 
washed out three times with phosphate buffered saline (PBS) and S-specific mAbs 
detected with a goat anti-Mouse IgG+IgM+IgA DyLight®594-conjugated antibody 
(Bethyl Laboratories, Inc., Montgomery, TX). Positive clones were also screened in 
PEDV CO13-infected cell cultures using a goat anti-Mouse IgG+IgM+IgA FITC-
conjugated antibody (MP Biomedicals, Santa Ana, CA) as above. Positive primary clones 
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were subcloned, expanded and re-screened in ORFV-PEDV-S- and PEDV (CO13 and S-
INDEL) infected cells. 
 
Neutralization assays 
The neutralizing activity of S-specific mAbs was initially assessed by FFN assays 
as previously described [26]. Hybridoma culture supernatants were first screened and 
clones with PEDV neutralizing antibody titers greater than 4 were used for ascites 
production (Envigo, Inc., Indianapolis, IN). Immunoglobulin isotyping was performed 
using a lateral flow assay kit (Bio-Rad, Hercules, CA) and mAbs were purified using 
NAbTM protein G spin columns (IgG; Thermo Fisher Scientific, Waltham, MA) or the 
ammonium sulfate precipitation method (IgM). Following purification, all mAbs were 
diluted in PBS to final concentration of 3 µg/mL. Normalized mAbs were re-screened by 
FFN assays to confirm their neutralizing activity against PEDV. Neutralizing antibody 
titers were expressed as the reciprocal of the highest mAb dilution capable of reducing 
PEDV infectivity by 80%.  
To confirm the neutralizing activity, the mAbs were also screened by plaque 
reduction neutralization (PRN) assay [27]. For this, Vero cells were seeded in six-well 
plates at a density of 4 × 105 cells/well and incubated at 37°C with 5% CO2 until the cells 
were approximately 90% confluent. The mAbs were subjected to serial 2-fold dilutions 
(starting concentration 25 μg/mL) and each dilution incubated with 50 PFU of PEDV 
strain CO13 for 1h at 37oC with 5% CO2. After incubation the antibody-virus mixture 
was added to the Vero cells and incubated for 1.5 h gently rocking the plates every 15 
min to distribute the inoculum homogeneously throughout the well. Cells were overlaid 
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with semisolid medium (2% agar, 2X MEM, and 3 µg/mL TPCK-treated trypsin) and 
incubated at 37oC with 5% CO2 for 72-96 h. Next, 1 ml of 0.2% crystal violet (Sigma-
Aldrich, St Louis, MO) in 0.01% formaldehyde and 20% acetone solution was added to 
each well and the cells were fixed and stained for 15 min at RT. Viral plaques were 
counted and used to determine the PRNT for each mAb. Plaque counts for each antibody 
were used to calculate percent reduction in plaques as follows: % reduction = 100 × [1 − 
(average number of plaques for each dilution/average number of plaques in the virus 
control well). Each mAb was tested in duplicate and four control wells used on each 
assay, including, a virus control (no antibody), a negative control (MEM only) 
Additionally, convalescent PEDV polyclonal serum and unrelated mAbs controls (anti-
PRRS, and anti-PEDV N protein antibody), were used on every PRNT assay. 
 
Western blots 
The reactivity of PEDV mAbs developed here were evaluated by using denaturing 
Western blots. Each antibody was tested against sucrose purified whole virus 
preparations, a recombinant/truncated version of the S protein (residues 630-800; Hain et 
al., 2016), and a recombinant N protein [26]. Approximately, 20 µg of each antigen were 
resolved by SDS-PAGE in 4-20% acrylamide gels (Bio-Rad, Hercules, CA) and 
transferred to nitrocellulose membranes. Blots were incubated with 5% non-fat-dry-milk 
TBS-Tween 20 (0.1%; TBS-T) solution for 1 hr at RT and probed with the mAbs and 
control antibodies overnight at 4oC. Blots were washed three times with TBS-T for 10 
min at RT and incubated with a goat anti-mouse IgG-HRP- or goat anti-mouse IgM-
HRP-conjugated antibody for 2 hr at RT. Blots were washed three times with TBS-T for 
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10 min and developed by using a chemiluminescent substrate (Clarity, ECL; Bio-Rad, 
Hercules, CA). 
 
Epitope mapping by ELISA 
The specificity and epitope mapping of the neutralizing mAbs was investigated by 
ELISAs. Initially, the mAbs were screened against whole virus preparations (prototype or 
I-INDEL strains) or truncated versions of the S protein known to contain neutralizing 
epitopes (residues 499-630 or 630-800) [18,21]. Polystyrene microtiter plates 
(Immunolon 1B, Thermo Scientific, Waltham, MA) were coated with the appropriate 
antigen (50 ng/well of UV inactivated sucrose purified whole virus antigen, 100 ng/well 
of S630-800, or 25 ng/well of S499-630 as previously described [26]. Optimal assay 
conditions, including the amount of antigen, and secondary antibody dilution were 
determined by a checkerboard titration and conditions that resulted in the highest signal 
to noise ratio were used. Serial 2-fold dilutions of the mAbs and appropriate controls 
were diluted in PBS-T 5% non-fat dry milk, and 100 µl of diluted samples were added to 
paired coated and uncoated control wells and incubated at room temperature for 1 h. 
Unbound antibodies were washed with PBS-T (three times) followed by incubation with 
streptavidin-HRP specific IgG and IgM conjugate (Pierce, Rockford, IL) according to 
each mAb isotype. Reactions were developed with 3,3’,5’5’ – tetramethylbenzidine 
substrate (TMB) (KPL Inc., Gaithersburg, MA) and OD values determined at 450 nm 
using a microplate reader (BioTek Instruments Inc., Winooski, VT). OD values for each 
test and control samples were normalized to the OD value of uncoated wells and results 
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expressed as sample to positive (O.D). Endpoint ELISA titers were determined for each 
mAb as previously described [28]. 
To epitope specificity of neutralizing mAbs was assessed by peptide ELISAs. 
Previously described neutralizing epitopes (744-759, 747-774 and/or 756-771) located 
near the S1-S2 junction or another neutralizing antibody located in the C-terminus of S2 
(1371-1377) were chemically synthesized (Genscript, NJ) and used in pepscan ELISAs. 
NuncTM Immbolizer® amino plates (ThermoFisher Scientific, Waltham, MA)) were 
coated with individual peptides (744-759, 80 ng/well; 756-771, 133 ng/well; 747-771, 
200 ng/well and 1371-1377, 400ng/well) in bicarbonate/carbonate coating buffer (15 mM 
sodium carbonate, 35 mM sodium bicarbonate, pH 9.6) in alternate wells. After 
incubation at 37oC for 1h, plates were incubated overnight at 4oC next, plate were washed 
four times with PBS tween 20 (PBS-T, 0.05%) and blocked 2 hr at 37oC with PBS-T 2% 
non-fat dry milk. Blocking reagent was removed and plates washed three times with 
PBS-T (300 µl). mAb incubations and reaction development were performed as above. 
OD values for each test and control samples were normalized to the OD value of 
uncoated wells and results expressed as OD values.  
 
Statistical analysis 
Statistical analysis was performed using SPSS 14 software.  
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           Figure 5.1.  Summary of the properties and characteristics of mouse 
monoclonal antibodies against PEDV and specific PEDV spike by IFA: All 
mAbs specifically recognized cells infected with the recombinant ORFV-PEDV-S, 
expressing the full length PEDV S and cells infected with the PEDV strain CO13. 
All mAbs recognized cells infected with the S-INDEL variant PEDV strain 
USA/IOWA/106/2013, except mAb SD125-2 which did not recognize this strain.   
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Figure 5.2A.  Evaluation of the specificity of the PEDV-S mAbs by Western blots 
using whole virus preparations, recombinant S- (amino acid [aa] 630-800 or aa 
499-600) and N proteins expressed in E. coli.  On Western blots, eight of nine mAbs 
recognized the full-length spike protein in whole PEDV preparations and the truncated 
S protein spanning the S1-S2 junction region (aa 630-800).  mAb SD37-11 did not 
recognize the full-length spike and mAb SD125-2 did not recognize the S1-S2 
recombinant protein (aa 630-800). None of the mAbs reacted with the recombinant N 
protein. 
V 250 
N 51 
 S 24 
                 +     +     -       -       +       -     +     +      -     +     +      -    +    -     - 
        L          SD 33-1      SD37-11         SD120-1       SD121-1     SD125-2 
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Figure 5.2B. Evaluation of the specificity of the PEDV-S mAbs by ELISA using whole virus preparations, recombinant S- 
(amino acid [aa] 630-800 or aa 499-600) and N proteins expressed in E. coli. Specificity of the mAbs tested by ELISA, all mAbs 
reacted against B: PEDV strains CO13 and C: S-INDEL Iowa106. The reactivity of the mAbs against truncated versions of the S 
protein D: aa 499-600 and E: aa 630-800. Nine mAbs reacted against the S1-S2 region (aa 630-800), while only one mAb (SD131-
3) reacted against the product corresponding to aa 499-600, which contains the putative receptor binding domain of the S1 subunit. 
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Figure 5.3.  Patterns of plaque reduction of serially diluted mouse monoclonal antibody against PEDV in PRNT 
assays using in 6-well plates and FFN using 96 well plate using Vero cells. Two-fold serial dilutions of the mAbs' 
working stocks (1:20 - 1:1280) were tested in triplicate by FFN or PRN assays. Endpoint titers were considered the 
reciprocal of the highest mAb dilution capable of reducing PEDV infectivity by 90 (FFN) or 80% (PRN) in vitro.  
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   Figure 5.4. Correlation between endpoint FFN, PRNT and ELISA titers. A: endpoint neutralizing and S1-S2 
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Figure 5.5. Mapping the mAbs against of the direct epitope regions within the S1-S2 
junction region which are capable of inducing neutralizing antibodies against the 
porcine epidemic diarrhea virus using peptide ELISA. A: all mAbs were screened 
against two smaller neutralizing epitopes contained almost entirely within the 747-774 
epitope (744-759 and 756-771), six mAbs (SD120-1, SD129-5, SD131-3, SD137-90, 
SD138-108, and SD142-2) recognized the epitope 747-774, B: mAb SD125-2 specifically 
reacted against epitope 1371-1377. C: Six mAbs recognized epitope 744-756 (SD37-11, 
SD121-1, SD129-5, SD137-90, SD138-108, and SD142-2), D: while only two mAbs 
recognized epitope 756-771 (SD120-5 and SD129-5). 
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mAb Clone IFA Western Blot 
PEDV 
Colorado 
ORFV-
S 
Serotype PEDV 
Indel 
strain 
N PEDV 
Colorado 
PEDV 
INDEL 
S 630-
800 aa 
N 
SD-33.1 + + IgM + - +  +  + - 
SD-PRRSV - - IgG1 - - - - - - 
Poly sera + + +   + + + + + + 
SD 37-11 + + IgG2a + - - + + - 
SD-129-3 + + IgG + - + + + - 
SD-121-1 + + IgG + - + + + - 
SD-131-3 + + IgG2b + - + + + - 
SD-138-108 + + IgG3 + - + + + - 
SD-137-90 + + IgG1 + - + + + - 
SD-142-2 + + IgG2a + - + + + - 
SD-120-1 + + IgG + - + + + - 
SD-129-5 + + IgG + - + + + - 
SD-125-2 + + IgG - - + - - - 
SD-237-11 + + IgM + - + + - - 
Table 5.1. Characterization of mouse mAbs against PEDV spike protein: The 
specificity of the mAbs was assessed by IFA and Western blot using purified whole 
PEDV antigen, a recombinant truncated S protein (aa position 630-800) and the full 
length recombinant N protein. Immunoglobulin isotyping was performed using a 
commercial lateral flow assay kit.  
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mAb Clone   
ELISA 
Peptide ELISA Plaque 
reduction 
PRNT80 
FFN ELISA 
Spike 
end 
point 
NP 499-
600 
 600-
850 
(3) 
Whole 
virus (3) 
PEDV 
INDEL 
1371-
1377 (5) 
744-
759 (5) 
  
747-774 
(6) 
  
756-771  
(3) 
  
PEDV 
Colorado 
PEDV 
Colorado 
PEDV 
Indel 
Using 
Medcalc 
software 
33.1 - - - + + - - - - >1/20 >1/20 >1/20 - 
PRRSV - - - - - - - - - >1/20 >1/10 >1/10 - 
Poly sera  + + + + + + + + + 1/1250 >1250 >1250 1/1250 
SD 37-11 - - + + + - + - - 1/80 1/80 1/80 1/80 
SD-129-3 - - + + + - + - - 1/80 1/80 1/40 1/80 
SD-121-1 - - + + + - + - - 1/80 1/40 1/40 1/80 
SD-131-3 - +    + + - - - - 1/20 1/40 1/40 1/20 
SD-138-108 - - + + + + + - 1/640 1/640 1/160 1/320 
SD-137-90 - - + + + - + + - 1/320 1/640 1/160 1/320 
SD-142-2 - - + + + - + + - 1/160 ≥1/80 1/80 1/160 
SD-120-1 - - + + + - - + + 1/40 1/40 1/80 1/40 
SD-129-5 - - + + + - - + + 1/40 1/80 1/40 1/80 
SD-125-2 - - - + - + - - - 1/160 1/80 >1/20 S2 
(1/160) 
SD- 237-11 - - - + + + - - - 1/320 1/640 1/80 S2 
(1/320) 
Table 5.2. Mapping of mAb reactivity against the epitope regions capable of 
inducing neutralizing antibodies against PEDV infected Vero cells. Also the table 
shows the average neutralizing titer of three different tests for each antibody. 
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Chapter 6 
 
Development of assays for serological diagnosis of the two distinct lineages of bovine 
Influenza D co-circulating in the United States  
 
Introduction 
Influenza viruses are single-stranded, negative-sense, segmented RNA viruses in 
the family Orthomyxoviridae. Influenza A virus and influenza B virus contain eight 
genomic segments with two surface glycoproteins, hemagglutinin (HA) and 
neuraminidase (NA); whereas influenza C and influenza D are closely related and have 
only seven segments with one surface glycoprotein, the hemagglutinin-esterase-fusion 
protein (HEF). HEF is responsible for receptor binding, receptor destroying, and 
membrane fusion activities. In influenza A and B viruses, separate HA and NA proteins 
perform these functions in a cooperative fashion [1,2]. 
Among ten different IDV genomic sequences analyzed, seven distinct genotypes 
were identified, suggesting a reassortment between two clades in the U.S. These two 
lineages of IDV co-circulate in cattle herds in the U.S. and frequently reassort. The 
antigenic analysis of IDV revealed a good correlation between HEF phylogeny and 
reactivity in the HI assay [3].  
The nucleoprotein (NP) and matrix (M) proteins are highly conserved among 
members of each genus of influenza viruses. Although there is high intragenic homology 
between influenza viruses, NP and M1 are highly variable among the three types of 
influenza viruses with only 20–30% intergenic homologies [4]. 
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Serological studies showed that IDV has been present in beef cattle at least since 
2004. Cattle are the reservoir for IDV and young, weaned, and immunologically naive 
calves are most susceptible to influenza virus infection due the decline of maternal 
antibody levels after 6 months of age [5]. Serologic evidence within small ruminants in 
different states in U.S., suggests IDV exposure in 13.5% and 13.3% of sheep and goat 
farms, respectively, with no presence in chickens or turkeys [6].  
The seroprevalence of IDV among cattle has been estimated at 62% either alone 
or with other respiratory infections which can play an important role in the severity of the 
IDV disease [7]. A recent study showed that IDV has been present in the Mississippi 
cattle population since at least 2004, giving the weaned, comingled calves a critical role 
to play in maintenance and transmission of IDV. This study also showed that 94% of 
neonatal calves sampled in 2013 and 2014 possessed maternal immunity against IDV, 
which decreased by six to eight months of age [8]. Calves acquire passive immunity 
within the first 24 hr through maternal immunoglobulins in colostrum [9]. The half-life of 
passively acquired IgG is 21.2–35.9 days and they maintain passive immunity for three to 
four months [10]. 
Accurate and rapid serological diagnostic assays, especially enzyme-linked 
immunosorbent assays (ELISAs) and virus neutralization assays are important tools in 
veterinary and human medicine. The traditional diagnosis of influenza virus has been 
carried out either through direct detection of the virus itself, or through detection of 
antibodies specific for the virus through hemagglutinating inhibition (HI), agar gel 
precipitation (AGP), and a virus neutralization test called the micro-neutralization assay 
(MN) [11,12,13].  
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Influenza D viral nucleic acids can be detected by RT-PCR-based methods [4] for 
virus identification but the antigen detection methods have low efficacy in the large-scale 
surveillance of herds because influenza viruses can clear the bloodstream within one 
week of clinical signs of infection [14]. The AGP test is one method used to test for all 
influenza virus-specific antibodies, however, this test has several disadvantages, like low 
sensitivity and a long processing time for test results [15,16]. 
Although the HI test is the most commonly used test to determine the presence of 
antibodies to an influenza virus in the serum, it can be expensive and requires many 
standardizations. Also the HI test is labor-intensive [17].  Although the MN assay is a 
more sensitive assay than the HI assay for the detection of the protective humoral 
immunity against influenza viruses, it requires further consideration as a formal tool for 
the routine evaluation of vaccine-induced antibody responses [18]. Therefore, our aim 
was to develop an enzyme-linked immunosorbent assay (ELISA) based on two different 
epitopes. Also, we designed a quick and accurate virus neutralization assay called a 
fluorescent focus neutralization (FFN) assay that is based on a fluorescent signal and 
polyclonal antibody specific for the virus. The ELISA and FFN methods may be useful 
and effective methods for the bovine influenza D surveillance system, especially since 
the two different lineages of IDV cross react by HI. New assays which are specific for 
each lineage may give further critical information needed for surveillance of the virus or 
evaluation of vaccine efficacy. 
 
Methods 
Cell Culture and Virus Production 
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Madin Darby canine kidney (MDCK) cells (ATCC CCL-34) were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine 
serum (PAA Laboratories Inc., Dartmouth, MA, USA) and 1% penicillin and 
streptomycin (Life Technologies, Carlsbad, CA, USA). Influenza 
D/bovine/Oklahoma/660/2013 (D/660) and D/swine/ Oklahoma/1334/2011 (D/OK) were 
previously isolated from bovine or swine with respiratory disease symptoms [3]. The 
cells were allowed to reach only 60-70% confluence at the time of infection. The virus 
was propagated by infecting MDCK cells at a 0.01 multiplicity of infection (MOI) and 
incubated at 33°C with ~5% CO2 for 5 days. For virus growth/maintenance media, 
DMEM with 0.1 μg/mL exogenous tosylsulfonyl phenylalanyl chloromethyl ketone 
(TPCK) treated trypsin (Sigma, St. Louis, MO, USA) was used. After 5 days, the infected 
cell cultures were frozen and thawed three times and the supernatant centrifuged at 500xg 
for 15 min at 4o C to remove the cellular debris. Virus titer was determined using MDCK 
cells according to Reed and Meunch’s method [19]. 
 
Serum sample collection 
Approximately 460 bovine serum samples were acquired from the South Dakota 
State Animal Disease Research and Veterinary Diagnostic Laboratory. The selection of 
the samples was random for investigation and mixed between young and adult animals. 
Among them, 100 samples were from farms located in the Midwest region including 
South Dakota (SD), 30 from Angus bulls- Western SD, 75 Holstein cows-Eastern SD, 10 
Beef cattle- SW MN, 50 export cattle-MN, 95 export cattle-PA, 99 Holstein heifers-WA, 
and 5 from Jersey cows-WI. 
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Hemagglutination inhibition assay 
All the bovine samples were tested by HI according to the WHO standard manual 
[20]. Serum samples were pretreated with receptor destroying enzyme (Denka 261 
Seiken, Chuo-ku, Tokyo, Japan) according to manufacturer’s protocol. The HI assay was 
performed using 1% turkey RBCs (Lampire Biological Laboratories, 264 Pipersville, PA, 
USA). An antibody titer of 1:40 was used as a threshold where a titer less than 1:40 was 
judged as negative while a titer equal to, or higher than 1:40 was viewed as positive. 
Serial 2-fold dilutions of serum sample were tested in duplicate. The titers were 
expressed as the reciprocal of the highest dilution of serum which gave complete 
hemagglutination. All samples were assayed in three separate experiments and the mean 
antibody titers were calculated. 
 
Indirect immunofluorescence assay  
MDCK cells were seeded in 96 well tissue culture plates (ThermoScientific, 
Waltham, MA) and grown to 70% confluence over two days. Cells were washed three 
times with serum free medium containing 2.5µg/ml of TPCK treated trypsin (Sigma- 116 
Aldrich, St. Louis, MO, product T1426). Alternate rows of wells were infected with 
150µl of the IDV/D/660 virus culture whose titer was adjusted to 200 TCID50/100µl in 
infection media. Forty-eight hours after infection, cells were washed with PBS (Boston 
Bioproducts, Ashland, MA) and fixed with pre-chilled 80% acetone at 4°C for 20 
minutes. Fixed cells were incubated 1 hr at 37°C with test sera at serial 2-fold dilutions 
starting at 1:10 to 1:1280. After washing with PBS, FITC-labeled anti-bovine IgG 
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antibody (Jackson ImmunoResearch Laboratories, Inc, USA) diluted 1:250 was applied 
and plates incubated at 37°C for 1 hr. Positive and negative (FBS) controls were included 
in each plate. Finally, the cells were observed with a fluorescence microscope for 
characteristic cytoplasmic fluorescence. All the bovine serum samples were tested by the 
IFA and classified as positive or negative. 
 
Preparation of antigens used for ELISA 
Bacterial expression and purification of the IDV nucleocapsid protein (NP): 
A full length IDV NP gene sequence of the influenza D virus strain 
D/bovine/Ok/660/2013 (GenBank: KF425663.1) was synthesized with the addition of a 
3′ 6 × -His tag by GeneArt® Gene Synthesis (GeneScribt, Piscataway, NJ, USA) and 
subsequently, expressed in E. coli. The codon optimized and amplified DNA was 
directionally cloned into the pET- 28a (Novagen, Madison, WI) plasmid for bacterial 
expression using the Xho I and BamHF enzymes (New England Biologicals, Ipswich, 
MA). Following the verification of successful cloning by restriction digestion and 
sequencing, E. coli BL21 cells (Invitrogen, Carlsbad, CA) were transformed with 2.5 ul 
of the plasmids. Transformed cultures were induced with 0.5mM isopropyl β-D-1- 138 
thiogalactopyranoside (IPTG, Sigma-Aldrich, St. Louis, MO), for 6 hr at 37°C. The 
insoluble protein fraction was denatured using 8 M urea, then purified three times using 
nickel-NTA affinity column chromatography and refolded back to its native 
conformational state. Individual affinity column elutions were collected, pooled and 
confirmed by SDS-PAGE, then aliquoted/frozen at −80 °C. The purified protein was 
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assessed by a Western blot using our anti rabbit IDV polyclonal antisera previously 
produced in our laboratories. 
 
Bacterial and mammalian expression and purification of the IDV 
Hemagglutinin-estrase (HE):  A recombinant plasmid, containing the synthetic 
truncated sequence of the region from 400 to 1665 of the HE sequence of the influenza D 
virus strain D/bovine/Ok/660/2013 (GenBank: KF425662.1) with the addition a 3′ 6 × -
His tag by GeneArt® Gene Synthesis (GeneScribt, Piscataway, NJ, USA) was subcloned 
in the Pet28 system for bacterial expression according to [21]. The plasmid DNA of the 
HE truncated sequence and mutation at amino acid site 212 was linearized by restriction 
enzyme BamH1 and Xho1 digestion and then cloned into PCDNA3.1 mammalian 
expression vector. 
 
Whole Virus antigen:  Sucrose purified/UV-inactivated IDV strain D/660 and 
C/OK strains were used as a whole virus purified control antigens for IFA, Western and 
ELISA. Trypsin treated cleavage viruses were used as a control for HE cross-reactivity. 
 
Determination of cross reactivity between the two lineages of IDV:  Rabbit 
polyclonal primary antibody (IgG) against IDV D/660 and D/OK were used as controls in 
our study and also used to study the cross reactivity between the two clades D/660 and 
D/OK which are antigenically different. Monoclonal antibody produced in our 
laboratories against D/660 were also used in our study. The cross reactivity between the 
175 
 
 
 
 
two lineages was evaluated using Western blot methods and IFA of the mammalian 
expression system of HE protein. 
 
Western Blot:  Western blotting was performed using sucrose purified viruses and 
recombinant NP and HE proteins. Fifty micrograms of protein were resolved by SDS-
PAGE in 7% acrylamide gels and transferred to nitrocellulose membranes. After blocking 
the blots with 5% non-fat-dry-milk TBS-Tween 20 (0.1%; TBS-T) solution for 2 hr at 
RT, they were probed with the hyperimmune polyclonal antibodies, mAbs and the 
selected bovine antibodies overnight at 4oC diluted in 5% non-fat-dry-milk TBS-Tween 
20. Blots were washed three times with TBS-T for 10 min at RT and incubated with a 
goat anti-bovine IgG-HRP (Jackson ImmunoResearch Laboratories, INC, USA) 
conjugate secondary antibody for bovine sera, a goat anti-rabbit IgG-HRP conjugate 
secondary antibody for rabbit-polysera and a goat anti-mouse IgM-HRP conjugate 
secondary antibody for the mAbs for 2 hr at RT. Commercial anti-HIS antibody 
(Invitrogen, Carlsbad, CA) at (1:10000) was used as primary antibody for the 
confirmation of the recombinant protein expression. Fetal bovine sera was used as a 
negative control. Blots were washed three times with TBS-T for 10 min and the bands 
were visualized by staining with 4-chloro-1- 180 naphthol (ThermoFisher, Grand Island, 
NY). 
 
Samples for assay development and validation 
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Positive bovine samples from HI, IFA and Western blot were collected for the 
preparation of a strong positive bovine sera specific for IDV and used for assay 
development. 
 
Indirect ELISA development and optimization 
UV inactivated sucrose purified viruses, NP and HE recombinant proteins 
expressed in E. coli, were used in indirect ELISAs. Polysorb microtiter plates 
(Immunolon polysorb, 96 well, Thermo Scientific, Waltham, MA) were coated with the 
appropriate antigen (50 ng/well of UV inactivated sucrose purified whole virus antigen, 
HE, 100 ng/well; NP, 25 ng/well [22]. Optimal assay conditions (concentration of 
antigen, serum, anti-bovine biotinylated antibodies and secondary antibody dilutions) 
were determined by a checkerboard titration which gave the highest signal to noise ratio. 
In addition, fetal bovine serum as negative control and a single lot of pooled convalescent 
of IDV serum positive by IFA, HI and Western blot was used to generate quality control 
standards that gave high and low optical density (high OD = 2.0 to 2.5; low OD = 0.5 to 
1.0; and negative OD < 0.2). The appropriate antigen concentration was diluted in 
bicarbonate/carbonate coating buffer (15 mM sodium carbonate, 35 mM sodium 
bicarbonate, pH 9.6) in alternate wells. Plates were washed four times with PBS tween 20 
(PBS-T, 0.05%) after one hour incubation at 37°C, and blocked overnight at 4°C with 
PBS-T 10% 1:1 goat to swine serum. Blocking reagent was removed and plates washed 
three times with PBS-T (400 µl). Serial double fold dilution of the controls were diluted 
in PBS-T 10% goat sera, and 100 µl of diluted samples were added to paired coated and 
uncoated control wells and incubated at room temperature for 1 hr. Unbound antibodies 
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were washed with PBS-T (three times) followed by incubation with goat-anti-bovine-
biotyinylated IgG (Jackson ImmunoResearch Laboratories, Inc., USA) for one hr at RT. 
After washing three times with PBS-T, streptavidin-HRP specific conjugate (Pierce, 
Rockford, IL) was added and incubated one hr at RT. Reactions were developed with 
3,3’,5’5’ – tetramethylbenzidine substrate (TMB) (KPL Inc., Gaithersburg, MA) and OD 
values determined at 450 nm using a microplate reader (BioTek Instruments Inc., 
Winooski, VT). OD values for each test and control samples were normalized to the OD 
value of uncoated wells and results expressed as sample to positive (O.D).  
Bovine sera from multiple animal populations and farms were used in our study 
as described above. Receiver operating characteristic (ROC) analysis was calculated for 
each assay to assess diagnostic performance, which included determination of sensitivity, 
specificity and threshold cutoff using MedCalc version 11.1.1.0 (MedCalc software, 
Mariakerke, Belgium).  
 
Fluorescent Focus Neutralization test 
An IDV virus neutralization assay using a FFN format was developed for rapid 
and accurate detection of neutralizing antibodies produced in response to IDV infection. 
The FFN was evaluated using serum samples. Heat-inactivated samples were diluted in a 
2-fold dilution series starting at 1:10 in MEM plus 1μg/ml TPCK-treated trypsin in 96-
well plates. An equal amount of cell culture adapted IDV/D/660 stock at a concentration 
of 100 foci forming units/100 μl was added to each well and plates incubated for 1 h at 
37°C. The virus/sample mixture was then added to washed confluent monolayers of 
MDCK cells and incubated for 2hr at 37°C. Plates were washed again with 
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DMEM/TPCK-trypsin medium and incubated 44 hr to allow for replication of non-
neutralized virus. Plates were then fixed with 80% acetone and incubated with 100 µl of 
rabbit polyclonal primary antibody (IgG) against both D/660 and D/OK Bovine IDV at a 
1:250 dilution to each of the wells. The plates were incubated at 37°C for an hour. 
Following washing with PBS three times, 60 µl of affinity purified fluorescein labeled 
goat anti-rabbit IgG secondary antibody (KPL, Gaithersburg, MD, USA) at a 1:1000 
dilution was added and incubated at 37°C for 1 hr to allow visualization of infected cells. 
Endpoint neutralization titers were determined as the highest serum dilution resulting in a 
90% or greater reduction in fluorescent foci relative to controls. 
 
Measurement of statistical testing agreement and correlation: 
Multiple comparison, inter-rater agreement (kappa measure of association) and 
Pearson’s correlation tests were calculated among all four tests (HI, iELISA, FFN and 
IFA) using IBM, SPSS version 20 software (SPSS Inc., Chicago, IL).  
 
Results 
HI assay: All the randomly collected serum samples from different states were 
tested by HI using D/660 after treatment by RDE. About 317 samples were positive out 
of 400 cows and bulls and 100 serum samples were negative from young cattle and 
calves 7-8 months old.  However, the HI test using D/OK showed only 166 positive from 
400 and 100 negative out of 100.  
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Immunofluorescence assay (IFA): About 166 of the 400 field samples tested by 
the IFA were classified as positive and 100 out of 100 as negative. Classically, the IDV 
positive control serum showed clear cytoplasmic fluorescence started from 1:40 dilution, 
while negative serum did not (Figure 6.1).  
 
Expression of recombinant IDV-NP and IDV-HE antigens by bacterial 
system: The protein yield by the IPTG induced E. coli culture was approximately 25mg 
PEDV-NP/liter of 2XYT medium with a purity of greater than 95%. The purity of the 
recombinant protein was assessed by SDS-PAGE in which the expected band of 64 kDa 
for NP and 65 for HE migrated upon staining with Coomassie brilliant blue R250 (Figure 
6.2). Confirmation of the specificity of the recombinant proteins was characterized by 
Western blot using convalescent IDV-positive serum, fetal bovine serum as negative 
control, and anti-His mAb, and anti-rabbit-IDV polysera as shown in Figure 6.3.  
 
Western Blot: Western blotting was done for three purposes, first to investigate 
some selective serum samples against whole virus, NP and HE using anti-bovine-HRP to 
confirm the seroconversion status as shown in Figure 6.4.  Second, to map our produced 
monoclonal antibody in our laboratories. In order to map the mAb of isotype IgM, 
sucrose purified whole virus D/660 and D/OK were treated with trypsin for 1 hr at a 
concentration of 10µg/ml before running the gel. Non treated viruses were also used as a 
control, all plus the NP and HE proteins. Our mAb showed cross reactivity with HE 
recombinant protein and no reactivity with NP. It also it cross reacted with both D/660 
and D/OK when trypsin treated and did not react with the whole virus as shown in Figure 
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6.5.A compared to Figure 6.5.B (Non-cleaved virus with anti-rabbit sera). Lastly, we 
used Western blot as a sensitive test to study the cross reactivity between D/660 and 
D/OK using our rabbit antisera against both of them alternatively. As shown in Figure 
6.6a and 6.6b, both anti-rabbit sera reacted with both viruses treated with trypsin and 
non-treated, demonstrating the cross reactivity between the two clades using our rabbit 
antisera. 
 
Indirect ELISA: Receiver Operator Characteristic (ROC) analysis of the indirect 
ELISA with the IFA was used to characterize the sensitivity and specificity values and 
cutoff. The optimal cutoff values and corresponding sensitivity and specificity of our NP 
and HE based tests are presented in Figure 6.7. Specifically, ROC analysis for the NP-
iELISA showed 87.9 % sensitivity and 96.2% specificity with a 0.599 cutoff. While the 
ROC analysis for the HE-iELISA showed estimated sensitivity and specificity of 86.9% 
and 96.2 %, respectively with a cutoff of 0.481 (Figure 6.7). The Pearson’s correlation 
test between all diagnostic platforms had a high correlation values between the assays, 
Table 6.2 illustrates the correlation between the assays and the P value. 
 
Cross reactivity between the two lineages of IDV: Investigation of the cross 
reactivity between IDV-D/660 and IDV-D/OK were done using our rabbit antisera 
specific for both IDV lineages produced in our laboratories. Using Western blot with 
different epitopes from, whole virus D/660, D/OK, trypsin treated D/660, trypsin treated 
D/OK, recombinant N and HE proteins showed that there is a strong cross reactivity 
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between the two lineages as in Figure 6.6.a and 6.6.b. Therefore, our rabbit antisera will 
provide a good tool for the diagnosis of IDV in the U.S. 
Mutation by deletion at the amino acid site 212 of the HE protein and transfection 
in MDCK using lipofectamin 3000 did not effect the antigenic recognition of the epitope 
against mAb and rabbit antisera for both lineages. Figure 6.8. 
 
FFN: The FFN assay was initially evaluated using well-recognized positive 
convalescent serum samples by Western blot, IFA, HI and ELISA. Essentially, the 100 
negative samples showed serum FFN endpoint titers of <1:20 and included calves 
between 6-7 months old.  While 349 samples out of the 350 positive sample set of cows 
and bulls had endpoint titers from 1:80 to 1:1280. An example of positive convalescent 
sera and negative FBS is shown in Figure 6.9.  
 
Statistical correlation between HI, FFN and iELISA-HE: There was a good 
correlation between the HI results after transformation to Log-2 and FFN which showed a 
value of 0.581, between HE-iELISA and FFN-log2 showed 0.548, and iELISA based on 
HE and HI-log was 0.522. (Table 6.2 and Figure 6.10). 
 
Discussion 
The most common serological assays to detect antibodies to influenza virus are 
the HI and the MN assays. The HI assay detects antibodies that able to block the 
influenza virus hemagglutinin binding to sialic acid-linked receptors on red blood cells, 
while the MN test detects functional antibodies directed toward the hemagglutinin, 
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therefore preventing infection of cells in tissue culture [11,23]. One of the disadvantages 
of HI is that reference sera always needs to be included when performing the test [13]. 
For IDV, the HI test was not able to consistently cross react between the two 
genetic clusters (D/OK-like and D/660-like viruses) for IDV, which have been identified 
to be antigenically distinct [24]. In this study, we used our rabbit polyclonal antisera 
against both D/OK and D/660 to study the cross-reactivity between them. As shown in 
Figure 6.6, a strong cross reactivity exists when using the alternative rabbit polyclonal 
antisera. Therefore, our FFN test, which is a neutralization test based on using rabbit 
polyclonal antisera as the detection antibody, will detect antibody to both strains of IDV 
in virus neutralization assays using either type of IDV as the indicator virus, providing a 
good tool for the surveillance of IDV in the U.S.  
Furthermore, our study found also that both D/OK-like and D/660-like IDVs were 
co-circulating in the same South Dakota herds as shown in Table 6.1. The HI results 
using both clades D/660 and D/OK were different in seropositive status but the FFN 
results were able to cover both. There are many different formats of the MN assay all 
over the world, such as the 2-day enzyme-linked immunosorbent assay (ELISA) protocol 
[25], 3-day HA protocol [15], and 7-day HA protocol [12]. Time is critical for the 
purposes of seroepidemiology; therefore, the accurate and shorter protocols of 2 to 3 days 
are better. Our FFN test will not only be able to detect the protective antibodies against 
the two antigenically different clades of IDV co-circulating in the U.S. that the HI was 
not able to detect but also will save time. 
The IDV/D/660 clade has a K replacing R of the D/OK clade at position 212. 
Although HI results and molecular models of the two clades revealed that amino acid 212 
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plays an important role in IDV antigenicity and antibody recognition [24], in our study 
we investigated the cross reactivity between the two clades. In order to do this, we treated 
both sucrose purified viruses with TPCK-treated trypsin to cleave the HE protein, then 
we used both rabbit polyclonal antisera against both clades alternatively as shown in 
Figure 6.6. Both cleaved and non-cleaved viruses reacted with both rabbit antisera. Also, 
both polyclonal antisera specific to both clades reacted with the D/OK HE recombinant 
protein.  
Moreover, to investigate whether the amino acid 212, which is located in the apex 
of the HE receptor binding domain, has a critical role in the antibody recognition or not, 
we did a mutation by deletion in this region and cloned the mutant in the PcDNA3.1 
mammalian expression vector. We then transfected MDCK cells with the construct. The 
transfected cells stained by both rabbit polyclonal antisera specific to the two IDV clades 
and cross reacted with the mutant HE. This suggests that the amino acid 212 region alone 
is not only the cause of why HI titers were different between the two clades but also may 
be another region like V115I and D372G in the esterase domain [24] playing the critical 
role together in the antigenic differences with the recognition of the receptor. 
In order to map our produced mAb, we used Western blot techniques, in which 
we blotted the whole virus of both clades in both forms, cleavage by trypsin and non-
cleaved. Our mAb did not recognize the non-cleaved whole virus but reacted strongly 
with the cleaved version. After that, we confirmed the results by blotting the mAbs with 
both recombinant NP and HE bacterial expressed protein and this showed no recognition 
with NP but a strong signal with HE (Figure 6.4).  
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Neutralization assays are not able to detect the cross-reactive antibodies to the 
stem region of influenza viruses which decreases specificity, particularly in the older ages 
of animals [26]. Also, the neutralizing assay only detects the protective antibodies against 
specific epitopes but not the non-neutralizing antibodies which are produced against other 
epitopes like M, NP and PB1, which the immune system can produce that also reflect the 
serostatus of the animal. Therefore, our second aim after producing an accurate and quick 
neutralizing test (FFN) that was able to detect antibodies against the two different clades 
of IDV, was to develop another serological test that can detect both neutralizing and non- 
neutralizing antibodies against the IDV. This provides the veterinarian and researcher 
with good tools for IDV surveillance and vaccine evaluation. ELISAs are the most cost-
effective and rapid serological assay, especially in the absence of active infection.  
Nucleoprotein, one of the major structural proteins of IDV, plays a critical role as 
a genus-specific antigen which distinguishes between the influenza A, B, and D viruses.  
It is responsible for the loss of cross-recognition of viral antigens among influenza 
viruses [4]. Moreover, the NP is a conservative domain among the different IDV strains 
so it presents a good target for the seroprevalence of IDV. Therefore, we developed 
separate iELISAs based on NP and HE.  
Our NP ELISA was able to detect 332 positive samples from 350 expected 
positive samples and 96 negative samples from 100 as shown in Table 6.1. The 
sensitivity and specificity of the iELISA-NP was very good, although it showed higher 
specificity than sensitivity. This might be due to the lower number of negative samples in 
our study, therefore more negative samples are needed for the next steps of optimization 
of the test. Our HE-iELISA showed a good correlation with the HI and FFN results as 
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shown in Table 6.2 and Figure 6.10, which confirmed the specificity of the HI and FFN 
directed toward the protective antibodies against HE. The HE protein of influenza D is 
responsible for recognition and binding of the receptor therefore entrance and infection of 
the virus [3]. 
In South Dakota, the preliminary prevalence of IDV is approximately 90% in 
dairy cattle and 4-7% in healthy 7 month old calves. Furthermore, when we studied the 
seroprevalence from 7 month old calves to adult cattle, we found an increase from 7.7% 
at 8 month old calves to 90% in adult cattle. This may reflect the increased spread of IDV 
among cattle in U.S. compared to a previous study that showed 11.3% in calves and 66.5 
% in adults [8]. The differences in the calf percentage may be related to the maternal 
immunity transferred from the high percent of positive adult cattle to the calves that helps 
in temporary protection. However, conclusions from our observations are still limited 
based on the low sample size.  
The main importance of the FFN over indirect ELISAs in IDV surveillance is that 
indirect ELISAs require the use of species-specific enzyme-conjugated antibodies, while 
FFN does not.  Also FFN can detect only the neutralizing antibodies [21]. NP-ELISA 
methods can detect the antibodies which target the common viral proteins [22]. NP 
ELISAs should be effective for large-scale surveillance of IDV in herds. Further 
development of the FFN using milk and colostrum samples from cattle from a herd that 
has experienced an acute IDV outbreak serum will be valuable tools to quantify the 
maternal immunity and acquired immunity transferred to calves. 
In conclusion, our study and serological assays developed here will play an 
important role in seroprevalence studies, surveillance and diagnosis of IDV. Also, our 
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new diagnostic tests will play a critical role in vaccine evaluation. More study will be 
needed to confirm the difference between D/OK and C/OK in the HI test which may be 
related to the receptor binding. 
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Table 6.1. Summary of the serological survey from different bovine farms in the U.S.  
HI/D/660 90%, HI/C/Ok 47%, ELISA-NP 94.8%, ELISA-HE 89.8%, IFA 81.7% and 
99.7% FFN. 
 
  
Farms and state 
Seropositive 
Total 
Number 
Hi 
IDV/D/660 
ELISA 
NP 
ELISA 
HE IFA 
HI IDV/D/ 
OK FFN 
Angus bulls- Western SD 10 6/10 10/10 6/10 6/10 5/10 10/10 
Beef cattle-SW MN 10 7/10 10/10 8/10 7/10 6/10 10/10 
Diary-SD 10 10/10 10/10 10/10 10/10 4/10 10/10 
Jersey cows-WI 5 5/5 5/5 5/5 4/5 2/5 5/5 
Holstein cows - Eastern 
SD- Dairy 50 40/50 45/50 48/50 43/50 35/45 50/50 
Dairy-SD 20 15/20 18/20 17/20 16/20 9/10 20/20 
Export cattle - PA 95 95/95 95/95 95/95 90/95 20/95 95/95 
Holstein Heifers - WA 100 99/100 99/100 85/100 80/100 50/100 99/100 
Angus cattle – Eastern-
SD 10 0/10 0/10 0/10 0/10 0/10 0/10 
Holstein cows -Eastern 
SD calves 7-8 month 90 0/90 4/90 6/90 5/90 0/90 0/90 
Export cattle - MN 50 40/50 40/50 40/50 30/50 35/50 49/50 
Total positive 350 317/350 332/350 314/350 286/350 166/350 349/350 
Total negative 100 0/100 4/100 6/100 5/100 0/100 0/100 
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A 
B 
Figure 6.1.  IFA on IDV infected MDCK cells using positive and negative 
bovine serum samples and anti-bovine FITC. A: Positive convalescent 
bovine anti-IDV sera showing strong fluorescent staining of virus infected 
cells. B: Negative serum sample show no specific fluorescent staining. 
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Figure 6.2. SDS-PAGE/Coomassie blue staining of E. coli expressed 
and purified NA and HE antigen showing size and purity of 
expressed proteins. 
Lane 1: NP shown at size of 62 kDa, Lane. 2: ladder, and Lane 3: HE at 
size of 64 kDa 
1         2          3 
63kDa 
65kDa 
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Figure 6.3. Confirmation of the specificity of the recombinant proteins 
compared to whole virus.  
Lane 1: FBS with recombinant NP 
Lane 2: Ladder 
Lane 3: FBS with recombinant HE 
Lane 4: whole virus D/660 positive with anti IDV convalescent sera 
Lane 5: Ladder 
Lane 6: Recombinant NP with anti-mouse his-tag 
Lane 7: Recombinant NP with anti-rabbit D/660 sera  
Lane 8: Ladder 
Lane 9: Recombinant HE (64kDa) with anti-mouse his-tag 
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Figure 6.4. Western blot identification of selected IDV proteins using 
the IDV-convalescent sera.  
Lane 1: IDV/D/OK whole virus 
Lane 2: IDV/D/660 whole virus 
Lane 3: NP Recombinant protein 
Lane 4: ladder 
Lane 5: IDV/D/660 whole virus 
Lane 6: IDV/D/OK whole virus 
Lane 7: IDV-NP Recombinant protein 
Lane 8: IDV-HE recombinant protein 
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Figure 6.5.A. Mapping the IDV-mAb                               
Lane1: IDV-Np recombinant protein 
Lane2: IDV/D/660 
Lane3: IDV/D/OK 
Lane4: ladder 
Lane5: Trypsin treated IDV/D/660 
Lane 6: Trypsin treated IDV/D/OK 
Lane7: IDV-HE recombinant protein 
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Figure 6.5.B. 
Uncleaved IDVD/660 
with rabbit antisera 
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B. Using polyclonal rabbit anti IDV/C/OK 
sera which showed strong cross reaction. 
 
A. Using polyclonal rabbit anti 
IDV/D/660 sera which showed strong 
cross reaction. 
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Figure 6.6. Cross reactivity between the two IDV different clades of D/660 and 
C/OK using specific polyclonal rabbit anti-IDV sera against each virus. 
Lane1: Ladder  
Lane 2: IDV-NP recombinant protein 
Lane 3: IDV/D/660  
Lane 4: IDV/D/OK 
Lane 5: Trypsin treated IDV/D/660 
Lane 6: Trypsin treated IDV/D/OK 
Lane7: IDV-HE Recombinant protein 
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Figure 6.7. Receiver operator characteristic (ROC) assessment and 
determination of diagnostic sensitivity and specificity of the IDV-NP (A), and 
IDV-HE (B) iELISA. ROC analysis was performed using MedCalc version 11.1.1.0 
(MedCalc software, Mariakerke, Belgium). In each panel, the dot plot on the left 
represents the negative testing population, and the dot plot on the right represents the 
positive population. The horizontal line bisecting the dot plots represents the cutoff 
value that gives the optimal diagnostic sensitivity and specificity.  
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Correlation table      
  
ELISA-
HE 
ELISA-
NP FFN (Log) HI_Log IFA_log 
ELISA-HE Correlation Coefficient 0.517 0.548 0.522 0.556 
 Significance Level P <0.0001 <0.0001 <0.0001 <0.0001 
ELISA-NP Correlation Coefficient 0.517  0.484 0.435 0.512 
 Significance Level P <0.0001  <0.0001 <0.0001 <0.0001 
FFN (Log) Correlation Coefficient 0.548 0.484  0.581 0.705 
 Significance Level P <0.0001 <0.0001  <0.0001 <0.0001 
Hi_Log Correlation Coefficient 0.522 0.435 0.581  0.732 
 Significance Level P <0.0001 <0.0001 <0.0001  <0.0001 
IFA_log Correlation Coefficient 0.556 0.512 0.705 0.732  
 Significance Level P <0.0001 <0.0001 <0.0001 <0.0001  
 n 450     
  
 
Table 6.2. Pearson correlation coefficient between all the diagnostic assays. 
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Figure 6.8. Cross reactivity of the mutant HE protein at site 212 
amino acid.  MDCK cells stained with both IDV lineages of anti-
rabbit-sera and mAb after transfection in MDCK.  
A: Cross reaction with anti-rabbit D/660.  
B: Cross reaction with anti-rabbit D/OK.  
C: Control Mock.  
D: Cross reacted with IDV-mAb 
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A-Fetal Bovine Serum B- Control IDV positive Serum Dilution 
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End 
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Figure 6.9. Example of positive and negative FFN results. A: fetal bovine serum as 
negative in which there was no antibody to prevent the viral replication. B: IDV positive 
serum that has antibodies specific to IDV and did to inhibit virus replication showing 
~90% reduction in FFU at a 1/1280 dilution. 
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Figure 6.10. Scatter correlation between. A: fetal bovine serum as negative with no 
antibody to prevent viral replication. B: IDV positive serum with antibodies specific 
to IDV and was able to inhibit the virus to a titer of 1/1280. 
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Chapter 7 
Conclusions 
Timely and accurate veterinary diagnostic services and reagents arm veterinarians 
and public health officials with the tools to control new emerging diseases and improve 
animal and therefore, human health. Studying the molecular biology of new emerging 
viruses is the key to developing diagnostic reagents, new laboratory-based diagnostic 
tests, methods for new viruses’ detection and developing new products that can help in 
treatment, disease prevention, management and controls. 
In 2013, PEDV suddenly emerged in the United States and has been proven a 
significant pathogen of swine. PEDV caused a devastating economic loss and high 
mortalities in piglets. Our goal was to serve both the industrial and academic researcher 
with quick and accurate diagnostic tools and reagents. The well-validated NA PEDV 
iELISA, bELISA, FMIA and FFN assays in our study are useful for a range of 
serological investigations. They can complement the nucleic acid detection assays and 
determine the PEDV status of asymptomatic individuals cost-effectively, thus becoming 
tools in management strategies and the monitoring of virus exposure within the herd. The 
FMIA will be a valuable tool for isotyping the antibody responses and by multiplexing 
the assay, we will be able to determine the exposure to multiple pathogens 
simultaneously. Moreover, the FFN is useful in determining whether the antibodies 
measured are providing a biological function of blocking virus infectivity or not. Our 
spike FMIA correlated with other assays on sample matrices, such as milk and colostrum 
for measuring passive transfer of antibodies and oral fluids for pen-based surveillance. 
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Another porcine deltacoronavirus disease syndrome emerged in the U.S in early 
2014, more diagnostic assays and reagents were needed. PDCoV also, causes enteric 
disease in swine, but the impact is not as severe as PEDV.  The monoclonal antibody 
reagents developed in our study provide important research and diagnostic tools for the 
both the researcher and the industry. They are valuable for fluorescence and 
immunohistochemical staining methods utilized in diagnostic and pathogenesis studies. 
The serological assays allow the detection of antibodies developed in response to PDCoV 
infection. Our PDCoV indirect ELISA and NP based FMIA will allow high-throughput 
screening of swine serum samples. Our assays are adequately optimized and validated for 
sero-surveillance on a herd level, but further improvement is needed for full confidence 
on an individual animal basis. We were able to validate these assays and to adapt them to 
different sample matrices such as milk. Our PDCoV FFN test validation is ongoing and 
will be an important tool to validate vaccines. Since lactogenic immunity is likely critical 
for protection of nursing piglets, these assays will be modified for detection of IgA as 
well. So our specific reagents and serological assays will allow for improved diagnosis of 
PDCoV. Since many aspects of PDCoV infection and transmission are still not fully 
understood, the reagents and assays developed in this project should provide valuable 
tools to help understand this disease and to aid in the control and surveillance of PDCoV 
outbreaks.  
Besides providing diagnostic reagents and assays, another objective of this study 
was to do epitope mapping of the S protein of PEDV, enhancing our understanding of the 
virus.  Iimmunization of BALB/c mice with purified and inactivated whole virus 
preparations of PEDV followed by somatic cell fusion resulted in hybridoma cell lines 
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secreting mAbs specific for the S protein that exhibited marked neutralizing activity 
against PEDV in vitro. Epitope mapping of the resultant neutralizing mAbs led to the 
identification of important antigenic determinants within the S protein. Notably, most 
mAbs obtained here reacted against linear epitopes within the S2 subunit, indicating that 
this region contains immunodominant neutralizing epitopes of PEDV.  Our epitope 
mapping results demonstrated that particular domains on the spike are associated with 
enhanced neutralization, depending on their structure and mechanism of action. For 
instance, 744-759 aa is considered to be the cleavage site domain of the S1-S2 to the 
target cell, whereas the receptor binding domain is localized to the 499-600, showing less 
neutralizing ability. The viral plaque formation was not completely inhibited by the 
mAbs specific to 499-600 aa domain in the spike protein of the PEDV. We believe that 
this, at least in part, is due to the addition of trypsin, which was required to activate the 
receptor-ligand interaction between the Vero cells and PEDV. It is likely that the added 
trypsin degraded the antibodies, which resulted in the incomplete inhibition of the PEDV-
mediated plaque formation. However, our results revealed that the COE region of the 
PEDV spike protein might contain the major neutralizing epitope for the virus as it the 
end point was 1/40 dilution of the antibody. This finding supports the previous 
observation that the same region of the TGEV spike protein also contains neutralizing 
epitopes. The neutralizing epitopes have been mapped and analyzed focused on the 
region encoded 630-800 and the neutralizing peptides included in this domain.  The 630-
800 aa region is the most immunodominant region in the spike. We found that the 
antibodies against this epitope have neutralizing activity for PEDV-infected Vero cells. 
Furthermore, the 630-800 aa region was able to react with PEDV antiserum and evoke 
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the formation of neutralization antibodies in mice and spans the S1-S2 junction region of 
the S protein. Our results demonstrated that the cleavage site between S1 and S2 may be 
a target for subunit vaccines. It contains the epitope region 744-759 or 15 aa in the 
beginning of N terminal domain of S2 and 756-771 that is presumed to be located in the 
spherical head of the S protein of PEDV and represents a considerable immunodominant 
region of PEDV S protein. Both epitopes play an important role after the cleavage 
between S1 and S2 by trypsin in the pathogenesis of PEDV. Our mAbs specific to the 
cleavage site between S1 and S2 in addition to the 1371-1377 showed much higher 
neutralization in the two neutralizing tests compared to the region encoded the RBD. 
There was a high correlation between the three different tests; FFN, PRNT and ELISA. In 
summary, by using a panel of PEDV S-specific neutralizing mAbs we have shown that an 
immunodominant neutralizing epitope of PEDV S maps to the amino-terminus of the S2 
subunit. While seven neutralizing mAbs generated after immunization of mice with 
whole virion preparations recognized a domain in S2, only one mAb reacted against S1. 
These results suggest that S2 subunit may contain important, perhaps, immunodominant 
neutralizing determinants of PEDV. This study provides important information and tools 
that may lead to the development of improved prevention, control and/or diagnostic 
strategies for PEDV. 
Utilizing many of the same research techniques, we were able to study the 
Influenza D virus, which is a newly described disease of cattle. It is wide spread in the 
U.S. with two antigenically different lineages. It affects all age groups of bovine and 
causes significant respiratory disease. The purpose of this study was to analyze the viral 
proteins of IDV in order to produce an accurate diagnostic test in which to determine the 
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seroprevalence among cattle herds. We wanted a test based on the most conservative 
domain which will be able to detect the antibodies against the two different IDV clades 
circulating in the U.S. Our NP based ELISA was able to detect 332 positive samples from 
350 expected positive samples and 96 negative samples from 100 assumed negative 
sampels. The sensitivity and specificity of the NP-iELISA was very good, although it 
showed higher specificity than sensitivity due to the lower number of negative samples in 
our study.  Therefore, more negative samples will be needed for second generation 
optimization of the test. The main benefit of the FFN over iELISAs in IDV surveillance 
is that iELISAs require the use of species-specific enzyme-conjugated antibodies, while 
the FFN assays do not.  Also, FFNs detect only the neutralizing antibodies while NP-
ELISA methods can detect the antibodies which target the common viral proteins. The 
HE-iELISA produced in this study showed a good correlation with the HI and FFN 
results, which confirmed the specificity of the HI and FFN directed toward the protective 
antibodies against the HE protein of influenza D is responsible for recognition and 
binding of the receptor therefore entrance and infection of the virus. 
In South Dakota, the presence of IDV appears to approach 90% in dairy cattle and 
4-7% in healthy calves. The maternal immunity transferred from the cows to the calves 
may help in temporary protection. Our NP ELISAs should be effective for large-scale 
surveillance of IDV in herds. Further development of the FFN using milk and colostrum 
samples from cattle from herds that have recently experienced an acute IDV outbreak 
will be valuable tools to quantify the maternal immunity and acquired immunity 
transferred to calves. Our study and serological assays developed here will play an 
important role in future seroprevalence studies, surveillance and diagnosis of IDV. Also, 
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our new diagnostic tests will play a critical role in vaccine evaluation. More study will be 
needed to confirm the difference between D/660 and D/OK in HI test which may related 
to the receptor binding.  
The overall purpose of this doctoral work was to develop ways to monitor and 
assess recently emerging diseases affecting livestock in the U.S. and beyond.  These viral 
diseases; PEDV and PDCoV in swine, and IDV in cattle, are devastating not only for the 
susceptible animals but also the economies of the area where these viruses have emerged. 
The information gained by this work played a significant role in diagnosing the diseases 
and vaccine development to help control them. It will continue to be valuable in the 
surveillance of these viruses. This study also gave a focused insight into the underlying 
mechanism of invasion of these viruses by studying the molecular characteristics. A deep 
molecular genetic study of the virus helps produce quick and accurate diagnostic assays 
which arm the livestock producers and veterinarians in controlling disease.  
 
